

## **Modular Program Report**

### Disclaimer

The following report(s) provides findings from an FDA-initiated query using Sentinel. While Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Sentinel, and seeking to better understand Sentinel capabilities.

Data obtained through Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from Sentinel in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the modular program run(s).

If you are using a web page screen reader and are unable to access this document, please contact the Sentinel Operations Center for assistance at info@sentinelsystem.org.



#### Overview for Request cder\_mpl1r\_wp023\_nsdp\_v01

Request ID: cder mpl1r wp023 nsdp v01

Query Tool: Cohort Identification and Descriptive Analysis Tool, version 2.2.0

<u>Query Description</u>: This report contains estimated numbers of idelalisib users and idelalisib users with concomitant use of several anti-cancer agents as well as cancer diagnoses around the time of idelalisib use.

<u>Data Source:</u> Data from July 23, 2014 to December 31, 2015 from 15 health plans contributing to the Sentinel Distributed Database (SDD) were included in this report. This request was distributed on May 19, 2016. See Appendix A for a list of the latest dates of available data for each Data Partner.

<u>Study Design:</u> This request was designed to determine concomitancy and indications for idelalisib use. It calculated the number of patients taking idelalisib and the number of patients taking idelalisib within the same time frame as 13 other specified agents. It also identified the cancer indication for each idelalisib episode, if the indication is present in the data. The number of qualifying patients with the exposure(s) of interest, number of eligible members, and member-days were calculated overall and were stratified by age group, sex, and year.

Exposure of Interest: The exposures of interest were idelalisib and concomitant use of idelalisib with each of the following 13 anti-tumor agents: bendamustine, bortezomib, chlorambucil, cyclophosphamide, doxorubicin, ibritumomab, ibrutinib, lenalidomide, obinutuzumab, ofatumumab, prednisone, rituximab, amd vincristine. In order to be considered concomitant use, a patient must have used the second drug within 7 days prior to the start of the idelalisib exposure episode through 30 days following the end of the idelalisib exposure episode. Exposures were defined by National Drug Codes (NDCs) and Healthcare Common Procedure Coding System (HCPCS) codes. Please refer to Appendix B for generic and brand names and Appendix C for specific HCPCS codes used to define exposures.

<u>Cohort Eligibility Criteria:</u> Those included in the cohort were required to be enrolled in plans with both drug and medical coverage. No specific continuous enrollment time was required prior to the exposure of interest. Gaps in coverage of up to 45 days were allowed. The following age groups were included in the cohort: 18-44, 45-54, 55-64, and 65+ years.

**Exposure Episodes**: Exposure episode lengths were defined using outpatient pharmacy dispensing days supplied to create a sequence of continuous exposure. Exposure episodes were considered continuous if gaps in days supply were less than 30 days. All qualifying incident exposure episodes that occured between July 23, 2014 and December 31, 2015 were examined.

<u>Sensitivity Analyses:</u> A sensitivity analysis was conducted to examine patients with three specific indications, in addition to patients with any indication. Specific indication groups include:

- 1) Chronic lymphocytic leukemia (CLL)
- 2) B-cell follicular non-Hodgkin lymphoma (FL)
- 3) Small lymphocytic lymphoma (SLL)

Individuals were required to have the indication of interest in the one year (365 days) prior or three months (90 days) following the idelalisib dispensing of interest. Indications were defined by International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) codes. Please refer to Appendix D for specific codes used to define each indication.

<u>Limitations:</u> Algorithms to define exposures and indications are imperfect and, therefore, may be misclassified.

Please see Appendix E for the specifications of parameters to be used in the analyses for this request.

**Notes:** Please contact the Sentinel Operations Center Query Fulfillment Team (qt@sentinelsystem.org) for questions and to provide comments/suggestions for future enhancements to this document.



Table of Contents					
<u>Glossary</u>	List of Terms Found in this Report and their Definitions				
Table 1	Idelalisib use with Concomitant use of Specific Anti-Cancer Agents between July 23, 2014 and December 31, 2015, by Concomitant use and Indication				
Table 2	Idelalisib use with Concomitant use of Specific Anti-Cancer Agents between July 23, 2014 and December 31, 2015, by Concomitant use, Indication, and Age Group				
Table 3	Idelalisib use with Concomitant use of Specific Anti-Cancer Agents between July 23, 2014 and December 31, 2015, by Concomitant use, Indication, and Sex				
<u>Table 4</u>	Idelalisib use with Concomitant use of Specific Anti-Cancer Agents between July 23, 2014 and December 31, 2015, by Concomitant use, Indication, and Year				
Appendix A	Available Data in the Sentinel Distributed Database (SDD) as of May 19, 2016				
Appendix B	Generic and Brand Drug Names used to Define Exposures in this Request				
Appendix C	Healthcare Common Procedure Coding System (HCPCS) Codes Used to Define Exposures in this Request				
Appendix D	International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Indications in this Request				
Appendix E	Specifications for Request ID CDER_MPL1R_WP017_NSDP_V01				
Appendix F	Count of Users, Episodes, Dispensings, Total Days Supplied, Years at risk, Eligible Members, Member-Years, Episodes with Events, and Number of Events by Scenario, Age Group, Sex, and Year				



# Glossary of Terms for Analyses Using Cohort Identification and Descriptive Analysis (CIDA) Tool\*

**Amount Supplied** - number of units (pills, tablets, vials) dispensed. Net amount per NDC per dispensing. This is equivalent to the "RxAmt" value in the Sentinel Common Data Mondel (SCDM).

**Blackout Period** - number of days at the beginning of a treatment episode that events are to be ignored. If an event occurs during the blackout period, the episode is excluded.

Care Setting - type of medical encounter or facility where the exposure, event, or condition code was recorded. Possible care settings include: Inpatient Hospital Stay (IP), Non-Acute Institutional Stay (IS), Emergency Department (ED), Ambulatory Visit (AV), and Other Ambulatory Visit (OA). For laboratory results, possible care settings include: Emergency department (E), Home (H), Inpatient (I), Outpatient (O), or Unknown or Missing (U). Along with the Principal Diagnosis Indicator, forms the Care Setting/PDX parameter.

Cohort Definition (drug/exposure)- indicates how the cohort will be defined: (1) 01: Cohort includes only the first valid incident treatment episode during the query period; (2) 02: Cohort includes all valid incident treatment episodes during the query period; (3) 03: Cohort includes all valid incident treatment episodes during the query period until an event occurs. Days Supplied - number of days supplied for all dispensings in qualifying treatment episodes.

**Enrollment Gap** - number of days allowed between two consecutive enrollment periods without breaking a "continuously enrolled" sequence.

**Episodes** - treatment episodes; length of episode is determined by days supplied in one dispensing or consecutive dispensings bridged by the episode gap.

**Episode Gap** - number of days allowed between two (or more) consecutive exposures (dispensings/procedures) to be considered the same treatment episode.

**Event Deduplication** - specifies how events are counted by the MP algorithm: (0) 0: Counts all occurrences of an HOI during an exposure episode; (1) 1: de-duplicates occurrences of the same HOI code and code type on the same day; (2) 2: de-duplicates occurrences of the same HOI group on the same day (e.g., de-duplicates at the group level).

**Exposure Extension Period** - number of days post treatment period in which the outcomes/events are counted for a treatment episode.

Exposure Episode Length - number of days after exposure initiation that is considered "exposed time."

**Lookback Period (pre-existing condition) -** number of days wherein a member is required to have evidence of pre-existing condition (diagnosis/procedure/drug dispensing).

Minimum Days Supplied - specifies a minimum number of days in length of the days supplied for the episode to be

Minimum Episode Duration - specifies a minimum number of days in length of the episode for it to be considered.

**Principal Diagnosis (PDX)** - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values. forms the Caresetting/PDX parameter.

**Query Period** - period in which the modular program looks for exposures and outcomes of interest.

**Treatment Episode Truncation Indicator** - indicates whether observation of the incident query code during follow-up requires truncation of valid treatment episodes. A value of Y indicates that the treatment episodes should be truncated at the first occurrence of an incident query code. A value of N indicates that the treatment episodes should not be truncated at the occurrence of the incident query code.

**Users** - number of members with exposure during the query period. Member must have no evidence of exposure(s) of interest (defined by incidence criteria) in the prior washout period. A user may only be counted once in a query period. **Washout Period (drug/exposure)\*\*** - number of days a user is required to have no evidence of prior exposure (drug dispensing/procedure) and continuous drug and medical coverage prior to an incident treatment episode.

**Washout Period (event/outcome)**\*\* - number of days a user is required to have no evidence of a prior event (procedure/diagnosis) and continuous drug and medical coverage prior to an incident treatment episode.

Years at Risk - number of days supplied plus any episode gaps and exposure extension periods all divided by 365.25.

<sup>\*</sup>all terms may not be used in this report

<sup>\*\*</sup>incident treatment episodes must be incident to both the exposure and the event



Table 1: Idelalisib use with Concomitant use of Specific Anti-Cancer Agents between July 23, 2014 and December 31, 2015, by Concomitant use and Indication

	Users	Dispensings	Days Supplied	Amount Supplied	Eligible Members with Indication	Member-Years	Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
Any idelalisib use										
Any Indication	219	781	21,274	42,354	45,938,002	34,458,133.1	0.00	97.14	3.57	27.24
Chronic lymphocytic leukemia (CLL)	105	405	10,931	21,890	37,389	29,277.0	2.81	104.10	3.86	26.99
B-cell follicular non-Hodgkin lymphoma (FL)	82 171	278 575	7,757 15,782	15,332 31,342	22,182	15,238.4	3.70	94.60	3.39	27.90
Small lymphocytic lymphoma (SLL)	1/1	373	13,762	31,342	86,698	60,976.1	1.97	92.29	3.36	27.45
	Users	Episodes	Percent of Total Idelalisib Users							
Idelalisib and Bendamustine										
Any Indication	9	9	4.11%							
Chronic lymphocytic leukemia (CLL)	1	1	0.95%							
B-cell follicular non-Hodgkin lymphoma (FL)	3	3	3.66%							
Small lymphocytic lymphoma (SLL)	7	7	4.09%	_						
Idelalisib and Bortezomib										
Any Indication	2	2	0.91%							
Chronic lymphocytic leukemia (CLL)	0	0	0.00%							
B-cell follicular non-Hodgkin lymphoma (FL)	0	0	0.00%							
Small lymphocytic lymphoma (SLL)	0	0	0.00%	_						
Idelalisib and Chlorambucil										
Any Indication	5	5	2.28%							
Chronic lymphocytic leukemia (CLL)	5	5	4.76%							
B-cell follicular non-Hodgkin lymphoma (FL)	0	0	0.00%							
Small lymphocytic lymphoma (SLL)	3	3	1.75%							
Idelalisib and Cyclophosphamide										
Any Indication	2	2	0.91%							
Chronic lymphocytic leukemia (CLL)	0	0	0.00%							
B-cell follicular non-Hodgkin lymphoma (FL)	1	1	1.22%							
Small lymphocytic lymphoma (SLL)	2	2	1.17%	_						
Idelalisib and Doxorubicin										
Any Indication	1	1	0.46%							
Chronic lymphocytic leukemia (CLL)	0	0	0.00%							
B-cell follicular non-Hodgkin lymphoma (FL)	0	0	0.00%							
Small lymphocytic lymphoma (SLL)	0	0	0.00%							



Table 1: Idelailsib use with Concomitant use of Spe	cinc Anti-Car	icer Agents i	between July 25, 20		
Idelalisib and Ibritumomab					
Any Indication	0	0	0.00%		
Chronic lymphocytic leukemia (CLL)	0	0	0.00%		
B-cell follicular non-Hodgkin lymphoma (FL)	0	0	0.00%		
Small lymphocytic lymphoma (SLL)	0	0	0.00%		
Idelalisib and Ibrutinib					
Any Indication	21	21	9.59%		
Chronic lymphocytic leukemia (CLL)	15	15	14.29%		
B-cell follicular non-Hodgkin lymphoma (FL)	2	2	2.44%		
Small lymphocytic lymphoma (SLL)	15	15	8.77%		
Idelalisib and Lenalidomide					
Any Indication	5	5	2.28%		
Chronic lymphocytic leukemia (CLL)	0	0	0.00%		
B-cell follicular non-Hodgkin lymphoma (FL)	2	2	2.44%		
Small lymphocytic lymphoma (SLL)	5	5	2.92%		
Idelalisib and Obinutuzumab					
Any Indication	4	4	1.83%		
Chronic lymphocytic leukemia (CLL)	3	3	2.86%		
B-cell follicular non-Hodgkin lymphoma (FL)	1	1	1.22%		
Small lymphocytic lymphoma (SLL)	3	3	1.75%		
Idelalisib and Ofatumumab					
Any Indication	2	2	0.91%		
Chronic lymphocytic leukemia (CLL)	2	2	1.90%		
B-cell follicular non-Hodgkin lymphoma (FL)	0	0	0.00%		
Small lymphocytic lymphoma (SLL)	0	0	0.00%		
Idelalisib and Prednisone					
Any Indication	46	47	21.00%		
Chronic lymphocytic leukemia (CLL)	29	29	27.62%		
B-cell follicular non-Hodgkin lymphoma (FL)	13	13	15.85%		
Small lymphocytic lymphoma (SLL)	34	35	19.88%		



Table 1: Idelalisib use with Concomitant use of Specific Anti-Cancer Agents between July 23, 2014 and December 31, 2015, by Concomitant use and Indication

Idelalisib and Rituximab			
Any Indication	81	85	36.99%
Chronic lymphocytic leukemia (CLL)	51	55	48.57%
B-cell follicular non-Hodgkin lymphoma (FL)	24	24	29.27%
Small lymphocytic lymphoma (SLL)	60	62	35.09%
Idelalisib and Vincristine			
Any Indication	1	1	0.46%
Chronic lymphocytic leukemia (CLL)	0	0	0.00%
B-cell follicular non-Hodgkin lymphoma (FL)	0	0	0.00%
Small lymphocytic lymphoma (SLL)	1	1	0.58%



Table 2: Idelalisib use with Concomitant use of Specific Anti-Cancer Agents between July 23, 2014 and December 31, 2015, by Concomitant use, Indication, and Age Group

<sup>\*</sup>A user may have multiple indications which may result in double counting

	Users	Dispensings	Days Supplied	Amount Supplied	Eligible Members with Indication	Member-Years	Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
Any idelalisib use										
Any Indication										
18-44 Years	9	24	673	1,316	23,614,134	16,258,012.1	0.00	74.78	2.67	28.04
45-54 Years	26	93	2,528	5,026	9,304,524	6,575,969.8	0.00	97.23	3.58	27.18
55-64 Years	67	223	5,965	11,864	8,219,330	5,975,767.6	0.01	89.03	3.33	26.75
65+ Years	119	441	12,108	24,148	6,592,965	5,648,383.5	0.02	101.75	3.71	27.46
Chronic lymphocyti	c leuken	nia (CLL)								
18-44 Years	2	10	279	558	1,028	594.0	1.95	139.50	5.00	27.90
45-54 Years	5	10	282	564	3,173	2,063.2	1.58	56.40	2.00	28.20
55-64 Years	38	127	3,416	6,832	9,262	6,462.2	4.10	89.89	3.34	26.90
65+ Years	62	258	6,954	13,936	25,103	20,157.5	2.47	112.16	4.16	26.95
B-cell follicular non	-Hodgki	n lymphoma	(FL)							
18-44 Years	5	9	244	488	2,015	1,195.7	2.48	48.80	1.80	27.11
45-54 Years	15	59	1,615	3,200	3,545	2,217.5	4.23	107.67	3.93	27.37
55-64 Years	18	74	1,944	3,832	6,511	4,249.9	2.76	108.00	4.11	26.27
65+ Years	44	136	3,954	7,812	10,917	7,575.3	4.03	89.86	3.09	29.07
Small lymphocytic l	ymphon	na (SLL)								
18-44 Years	7	13	364	698	11,206	6,918.1	0.62	52.00	1.86	28.00
45-54 Years	25	90	2,452	4,874	12,933	8,140.3	1.93	98.08	3.60	27.24
55-64 Years	48	165	4,515	8,964	22,742	14,936.2	2.11	94.06	3.44	27.36
65+ Years	92	307	8,451	16,806	42,871	30,981.4	2.15	91.86	3.34	27.53

	Users	Episodes	Percent of Total Idelalisib Users
Idelalisib and Bendan	nustine		
Any Indication			
18-44 Years	1	1	11.11%
45-54 Years	0	0	0.00%
55-64 Years	4	4	5.97%
65+ Years	4	4	3.36%
Chronic lymphocyti	ic leukem	ia (CLL)	
18-44 Years	0	0	0.00%
45-54 Years	0	0	0.00%
55-64 Years	1	1	2.63%
65+ Years	0	0	0.00%
B-cell follicular non	-Hodgkir	ı lymphoma	(FL)
18-44 Years	0	0	0.00%
45-54 Years	0	0	0.00%
55-64 Years	1	1	5.56%
65+ Years	2	2	4.55%
Small lymphocytic	lymphom	na (SLL)	
18-44 Years	1	1	14.29%
45-54 Years	0	0	0.00%
55-64 Years	2	2	4.17%
65+ Years	4	4	4.35%



	Indication, and Age Group					
Idelalisib and Bortezomib						
Any Indication		0	0.000/			
18-44 Years	0	0	0.00%			
45-54 Years	0	0	0.00%			
55-64 Years	2	2	2.99%			
65+ Years	0	0	0.00%			
Chronic lymphocytic			0.000/			
18-44 Years	0	0	0.00%			
45-54 Years	0	0	0.00%			
55-64 Years	0	0	0.00%			
65+ Years	0	0	0.00%			
B-cell follicular non-	_					
18-44 Years	0	0	0.00%			
45-54 Years	0	0	0.00%			
55-64 Years	0	0	0.00%			
65+ Years	0	0	0.00%			
Small lymphocytic l						
18-44 Years	0	0	0.00%			
45-54 Years	0	0	0.00%			
55-64 Years	0	0	0.00%			
65+ Years	0	0	0.00%			
Idelalisib and Chloram	ıbucil					
Any Indication	0	0	0.00%			
18-44 Years	0					
45-54 Years	0	0	0.00%			
55-64 Years	4	4	5.97%			
65+ Years	1	1	0.84%			
Chronic lymphocytic	c leukem	ia (CLL)				
Chronic lymphocytic 18-44 Years	c leukemi 0	<b>ia (CLL)</b> 0	0.00%			
Chronic lymphocytic	c leukem	0 0	0.00% 0.00%			
Chronic lymphocytic 18-44 Years	c leukemi 0	<b>ia (CLL)</b> 0	0.00% 0.00% 10.53%			
Chronic lymphocytic 18-44 Years 45-54 Years 55-64 Years 65+ Years	0 0 0 4 1	0 0 0 4 1	0.00% 0.00% 10.53% 1.61%			
Chronic lymphocytic 18-44 Years 45-54 Years 55-64 Years 65+ Years B-cell follicular non-	0 0 4 1	ia (CLL)  0  0  4  1  Iymphoma	0.00% 0.00% 10.53% 1.61%			
Chronic lymphocytic 18-44 Years 45-54 Years 55-64 Years 65+ Years  B-cell follicular non- 18-44 Years	0 0 4 1 -Hodgkin	0 0 4 1 Iymphomo	0.00% 0.00% 10.53% 1.61%			
Chronic lymphocytic 18-44 Years 45-54 Years 55-64 Years 65+ Years B-cell follicular non-	0 0 4 1	ia (CLL)  0  0  4  1  Iymphoma	0.00% 0.00% 10.53% 1.61% 0.00% 0.00%			
Chronic lymphocytic 18-44 Years 45-54 Years 55-64 Years 65+ Years  B-cell follicular non- 18-44 Years	0 0 4 1 -Hodgkin	0 0 4 1 Iymphomo	0.00% 0.00% 10.53% 1.61% 0.00% 0.00%			
Chronic lymphocytic 18-44 Years 45-54 Years 55-64 Years 65+ Years  B-cell follicular non: 18-44 Years 45-54 Years 55-64 Years 65+ Years	0 0 4 1	(CLL) 0 0 4 1 1 (ymphomo 0 0 0 0	0.00% 0.00% 10.53% 1.61% 0.00% 0.00%			
Chronic lymphocytic 18-44 Years 45-54 Years 55-64 Years 65+ Years  B-cell follicular non- 18-44 Years 45-54 Years 55-64 Years 65+ Years 55-64 Ilymphocytic I	c leukemi 0 0 4 1 -Hodgkin 0 0 0 0	(CLL) 0 0 4 1 1 (Iymphomo 0 0 0 0 0 (SLL)	0.00% 0.00% 10.53% 1.61% 0.00% 0.00% 0.00%			
Chronic lymphocytic 18-44 Years 45-54 Years 55-64 Years 65+ Years  B-cell follicular non- 18-44 Years 45-54 Years 55-64 Years 65+ Years 55-64 Years Small lymphocytic I	c leukemi 0 0 4 1 -Hodgkin 0 0 0 0 ymphom	0 0 4 1 1 Iymphoma 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0.00% 0.00% 10.53% 1.61% 0.00% 0.00% 0.00% 0.00%			
Chronic lymphocytic 18-44 Years 45-54 Years 55-64 Years 65+ Years  B-cell follicular non- 18-44 Years 45-54 Years 55-64 Years 65+ Years 55-64 Ilymphocytic I	c leukemic 0 0 4 1 -Hodgkin 0 0 0 ymphom 0	(CLL) 0 0 4 1 Iymphoma 0 0 0 0 a (SLL) 0	0.00% 0.00% 10.53% 1.61% 0.00% 0.00% 0.00% 0.00% 0.00%			
Chronic lymphocytic 18-44 Years 45-54 Years 55-64 Years 65+ Years  B-cell follicular non- 18-44 Years 45-54 Years 55-64 Years 65+ Years 55-64 Years Small lymphocytic I	c leukemi 0 0 4 1 -Hodgkin 0 0 0 0 ymphom	0 0 4 1 1 Iymphoma 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0.00% 0.00% 10.53% 1.61% 0.00% 0.00% 0.00% 0.00%			



Indication, and Age G						
Idelalisib and Cyclophosphamide						
Any Indication	_		0.000/			
18-44 Years	0	0	0.00%			
45-54 Years	0	0	0.00%			
55-64 Years	0	0	0.00%			
65+ Years	2	2	1.68%			
Chronic lymphocyti			0.000/			
18-44 Years	0	0	0.00%			
45-54 Years	0	0	0.00%			
55-64 Years	0	0	0.00%			
65+ Years	0	0	0.00%			
B-cell follicular non	_					
18-44 Years	0	0	0.00%			
45-54 Years	0	0	0.00%			
55-64 Years	0	0	0.00%			
65+ Years	1	1	2.27%			
Small lymphocytic l	ymphom	a (SLL)				
18-44 Years	0	0	0.00%			
45-54 Years	0	0	0.00%			
55-64 Years	0	0	0.00%			
65+ Years	2	2	2.17%			
Idelalisib and Doxorubicin						
	DICITI					
Any Indication		0	0.000/			
Any Indication 18-44 Years	0	0	0.00%			
Any Indication 18-44 Years 45-54 Years	0 0	0	0.00%			
Any Indication 18-44 Years	0	0	0.00% 1.49%			
Any Indication 18-44 Years 45-54 Years 55-64 Years 65+ Years	0 0 1 0	0 1 0	0.00%			
Any Indication 18-44 Years 45-54 Years 55-64 Years 65+ Years Chronic lymphocyti	0 0 1 0	0 1 0	0.00% 1.49% 0.00%			
Any Indication 18-44 Years 45-54 Years 55-64 Years 65+ Years Chronic lymphocyti 18-44 Years	0 0 1 0 c leukem	0 1 0 ia (CLL)	0.00% 1.49% 0.00%			
Any Indication 18-44 Years 45-54 Years 55-64 Years 65+ Years Chronic lymphocyti	0 0 1 0	0 1 0 ia (CLL) 0	0.00% 1.49% 0.00% 0.00%			
Any Indication 18-44 Years 45-54 Years 55-64 Years 65+ Years Chronic lymphocyti 18-44 Years	0 0 1 0 c leukem	0 1 0 ia (CLL)	0.00% 1.49% 0.00%			
Any Indication 18-44 Years 45-54 Years 55-64 Years 65+ Years Chronic lymphocyti 18-44 Years 45-54 Years 55-64 Years	0 0 1 0 c leukem: 0 0	0 1 0 ia (CLL) 0 0 0	0.00% 1.49% 0.00% 0.00% 0.00% 0.00%			
Any Indication 18-44 Years 45-54 Years 55-64 Years 65+ Years Chronic lymphocyti 18-44 Years 45-54 Years 55-64 Years 65+ Years 65+ Years	0 0 1 0 c leukem. 0 0 0 0	0 1 0 ia (CLL) 0 0 0 0	0.00% 1.49% 0.00% 0.00% 0.00% 0.00% 0.00%			
Any Indication 18-44 Years 45-54 Years 55-64 Years 65+ Years Chronic lymphocyti 18-44 Years 45-54 Years 55-64 Years 65+ Years B-cell follicular non 18-44 Years	0 0 1 0 c leukem: 0 0	0 1 0 ia (CLL) 0 0 0 0 1ymphoma	0.00% 1.49% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%			
Any Indication 18-44 Years 45-54 Years 55-64 Years 65+ Years Chronic lymphocyti 18-44 Years 45-54 Years 55-64 Years 65+ Years 65+ Years	0 0 1 0 c leukem. 0 0 0 0	0 1 0 ia (CLL) 0 0 0 0	0.00% 1.49% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%			
Any Indication 18-44 Years 45-54 Years 55-64 Years 65+ Years Chronic lymphocyti 18-44 Years 45-54 Years 55-64 Years 65+ Years B-cell follicular non 18-44 Years	0 0 1 0 <b>c leukem</b> 0 0 0 0	0 1 0 ia (CLL) 0 0 0 0 1ymphoma	0.00% 1.49% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%			
Any Indication 18-44 Years 45-54 Years 55-64 Years 65+ Years Chronic lymphocyti 18-44 Years 45-54 Years 55-64 Years 65+ Years B-cell follicular non 18-44 Years 45-54 Years 55-64 Years 55-64 Years 65+ Years	0 0 1 0 <b>c leukem.</b> 0 0 0 0 <b>-Hodgkin</b> 0	0 1 0 ia (CLL) 0 0 0 0 1ymphoma 0 0	0.00% 1.49% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%			
Any Indication 18-44 Years 45-54 Years 55-64 Years 65+ Years Chronic lymphocyti 18-44 Years 45-54 Years 55-64 Years 65+ Years B-cell follicular non 18-44 Years 45-54 Years 55-64 Years 55-64 Years 55-64 Years 55-64 Years 55-64 Years 65+ Years	0 0 1 0 <b>c leukem</b> 0 0 0 0 <b>-Hodgkin</b> 0 0	0 1 0 ia (CLL) 0 0 0 0 Iymphoma 0 0 0 0 a (SLL)	0.00% 1.49% 0.00%  0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%			
Any Indication 18-44 Years 45-54 Years 55-64 Years 65+ Years Chronic lymphocyti 18-44 Years 45-54 Years 55-64 Years 65+ Years B-cell follicular non 18-44 Years 45-54 Years 55-64 Years 55-64 Years 55-64 Years 55-64 Years 55-64 Years 65+ Years	0 0 1 0 c leukem 0 0 0 -Hodgkin 0 0 0 0 vymphom 0	0 1 0 ia (CLL) 0 0 0 0 Iymphoma 0 0 0 0 a (SLL)	0.00% 1.49% 0.00%  0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%			
Any Indication 18-44 Years 45-54 Years 55-64 Years 65+ Years Chronic lymphocyti 18-44 Years 45-54 Years 55-64 Years 65+ Years B-cell follicular non 18-44 Years 45-54 Years 55-64 Years 55-64 Years 55-64 Years 55-64 Years 55-64 Years 65+ Years	0 0 1 0 <b>c leukem</b> 0 0 0 0 <b>-Hodgkin</b> 0 0	0 1 0 ia (CLL) 0 0 0 1ymphoma 0 0 0 0	0.00% 1.49% 0.00%  0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%			
Any Indication 18-44 Years 45-54 Years 55-64 Years 65+ Years Chronic lymphocyti 18-44 Years 45-54 Years 55-64 Years 65+ Years B-cell follicular non 18-44 Years 45-54 Years 55-64 Years 55-64 Years 55-64 Years 55-64 Years 55-64 Years 65+ Years	0 0 1 0 c leukem 0 0 0 -Hodgkin 0 0 0 0 vymphom 0	0 1 0 ia (CLL) 0 0 0 0 Iymphoma 0 0 0 0 a (SLL)	0.00% 1.49% 0.00%  0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%			



	Indication, and Age Group					
Idelalisib and Ibritum	omab					
Any Indication						
18-44 Years	0	0	0.00%			
45-54 Years	0	0	0.00%			
55-64 Years	0	0	0.00%			
65+ Years	0	0	0.00%			
Chronic lymphocytic	c leukem	ia (CLL)				
18-44 Years	0	0	0.00%			
45-54 Years	0	0	0.00%			
55-64 Years	0	0	0.00%			
65+ Years	0	0	0.00%			
B-cell follicular non	-Hodgkin	lymphomo	ı (FL)			
18-44 Years	0	0	0.00%			
45-54 Years	0	0	0.00%			
55-64 Years	0	0	0.00%			
65+ Years	0	0	0.00%			
Small lymphocytic l	ymphom	a (SLL)				
18-44 Years	0	0	0.00%			
45-54 Years	0	0	0.00%			
55-64 Years	0	0	0.00%			
65+ Years	0	0	0.00%			
Idelalisib and Ibrutinil	)					
Any Indication						
18-44 Years	2	2	22.22%			
45-54 Years	2	2	7.69%			
55-64 Years	8	8	11.94%			
65+ Years	9	9	7.56%			
Chronic lymphocytic	c leukem	ia (CLL)				
18-44 Years	0	0	0.00%			
45-54 Years	2	2	40.00%			
55-64 Years	6	6	15.79%			
65+ Years	7	7	11.29%			
B-cell follicular non	-Hodgkin	lymphomo	(FL)			
18-44 Years	1	1	20.00%			
45-54 Years	0	0	0.00%			
55-64 Years	0	0	0.00%			
65+ Years	1	1	2.27%			
Small lymphocytic l	ymphom	a (SLL)				
18-44 Years	2	2	28.57%			
45-54 Years	2	2	8.00%			
55-64 Years	5	5	10.42%			
65+ Years	6	6	6.52%			



Indication, and Age G	Indication, and Age Group						
Idelalisib and Lenalidomide							
Any Indication							
18-44 Years	1	1	11.11%				
45-54 Years	0	0	0.00%				
55-64 Years	1	1	1.49%				
65+ Years	3	3	2.52%				
Chronic lymphocytic	c leukem	ia (CLL)					
18-44 Years	0	0	0.00%				
45-54 Years	0	0	0.00%				
55-64 Years	0	0	0.00%				
65+ Years	0	0	0.00%				
B-cell follicular non	-Hodgkin	lymphomo	ı (FL)				
18-44 Years	1	1	20.00%				
45-54 Years	0	0	0.00%				
55-64 Years	0	0	0.00%				
65+ Years	1	1	2.27%				
Small lymphocytic l	ymphom	a (SLL)	_				
18-44 Years	1	1	14.29%				
45-54 Years	0	0	0.00%				
55-64 Years	1	1	2.08%				
65+ Years	3	3	3.26%				
<b>Idelalisib and Obinutu</b>	ızumab						
Any Indication							
18-44 Years	1	1	11.11%				
45-54 Years	0	0	0.00%				
55-64 Years	1	1	1.49%				
65+ Years	2	2	1.68%				
Chronic lymphocytic	c leukem						
18-44 Years	0	0	0.00%				
45-54 Years	0	0	0.00%				
55-64 Years	1	1	2.63%				
65+ Years	2	2	3.23%				
B-cell follicular non	-Hodgkin						
18-44 Years	0	0	0.00%				
45-54 Years	0	0	0.00%				
55-64 Years	0	0	0.00%				
65+ Years	1	1	2.27%				
Small lymphocytic l	ymphom						
18-44 Years	1	1	14.29%				
45-54 Years	0	0	0.00%				
55-64 Years	0	0	0.00%				
65+ Years	2	2	2.17%				



Indication, and Age Group

Indication, and Age Group						
Idelalisib and Ofatum	umab					
Any Indication	0	0	0.009/			
18-44 Years	0	0	0.00%			
45-54 Years	0	0	0.00%			
55-64 Years	0	0	0.00%			
65+ Years	2	2	1.68%			
Chronic lymphocyti			0.009/			
18-44 Years	0	0	0.00%			
45-54 Years	0	0	0.00%			
55-64 Years	0	0	0.00%			
65+ Years	2	2	3.23%			
B-cell follicular non	_					
18-44 Years	0	0	0.00%			
45-54 Years	0	0	0.00%			
55-64 Years	0	0	0.00%			
65+ Years	0	0	0.00%			
Small lymphocytic						
18-44 Years	0	0	0.00%			
45-54 Years	0	0	0.00%			
55-64 Years	0	0	0.00%			
65+ Years	0	0	0.00%			
Idelalisib and Prednisone						
	one					
Any Indication		2	22.22%			
Any Indication 18-44 Years	2	2	22.22%			
Any Indication 18-44 Years 45-54 Years	2	3	11.54%			
Any Indication 18-44 Years 45-54 Years 55-64 Years	2 3 17	3 17	11.54% 25.37%			
Any Indication 18-44 Years 45-54 Years 55-64 Years 65+ Years	2 3 17 24	3 17 25	11.54%			
Any Indication 18-44 Years 45-54 Years 55-64 Years 65+ Years Chronic lymphocyti	2 3 17 24 c leukem	3 17 25 ia (CLL)	11.54% 25.37% 20.17%			
Any Indication 18-44 Years 45-54 Years 55-64 Years 65+ Years Chronic lymphocytic	2 3 17 24 c leukem 1	3 17 25 <i>ia (CLL)</i>	11.54% 25.37% 20.17% 50.00%			
Any Indication 18-44 Years 45-54 Years 55-64 Years 65+ Years Chronic lymphocyti 18-44 Years 45-54 Years	2 3 17 24 c leukem 1 1	3 17 25 <i>ia (CLL)</i> 1 1	11.54% 25.37% 20.17% 50.00% 20.00%			
Any Indication 18-44 Years 45-54 Years 55-64 Years 65+ Years Chronic lymphocyti 18-44 Years 45-54 Years	2 3 17 24 c leukem 1 1 1	3 17 25 <i>ia (CLL)</i> 1 1	11.54% 25.37% 20.17% 50.00% 20.00% 31.58%			
Any Indication 18-44 Years 45-54 Years 55-64 Years 65+ Years Chronic lymphocyti 18-44 Years 45-54 Years 55-64 Years	2 3 17 24 c leukem 1 1 12	3 17 25 ia (CLL) 1 1 12	11.54% 25.37% 20.17% 50.00% 20.00% 31.58% 24.19%			
Any Indication 18-44 Years 45-54 Years 55-64 Years 65+ Years Chronic lymphocyti 18-44 Years 45-54 Years 55-64 Years 65+ Years 65+ Years	2 3 17 24 c leukem 1 1 12 15	3 17 25 ia (CLL) 1 1 12 15	11.54% 25.37% 20.17% 50.00% 20.00% 31.58% 24.19%			
Any Indication 18-44 Years 45-54 Years 55-64 Years 65+ Years Chronic lymphocyti 18-44 Years 45-54 Years 55-64 Years 65+ Years 65+ Years B-cell follicular non	2 3 17 24 c leukem 1 1 12 15 -Hodgkin	3 17 25 ia (CLL) 1 1 12 15 lymphoma	11.54% 25.37% 20.17% 50.00% 20.00% 31.58% 24.19%			
Any Indication 18-44 Years 45-54 Years 55-64 Years 65+ Years Chronic lymphocyti 18-44 Years 45-54 Years 55-64 Years 65+ Years B-cell follicular non 18-44 Years 45-54 Years	2 3 17 24 6 leukem 1 1 12 15 -Hodgkin 0 2	3 17 25 ia (CLL) 1 1 12 15 lymphoma 0 2	11.54% 25.37% 20.17% 50.00% 20.00% 31.58% 24.19% 0.00% 13.33%			
Any Indication 18-44 Years 45-54 Years 55-64 Years 65+ Years Chronic lymphocyti 18-44 Years 45-54 Years 55-64 Years 65+ Years B-cell follicular non 18-44 Years 45-54 Years 55-64 Years	2 3 17 24 c leukem 1 1 12 15 -Hodgkin 0 2 4	3 17 25 ia (CLL) 1 1 12 15 Olymphoma 0 2 4	11.54% 25.37% 20.17% 50.00% 20.00% 31.58% 24.19% 0.00% 13.33% 22.22%			
Any Indication 18-44 Years 45-54 Years 55-64 Years 65+ Years Chronic lymphocyti 18-44 Years 45-54 Years 55-64 Years 65+ Years B-cell follicular non 18-44 Years 45-54 Years 55-64 Years 55-64 Years	2 3 17 24 c leukem 1 1 12 15 -Hodgkin 0 2 4 7	3 17 25 ia (CLL) 1 1 12 15 - lymphoma 0 2 4 7	11.54% 25.37% 20.17% 50.00% 20.00% 31.58% 24.19% 0.00% 13.33%			
Any Indication 18-44 Years 45-54 Years 55-64 Years 65+ Years Chronic lymphocyti 18-44 Years 45-54 Years 55-64 Years 65+ Years B-cell follicular non 18-44 Years 45-54 Years 55-64 Years 55-64 Years 55-64 Years 55-64 Years 55-64 Years 65+ Years	2 3 17 24 c leukem 1 1 12 15 -Hodgkin 0 2 4 7	3 17 25 ia (CLL) 1 1 12 15 1ymphoma 0 2 4 7	11.54% 25.37% 20.17%  50.00% 20.00% 31.58% 24.19%  0.00% 13.33% 22.22% 15.91%			
Any Indication 18-44 Years 45-54 Years 55-64 Years 65+ Years Chronic lymphocytii 18-44 Years 45-54 Years 55-64 Years 65+ Years B-cell follicular non 18-44 Years 45-54 Years 55-64 Years 55-64 Years 55-64 Years 65+ Years 65+ Years 55-64 Years	2 3 17 24 c leukem 1 1 12 15 -Hodgkin 0 2 4 7 (ymphom 1	3 17 25 ia (CLL) 1 1 1 12 15 ilymphoma 0 2 4 7 a (SLL) 1	11.54% 25.37% 20.17%  50.00% 20.00% 31.58% 24.19%  0.00% 13.33% 22.22% 15.91%			
Any Indication  18-44 Years 45-54 Years 55-64 Years 65+ Years Chronic lymphocyti  18-44 Years 45-54 Years 55-64 Years 65+ Years B-cell follicular non 18-44 Years 45-54 Years 55-64 Years 55-64 Years 65+ Years 55-64 Years 65+ Years 55-64 Years 45-54 Years 45-54 Years	2 3 17 24 c leukem 1 1 2 15 -Hodgkin 0 2 4 7 lymphom 1 3	3 17 25 ia (CLL) 1 1 12 15 i lymphoma 0 2 4 7 a (SLL) 1 3	11.54% 25.37% 20.17%  50.00% 20.00% 31.58% 24.19% 0.00% 13.33% 22.22% 15.91%  14.29% 12.00%			
Any Indication 18-44 Years 45-54 Years 55-64 Years 65+ Years Chronic lymphocytii 18-44 Years 45-54 Years 55-64 Years 65+ Years B-cell follicular non 18-44 Years 45-54 Years 55-64 Years 55-64 Years 55-64 Years 65+ Years 65+ Years 55-64 Years	2 3 17 24 c leukem 1 1 12 15 -Hodgkin 0 2 4 7 (ymphom 1	3 17 25 ia (CLL) 1 1 1 12 15 ilymphoma 0 2 4 7 a (SLL) 1	11.54% 25.37% 20.17%  50.00% 20.00% 31.58% 24.19%  0.00% 13.33% 22.22% 15.91%			



Indication, and Age Group					
Idelalisib and Rituxim	ab				
Any Indication	_	2	22.220/		
18-44 Years	2	2	22.22%		
45-54 Years	8	8	30.77%		
55-64 Years	24	25	35.82%		
65+ Years	47	50	39.50%		
Chronic lymphocytic		1 <b>a (CLL)</b> 0	0.00%		
18-44 Years	0				
45-54 Years	2	2	40.00%		
55-64 Years	18	19	47.37%		
65+ Years	31	34	50.00%		
B-cell follicular non	- <b>ноадк</b> іп 1	ı ıympnoma 1	20.00%		
18-44 Years	_	5	33.33%		
45-54 Years	5				
55-64 Years	3	3	16.67%		
65+ Years	15	15	34.09%		
Small lymphocytic l 18-44 Years	ympnom 2	a (SLL) 2	28.57%		
	_	8	32.00%		
45-54 Years	8				
55-64 Years	16	16	33.33%		
65+ Years	34	36	36.96%		
Idelalisib and Vincrist  Any Indication	ille				
18-44 Years	0	0	0.00%		
45-54 Years	0	0	0.00%		
55-64 Years	0	0	0.00%		
65+ Years	1	1	0.84%		
Chronic lymphocyti	c leukem	ia (CLL)			
18-44 Years	0	0	0.00%		
45-54 Years	0	0	0.00%		
55-64 Years	0	0	0.00%		
65+ Years	0	0	0.00%		
B-cell follicular non	-Hodgkin	lymphoma	(FL)		
18-44 Years	0	0	0.00%		
45-54 Years	0	0	0.00%		
55-64 Years	0	0	0.00%		
65+ Years	0	0	0.00%		
Small lymphocytic l	ymphom	a (SLL)			
18-44 Years	0	0	0.00%		
45-54 Years	0	0	0.00%		
55-64 Years	0	0	0.00%		
65+ Years	1	1	1.09%		



Table 3: Idelalisib use with Concomitant use of Specific Anti-Cancer Agents between July 23, 2014 and December 31, 2015, by Concomitant use, Indication, and Sex

							Users / 1K	Days		Days
	Users	Dispensings	Dave Sumplied	Amount Supplied	Eligible Members with Indication	Member-Years	Eligible Members	Supplied/ User	Dispensings / User	Supplied/ Dispensing
Aidalaliailaaa	Users	Dispensings	Days Supplied	Supplied	with indication	Wember-rears	iviembers	User	User	Dispensing
Any idelalisib use										
<b>Any Indication</b> Female	96	336	9,272	18,502	23,519,031	17,719,236.5	0.00	96.58	3.50	27.60
Male	123	445	12,002	23,852	22,416,713	16,737,341.4	0.01	97.58	3.62	26.97
Unknown	0	0	0	0	2,258	1,555.1	0.00			
Chronic lymphocyt	ic leuker	nia (CLL)								
Female	40	164	4,529	9,086	15,900	12,461.7	2.52	113.23	4.10	27.62
Male	65	241	6,402	12,804	21,487	16,814.0	3.03	98.49	3.71	26.56
Unknown	0	0	0	0	2	1.3	0.00			
B-cell follicular noi	n-Hodgki	in lymphoma (i	FL)							
Female	38	121	3,380	6,730	11,031	7,610.8	3.44	88.95	3.18	27.93
Male	44	157	4,377	8,602	11,151	7,627.6	3.95	99.48	3.57	27.88
Unknown	0	0	0	0	0	0.0				
Small lymphocytic	lymphor	na (SLL)								
Female	74	235	6,502	12,934	41,121	29,089.2	1.80	87.86	3.18	27.67
Male	97	340	9,280	18,408	45,573	31,884.3	2.13	95.67	3.51	27.29
Unknown	0	0	0	0	4	2.6	0.00			

## Percent of Total

	Users	Episodes	Idelalisib Users				
Idelalisib and Bendamustine							
Any Indication							
Female	4	4	4.17%				
Male	5	5	4.07%				
Unknown	0	0					
Chronic lymphocyt	Chronic lymphocytic leukemia (CLL)						
Female	0	0	0.00%				
Male	1	1	1.54%				
Unknown	0	0					
B-cell follicular no	n-Hodgki	n lymphoma (	(FL)				
Female	1	1	2.63%				
Male	2	2	4.55%				
Unknown	0	0					
Small lymphocytic	lymphon	na (SLL)					
Female	3	3	4.05%				
Male	4	4	4.12%				
Unknown	0	0					



Indication, and Sex						
Idelalisib and Bortezomib						
Any Indication						
Female	0	0	0.00%			
Male	2	2	1.63%			
Unknown	0	0				
Chronic lymphocy	tic leukem	ia (CLL)				
Female	0	0	0.00%			
Male	0	0	0.00%			
Unknown	0	0				
B-cell follicular no	n-Hodgkin	lymphoma (	(FL)			
Female	0	0	0.00%			
Male	0	0	0.00%			
Unknown	0	0				
Small lymphocytic	lymphom	a (SLL)				
Female	0	0	0.00%			
Male	0	0	0.00%			
Unknown	0	0				
Idelalisib and Chlora						
Idelalisib and Chlora Any Indication						
		2	2.08%			
Any Indication	mbucil	2 3	2.08%			
Any Indication Female Male Unknown	2 3 0	3				
Any Indication Female Male	2 3 0	3				
Any Indication Female Male Unknown	2 3 0	3				
Any Indication Female Male Unknown Chronic lymphocy	2 3 0	3 0 <i>ia (CLL)</i>	2.44%			
Any Indication Female Male Unknown Chronic lymphocy Female	2 3 0 tic leukem	3 0 <i>ia (CLL)</i> 2	2.44%			
Any Indication Female Male Unknown Chronic lymphocy Female Male	2 3 0 tic leukem 2 3 0	3 0 ia (CLL) 2 3 0	2.44%  5.00% 4.62% 			
Any Indication Female Male Unknown Chronic lymphocy Female Male Unknown	2 3 0 tic leukem 2 3 0	3 0 ia (CLL) 2 3 0	2.44%  5.00% 4.62% 			
Any Indication Female Male Unknown Chronic lymphocy Female Male Unknown B-cell follicular no	2 3 0 tic leukem 2 3 0 n-Hodgkin	3 0 ia (CLL) 2 3 0	2.44%  5.00% 4.62% 			
Any Indication Female Male Unknown Chronic lymphocy Female Male Unknown B-cell follicular no	2 3 0 tic leukem 2 3 0 n-Hodgkin	3 0 ia (CLL) 2 3 0 1 lymphoma (	2.44%  5.00% 4.62%  (FL) 0.00%			
Any Indication Female Male Unknown Chronic lymphocy Female Male Unknown B-cell follicular no Female Male	2 3 0 tic leukem 2 3 0 n-Hodgkin 0 0	3 0 iia (CLL) 2 3 0 1 lymphoma ( 0 0	2.44%  5.00% 4.62%  (FL) 0.00%			
Any Indication Female Male Unknown Chronic lymphocy Female Male Unknown  B-cell follicular no Female Male Unknown	2 3 0 tic leukem 2 3 0 n-Hodgkin 0 0	3 0 iia (CLL) 2 3 0 1 lymphoma ( 0 0	2.44%  5.00% 4.62%  (FL) 0.00%			
Any Indication Female Male Unknown Chronic lymphocy Female Male Unknown  B-cell follicular no Female Male Unknown Small lymphocytic	ambucil  2 3 0 tic leukem 2 3 0 n-Hodgkin 0 0 c lymphom	3 0 ia (CLL) 2 3 0 1 lymphoma ( 0 0	2.44% 5.00% 4.62% (FL) 0.00% 0.00%			



Indication, and Sex							
Idelalisib and Cyclophosphamide							
Any Indication		4	4.040/				
Female	1	1	1.04%				
Male	1	1	0.81%				
Unknown	0	0					
Chronic lymphocy	tic leukem						
Female	0	0	0.00%				
Male	0	0	0.00%				
Unknown	0	0					
B-cell follicular no	n-Hodgkir	ı lymphoma					
Female	0	0	0.00%				
Male	1	1	2.27%				
Unknown	0	0					
Small lymphocytic	lymphom	a (SLL)					
Female	1	1	1.35%				
Male	1	1	1.03%				
Unknown	0	0					
<b>Idelalisib and Doxor</b>	ubicin						
Any Indication							
Female	0	0	0.00%				
Male	1	1	0.81%				
Unknown	0	0					
Chronic lymphocy	tic leukem	ia (CLL)					
Female	0	0	0.00%				
Male	0	0	0.00%				
Unknown	0	0					
B-cell follicular no	n-Hodgkir	lymphoma	(FL)				
Female	0	0	0.00%				
Male	0	0	0.00%				
Unknown	0	0					
Small lymphocytic	lymphom	a (SLL)					
Female	0	0	0.00%				
Male	0	0	0.00%				
Unknown	0	0					
Idelalisib and Ibritun	nomab						
Any Indication							
Female	0	0	0.00%				
Male	0	0	0.00%				
Unknown	0	0					
Chronic lymphocy	tic leukem	ia (CLL)					
Female	0	0	0.00%				
Male	0	0	0.00%				
Unknown	0	0					
B-cell follicular no	n-Hodgkir	lymphoma	(FL)				
Female	0	0	0.00%				
Male	0	0	0.00%				
Unknown	0	0					
Small lymphocytic							
Female	0	0	0.00%				
Male	0	0	0.00%				
Unknown		0					
UHKHOWN	0	U					



Table 3: Idelalisib use with Concomitant use of Specific Anti-Cancer Agents between July 23, 2014 and December 31, 2015, by Concomitant use, Indication, and Sex

Indication, and Sex					
Idelalisib and Ibrutin	ib				
Any Indication	_	_	7.200/		
Female	7	7	7.29%		
Male	14	14	11.38%		
Unknown	0	0			
Chronic lymphocyt					
Female	4	4	10.00%		
Male	11	11	16.92%		
Unknown	0	0			
B-cell follicular no	n-Hodgkir				
Female	1	1	2.63%		
Male	1	1	2.27%		
Unknown	0	0			
Small lymphocytic	lymphom	ia (SLL)			
Female	6	6	8.11%		
Male	9	9	9.28%		
Unknown	0	0			
<b>Idelalisib</b> and <b>Lenalic</b>	domide				
Any Indication			2		
Female	3	3	3.13%		
Male	2	2	1.63%		
Unknown	0	0			
Chronic lymphocyt	tic leukem				
Female	0	0	0.00%		
Male	0	0	0.00%		
Unknown	0	0			
B-cell follicular no	n-Hodgkir	ı lymphoma	(FL)		
Female	1	1	2.63%		
Male	1	1	2.27%		
Unknown	0	0			
Small lymphocytic	lymphom	a (SLL)			
Female	3	3	4.05%		
Male	2	2	2.06%		
Unknown	0	0			
<b>Idelalisib and Obinut</b>	tuzumab				
Any Indication		_			
Female	2	2	2.08%		
Male	2	2	1.63%		
Unknown	0	0			
Chronic lymphocyt	tic leukem	ia (CLL)			
Female	1	1	2.50%		
Male	2	2	3.08%		
Unknown	0	0			
B-cell follicular no	n-Hodgkir				
Female	1	1	2.63%		
Male	0	0	0.00%		
Unknown	0	0	<del></del>		
Small lymphocytic	lymphom	a (SLL)			
Female	2	2	2.70%		
Male	1	1	1.03%		
Unknown	0	0			



Table 3: Idelalisib use with Concomitant use of Specific Anti-Cancer Agents between July 23, 2014 and December 31, 2015, by Concomitant use, Indication, and Sex

Indication, and Sex								
	Idelalisib and Ofatumumab							
Any Indication								
Female	1	1	1.04%					
Male	1	1	0.81%					
Unknown	0	0						
Chronic lymphocy	tic leukem							
Female	1	1	2.50%					
Male	1	1	1.54%					
Unknown	0	0						
B-cell follicular no	n-Hodgkin	lymphoma	(FL)					
Female	0	0	0.00%					
Male	0	0	0.00%					
Unknown	0	0						
Small lymphocytic	lymphom	a (SLL)						
Female	0	0	0.00%					
Male	0	0	0.00%					
Unknown	0	0						
Idelalisib and Predni	isone							
Any Indication								
Female	17	18	17.71%					
Male	29	29	23.58%					
Unknown	0	0						
Chronic lymphocy	tic leukem	ia (CLL)						
Female	8	8	20.00%					
Male	21	21	32.31%					
Unknown	0	0						
B-cell follicular no	n-Hodgkin	lymphoma	(FL)					
Female	6	6	15.79%					
Male	7	7	15.91%					
Unknown	0	0						
Small lymphocytic	lymphom	a (SLL)						
Female	14	15	18.92%					
Male	20	20	20.62%					
Unknown	0	0						
Idelalisib and Rituxii								
Any Indication								
Female	29	29	30.21%					
Male	52	56	42.28%					
Unknown	0	0						
Chronic lymphocy		ia (CLL)						
Female	19	19	47.50%					
Male	32	36	49.23%					
Unknown	0	0						
B-cell follicular no			(FL)					
Female	9	9	23.68%					
Male	15	15	34.09%					
Unknown	0	0						
Small lymphocytic								
Female	17	17	22.97%					
Male	43	45	44.33%					
iviale								
Unknown	0	0	44.55%					



Table 3: Idelalisib use with Concomitant use of Specific Anti-Cancer Agents between July 23, 2014 and December 31, 2015, by Concomitant use, Indication, and Sex

mulcation, and sex							
Idelalisib and Vincristine							
Any Indication							
Female	1	1	1.04%				
Male	0	0	0.00%				
Unknown	0	0					
Chronic lymphocyt	Chronic lymphocytic leukemia (CLL)						
Female	0	0	0.00%				
Male	0	0	0.00%				
Unknown	0	0					
B-cell follicular no	n-Hodgkii	n lymphoma (	(FL)				
Female	0	0	0.00%				
Male	0	0	0.00%				
Unknown	0	0					
Small lymphocytic	Small lymphocytic lymphoma (SLL)						
Female	1	1	1.35%				
Male	0	0	0.00%				
Unknown	0	0					



Table 4: Idelalisib use with Concomitant use of Specific Anti-Cancer Agents between July 23, 2014 and December 31, 2015, by Concomitant use, Indication, and Year

	Users	Dispensings	Days Supplied	Amount Supplied	Eligible Members with Indication	Member-Years	Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
Any idelalisib us	е	<u> </u>	, ii	•						, ,
Any Indication	)									
2014	99	212	6,064	12,068	37,580,728	14,924,033.6	0.00	61.25	2.14	28.60
2015	169	569	15,210	30,286	38,386,167	19,534,099.5	0.00	90.00	3.37	26.73
Chronic lymph	ocytic le	ukemia (CLL)								
2014	47	106	3,061	6,122	32,634	12,875.6	1.44	65.13	2.26	28.88
2015	84	299	7,870	15,768	31,284	16,401.4	2.69	93.69	3.56	26.32
B-cell follicula	r non-Ho	dgkin lymphon	na (FL)							
2014	43	91	2,614	5,198	19,019	7,024.3	2.26	60.79	2.12	28.73
2015	58	187	5,143	10,134	17,326	8,214.2	3.35	88.67	3.22	27.50
Small lympho	cytic lym <sub>i</sub>	ohoma (SLL)								
2014	83	172	4,940	9,820	74,416	27,766.1	1.12	59.52	2.07	28.72
2015	126	403	10,842	21,522	68,805	33,210.0	1.83	86.05	3.20	26.90

	Users	Episodes	Percent of Total Idelalisib Users
Idelalisib and Be			idelalisib osers
Any Indication		ile	
2014	, 5	5	5.05%
	-	4	2.37%
2015	4	•	2.57/6
Chronic lymph	•	. ,	2.420/
2014	1	1	2.13%
2015	0	0	0.00%
B-cell follicula	r non-Hoo	lgkin lympho	ma (FL)
2014	2	2	4.65%
2015	1	1	1.72%
Small lympho	cytic lymp	homa (SLL)	
2014	4	4	4.82%
2015	3	3	2.38%
Idelalisib and Bo	rtezomib		
Any Indication	1		
2014	2	2	2.02%
2015	0	0	0.00%
Chronic lymph	ocytic leu	kemia (CLL)	
2014	0	0	0.00%
2015	0	0	0.00%
B-cell follicula	r non-Hoo	lgkin lympho	ma (FL)
2014	0	0	0.00%
2015	0	0	0.00%
Small lympho	cytic lymp	homa (SLL)	
2014	0	0	0.00%
2015	0	0	0.00%



Indication, and			
Idelalisib and Ch	lorambuci	l	
Any Indication			2.020/
2014	3	3	3.03%
2015	2	2	1.18%
Chronic lympl			6.2007
2014	3	3	6.38%
2015	2	2	2.38%
B-cell follicula			
2014	0	0	0.00%
2015	0	0	0.00%
Small lympho			2 410/
2014	2	2	2.41%
2015	1	1	0.79%
Idelalisib and Cy Any Indication		amide	
2014	2	2	2.02%
2015	0	0	0.00%
Chronic lympl			0.0076
2014	0	0	0.00%
2015	0	0	0.00%
B-cell follicula			
2014	1	1	2.33%
2015	0	0	0.00%
Small lympho			0.0070
2014	2	2	2.41%
2015	0	0	0.00%
Idelalisib and Do	oxorubicin		
Idelalisib and Do			
		1	1.01%
Any Indication	า	1 0	1.01% 0.00%
Any Indication 2014	<b>1</b> 0	0	
Any Indication 2014 2015	<b>1</b> 0	0	
Any Indication 2014 2015 Chronic lymph	n 1 0 nocytic leur	0 kemia (CLL)	0.00%
Any Indication 2014 2015 Chronic lymph 2014	n 1 0 nocytic leur 0 0	0 kemia (CLL) 0 0	0.00% 0.00% 0.00%
Any Indication 2014 2015 Chronic lymph 2014 2015	n 1 0 nocytic leur 0 0	0 kemia (CLL) 0 0	0.00% 0.00% 0.00%
Any Indication 2014 2015 Chronic lympl 2014 2015 B-cell folliculo	n 1 0 nocytic leur 0 0 0	0 kemia (CLL) 0 0 gkin lympho	0.00% 0.00% 0.00% ma (FL)
Any Indication 2014 2015 Chronic lymph 2014 2015 B-cell follicula 2014	n 1 0 nocytic leur 0 0 or non-Hod	0 kemia (CLL) 0 0 gkin lympho 0 0	0.00% 0.00% 0.00% ma (FL) 0.00%
Any Indication 2014 2015 Chronic lymph 2014 2015 B-cell follicula 2014 2015	n 1 0 nocytic leur 0 0 or non-Hod	0 kemia (CLL) 0 0 gkin lympho 0 0	0.00% 0.00% 0.00% ma (FL) 0.00%
Any Indication 2014 2015 Chronic lymph 2014 2015 B-cell follicula 2014 2015 Small lympho	n 1 0 nocytic leur 0 0 nor-Hod 0 0 cytic lympi	0 kemia (CLL) 0 0 gkin lympho 0 0 homa (SLL)	0.00% 0.00% 0.00% ma (FL) 0.00% 0.00%
Any Indication 2014 2015 Chronic lympl 2014 2015 B-cell follicula 2014 2015 Small lympho 2014 2015	n 1 0 nocytic leur 0 0 nocytic leur non-Hod 0 0 cytic lympi 0 0 ritumomal	0 kemia (CLL) 0 0 gkin lympho 0 0 homa (SLL) 0	0.00% 0.00% 0.00% ma (FL) 0.00% 0.00%
Any Indication 2014 2015 Chronic lymph 2014 2015 B-cell follicula 2014 2015 Small lympho 2014 2015 Idelalisib and lb Any Indication	n 1 0 nocytic leur 0 0 nocytic leur non-Hod 0 0 cytic lympi 0 0 cytic lympi n 0 nocytic nocytic lympi n 0 nocytic nocy	0 kemia (CLL) 0 0 gkin lympho 0 0 homa (SLL) 0	0.00%  0.00%  0.00%  ma (FL)  0.00%  0.00%  0.00%
Any Indication 2014 2015 Chronic lympl 2014 2015 B-cell follicula 2014 2015 Small lympho 2014 2015	n 1 0 nocytic leur 0 0 nocytic leur non-Hod 0 0 cytic lympi 0 0 ritumomal	0 kemia (CLL) 0 0 gkin lympho 0 0 homa (SLL) 0 0	0.00%  0.00%  0.00%  ma (FL)  0.00%  0.00%  0.00%
Any Indication 2014 2015 Chronic lymph 2014 2015 B-cell follicula 2014 2015 Small lympho 2014 2015 Idelalisib and lb Any Indication 2014 2015	n 1 0 nocytic leur 0 0 nocytic lympi 0 0 cytic lympi 0 0 ritumomal n 0 0 0	0 kemia (CLL) 0 0 gkin lympho 0 0 homa (SLL) 0 0 0	0.00%  0.00%  0.00%  ma (FL)  0.00%  0.00%  0.00%
Any Indication 2014 2015 Chronic lymph 2014 2015 B-cell follicula 2014 2015 Small lympho 2014 2015 Idelalisib and lb Any Indication 2014 2015 Chronic lymph	n 1 0 nocytic leur 0 0 nocytic lympi 0 0 ritumomal n 0 0 nocytic leur	o kemia (CLL) 0 0 gkin lympho 0 0 homa (SLL) 0 0	0.00%  0.00%  0.00%  ma (FL)  0.00%  0.00%  0.00%  0.00%
Any Indication 2014 2015 Chronic lymph 2014 2015 B-cell follicula 2014 2015 Small lympho 2014 2015 Idelalisib and lb Any Indication 2014 2015 Chronic lymph 2014	n 1 0 0 nocytic leur 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	o kemia (CLL) 0 0 gkin lympho 0 homa (SLL) 0 0	0.00%  0.00%  0.00%  ma (FL)  0.00%  0.00%  0.00%  0.00%  0.00%
Any Indication 2014 2015 Chronic lymph 2014 2015 B-cell follicula 2014 2015 Small lympho 2014 2015 Idelalisib and lb Any Indication 2014 2015 Chronic lymph 2014 2015	n 1 0 0 nocytic leur 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0 kemia (CLL) 0 0 gkin lympho 0 0 homa (SLL) 0 0 0 kemia (CLL) 0	0.00%  0.00%  0.00%  ma (FL)  0.00%  0.00%  0.00%  0.00%  0.00%  0.00%
Any Indication 2014 2015 Chronic lymph 2014 2015 B-cell follicula 2014 2015 Small lympho 2014 2015 Idelalisib and lb Any Indication 2014 2015 Chronic lymph 2014 2015 B-cell follicula	n 1 0 0 nocytic leur 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	okemia (CLL) o o gkin lympho o homa (SLL) o o o kemia (CLL) o o gkin lympho	0.00%  0.00%  0.00%  ma (FL)  0.00%  0.00%  0.00%  0.00%  0.00%  0.00%  0.00%
Any Indication 2014 2015 Chronic lymph 2014 2015 B-cell follicula 2014 2015 Small lympho 2014 2015 Idelalisib and lb Any Indication 2014 2015 Chronic lymph 2014 2015 B-cell follicula 2014	n 1 0 0 nocytic leur 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	o kemia (CLL) o o o o o o o o o o o o o o o o o o o	0.00%  0.00%  0.00%  ma (FL)  0.00%  0.00%  0.00%  0.00%  0.00%  0.00%  0.00%  0.00%
Any Indication 2014 2015 Chronic lymph 2014 2015 B-cell follicula 2014 2015 Small lympho 2014 2015 Idelalisib and lb Any Indication 2014 2015 Chronic lymph 2014 2015 B-cell follicula 2014 2015	n 1 0 0 nocytic leur 0 0 0 or ritumomal n 0 0 nocytic leur 0 0 0 nocytic leur non-Hod	o kemia (CLL) 0 0 gkin lympho 0 0 homa (SLL) 0 0 0 kemia (CLL) 0 0	0.00%  0.00%  0.00%  ma (FL)  0.00%  0.00%  0.00%  0.00%  0.00%  0.00%  0.00%
Any Indication 2014 2015 Chronic lymph 2014 2015 B-cell follicula 2014 2015 Small lympho 2014 2015 Idelalisib and lb Any Indication 2014 2015 Chronic lymph 2014 2015 B-cell follicula 2014 2015 Small lympho Small lympho	n 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	o kemia (CLL) o o o o o o o o o o o o o o o o o o o	0.00% 0.00% 0.00% ma (FL) 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Any Indication 2014 2015 Chronic lymph 2014 2015 B-cell follicula 2014 2015 Small lympho 2014 2015 Idelalisib and lb Any Indication 2014 2015 Chronic lymph 2014 2015 B-cell follicula 2014 2015	n 1 0 0 nocytic leur 0 0 0 or ritumomal n 0 0 nocytic leur 0 0 0 nocytic leur non-Hod	o kemia (CLL) 0 0 gkin lympho 0 0 homa (SLL) 0 0 0 kemia (CLL) 0 0	0.00%  0.00%  0.00%  ma (FL)  0.00%  0.00%  0.00%  0.00%  0.00%  0.00%  0.00%  0.00%



Indication, and Year					
Idelalisib and II					
Any Indication					
2014	15	15	15.15%		
2015	6	6	3.55%		
Chronic lymp					
2014	9	9	19.15%		
2015	6	6	7.14%		
B-cell follicul					
2014	2	2	4.65%		
2015	0	0	0.00%		
Small lympho			4.4.460/		
2014	12	12	14.46%		
2015	3	3	2.38%		
Idelalisib and L		e			
Any Indication 2014	on 4	4	4.04%		
	•				
2015 Chronic lymp	1	l komia (CLI)	0.59%		
2014		0	0.00%		
	0		0.00%		
2015	0	0			
<b>B-cell follicul</b> 2014		gkin iympnol 2	ma (FL) 4.65%		
	2	_			
2015	0	0	0.00%		
Small lympho 2014	осутіс іутрі 4	noma (SLL) 4	4.82%		
	·	1	0.79%		
2015	1	1	0.79%		
Idalalisih and C	\h:nt	a la			
Idelalisib and C		ab			
Any Indication 2014		<b>ab</b> 3	3.03%		
Any Indication 2014	on 3		3.03% 0.59%		
Any Indication 2014 2015	on 3 1	3 1			
Any Indication 2014	on 3 1	3 1			
2014 2015 Chronic lymp 2014	on 3 1 ohocytic leul 2	3 1 Kemia (CLL)	0.59% 4.26%		
2014 2015 Chronic lymp 2014 2015	on 3 1 ohocytic leul 2 1	3 1 kemia (CLL) 2 1	0.59% 4.26% 1.19%		
2014 2015 Chronic lymp 2014	on 3 1 ohocytic leul 2 1	3 1 kemia (CLL) 2 1	0.59% 4.26% 1.19%		
Any Indication 2014 2015 Chronic lymp 2014 2015 B-cell follicul 2014	on 3 1 phocytic leul 2 1 ar non-Hod	3 1 kemia (CLL) 2 1 gkin lympho	0.59% 4.26% 1.19% ma (FL)		
Any Indication 2014 2015 Chronic lymp 2014 2015 B-cell follicul 2014 2015	on  3 1 phocytic leul 2 1 far non-Hod 1 0	3 1 kemia (CLL) 2 1 gkin lympho	0.59% 4.26% 1.19% ma (FL) 2.33%		
Any Indication 2014 2015 Chronic lymp 2014 2015 B-cell follicul 2014	on  3 1 phocytic leul 2 1 far non-Hod 1 0	3 1 kemia (CLL) 2 1 gkin lympho	0.59% 4.26% 1.19% ma (FL) 2.33%		
Any Indication 2014 2015 Chronic lymp 2014 2015 B-cell follicul 2014 2015 Small lympho	on  3 1 phocytic leul 2 1 lar non-Hod 1 0 pocytic lympl	3 1 kemia (CLL) 2 1 gkin lympho 1 0 homa (SLL)	0.59% 4.26% 1.19% ma (FL) 2.33% 0.00%		
Any Indication 2014 2015 Chronic lymp 2014 2015 B-cell follicul 2014 2015 Small lympho 2014 2015	on  3 1 shocytic leul 2 1 far non-Hod 1 0 cocytic lympl 3 0	3 1 kemia (CLL) 2 1 gkin lympho 1 0 homa (SLL) 3	0.59%  4.26% 1.19%  ma (FL) 2.33% 0.00%  3.61%		
Any Indication 2014 2015 Chronic lymp 2014 2015 B-cell follicul 2014 2015 Small lympho 2014	on  3 1 shocytic leul 2 1 lar non-Hod 1 0 cocytic lympl 3 0 Offatumumal	3 1 kemia (CLL) 2 1 gkin lympho 1 0 homa (SLL) 3	0.59%  4.26% 1.19%  ma (FL) 2.33% 0.00%  3.61%		
Any Indication 2014 2015 Chronic lymp 2014 2015 B-cell follicul 2014 2015 Small lympho 2014 2015	on  3 1 shocytic leul 2 1 lar non-Hod 1 0 cocytic lympl 3 0 Offatumumal	3 1 kemia (CLL) 2 1 gkin lympho 1 0 homa (SLL) 3	0.59%  4.26% 1.19%  ma (FL) 2.33% 0.00%  3.61%		
Any Indication 2014 2015 Chronic lymp 2014 2015 B-cell follicul 2014 2015 Small lymph 2014 2015 Idelalisib and Company Indication	on  3 1 phocytic leul 2 1 far non-Hod 1 0 pocytic lympi 3 0 phatumumal	3 1 kemia (CLL) 2 1 gkin lympho 1 0 homa (SLL) 3 0	0.59%  4.26% 1.19%  ma (FL) 2.33% 0.00%  3.61% 0.00%		
Any Indication 2014 2015 Chronic lymp 2014 2015 B-cell follicul 2014 2015 Small lymph 2014 2015 Idelalisib and Company and Com	on  3 1 phocytic leul 2 1 far non-Hod 1 0 pocytic lympl 3 0 pfatumumal on 2 0	3 1 2 1 gkin lympho 1 0 noma (SLL) 3 0 2	0.59%  4.26% 1.19%  ma (FL) 2.33% 0.00%  3.61% 0.00%		
Any Indication 2014 2015 Chronic lymp 2014 2015 B-cell follicul 2014 2015 Small lymph 2014 2015 Idelalisib and Company and Com	on  3 1 phocytic leul 2 1 far non-Hod 1 0 pocytic lympl 3 0 pfatumumal on 2 0	3 1 2 1 gkin lympho 1 0 noma (SLL) 3 0 2	0.59%  4.26% 1.19%  ma (FL) 2.33% 0.00%  3.61% 0.00%		
Any Indication 2014 2015 Chronic lymp 2014 2015 B-cell follicul 2014 2015 Small lymph 2014 2015 Idelalisib and C Any Indication 2014 2015 Chronic lymp	on  3 1 ohocytic leul 2 1 lar non-Hod 1 0 ocytic lympl 3 0 Ofatumumal on 2 0 ohocytic leul	3 1 Remia (CLL) 2 1 gkin lympho 1 0 homa (SLL) 3 0 2 0	0.59%  4.26% 1.19%  ma (FL) 2.33% 0.00%  3.61% 0.00%  2.02% 0.00%		
Any Indication 2014 2015 Chronic lymp 2014 2015 B-cell follicul 2014 2015 Small lympho 2014 2015 Idelalisib and Company and Co	on  3 1 shocytic leui 2 1 far non-Hod 1 0 cocytic lympi 3 0 Difatumumal on 2 0 shocytic leui 2 0	3 1 kemia (CLL) 2 1 gkin lympho 1 0 homa (SLL) 3 0 2 0 kemia (CLL) 2	0.59%  4.26% 1.19%  ma (FL) 2.33% 0.00%  3.61% 0.00%  2.02% 0.00%  4.26% 0.00%		
Any Indication 2014 2015 Chronic lymp 2014 2015 B-cell follicul 2014 2015 Small lymph 2014 2015 Idelalisib and C Any Indication 2014 2015 Chronic lymp 2014 2015	on  3 1 shocytic leui 2 1 far non-Hod 1 0 cocytic lympi 3 0 Difatumumal on 2 0 shocytic leui 2 0	3 1 kemia (CLL) 2 1 gkin lympho 1 0 homa (SLL) 3 0 2 0 kemia (CLL) 2	0.59%  4.26% 1.19%  ma (FL) 2.33% 0.00%  3.61% 0.00%  2.02% 0.00%  4.26% 0.00%		
Any Indication 2014 2015 Chronic lymp 2014 2015 B-cell follicul 2014 2015 Small lymph 2014 2015 Idelalisib and Company 2014 2015 Chronic lymp 2014 2015 B-cell follicul 2014 2015	on  3 1 phocytic leul 2 1 far non-Hod 1 0 pocytic lympl 3 0 phocytic leul 2 0 phocytic leul 2 0 phocytic leul 2 0 far non-Hod 0 0	3 1 2 1 gkin lympho 1 0 noma (SLL) 3 0 2 0 exemia (CLL) 2 0 gkin lympho 0 0	0.59%  4.26% 1.19%  ma (FL) 2.33% 0.00%  3.61% 0.00%  2.02% 0.00%  4.26% 0.00%		
Any Indication 2014 2015 Chronic lymp 2014 2015 B-cell follicul 2014 2015 Small lymph 2014 2015 Idelalisib and C Any Indication 2014 2015 Chronic lymp 2014 2015 B-cell follicul 2014	on  3 1 phocytic leul 2 1 far non-Hod 1 0 pocytic lympl 3 0 phocytic leul 2 0 phocytic leul 2 0 phocytic leul 2 0 far non-Hod 0 0	3 1 2 1 gkin lympho 1 0 noma (SLL) 3 0 2 0 exemia (CLL) 2 0 gkin lympho 0 0	0.59%  4.26% 1.19%  ma (FL) 2.33% 0.00%  3.61% 0.00%  2.02% 0.00%  4.26% 0.00%  ma (FL) 0.00%		
Any Indication 2014 2015 Chronic lymp 2014 2015 B-cell follicul 2014 2015 Small lymph 2014 2015 Idelalisib and Company 2014 2015 Chronic lymp 2014 2015 B-cell follicul 2014 2015	on  3 1 phocytic leul 2 1 far non-Hod 1 0 pocytic lympl 3 0 phocytic leul 2 0 phocytic leul 2 0 phocytic leul 2 0 far non-Hod 0 0	3 1 2 1 gkin lympho 1 0 noma (SLL) 3 0 2 0 exemia (CLL) 2 0 gkin lympho 0 0	0.59%  4.26% 1.19%  ma (FL) 2.33% 0.00%  3.61% 0.00%  2.02% 0.00%  4.26% 0.00%  ma (FL) 0.00%		
Any Indication 2014 2015 Chronic lymp 2014 2015 B-cell follicul 2014 2015 Small lymph 2014 2015 Idelalisib and C Any Indication 2014 2015 Chronic lymp 2014 2015 B-cell follicul 2014 2015 Small lymph 2014 2015 Small lymph	on  3 1 ohocytic leui 2 1 dar non-Hod 1 0 ocytic lympi 3 0 othocytic leui 2 0 ohocytic leui 0 ocytic lympi ocytic leui 0 ocytic lympi ocytic lympi	3 1 Remia (CLL) 2 1 gkin lympho 1 0 noma (SLL) 3 0 2 0 Remia (CLL) 2 0 gkin lympho 0 0 noma (SLL)	0.59%  4.26% 1.19%  ma (FL) 2.33% 0.00%  3.61% 0.00%  2.02% 0.00%  4.26% 0.00%  ma (FL) 0.00%		



Indication, and Year							
	Idelalisib and Prednisone						
Any Indication	n						
2014	20	20	20.20%				
2015	26	27	15.38%				
Chronic lympi	Chronic lymphocytic leukemia (CLL)						
2014	11	11	23.40%				
2015	18	18	21.43%				
B-cell follicule	ır non-Hod	gkin lymphoi	ma (FL)				
2014	8	8	18.60%				
2015	5	5	8.62%				
Small lympho	cytic lympl	homa (SLL)					
2014	17	17	20.48%				
2015	17	18	13.49%				
Idelalisib and Ri	tuximab						
Any Indication	n						
2014	42	42	42.42%				
2015	41	43	24.26%				
Chronic lympi	hocytic leul	kemia (CLL)					
2014	25	25	53.19%				
2015	28	30	33.33%				
B-cell follicule	ar non-Hod	gkin lymphoi	ma (FL)				
2014	15	15	34.88%				
2015	9	9	15.52%				
Small lympho	cytic lympl	homa (SLL)					
2014	32	32	38.55%				
2015	29	30	23.02%				
Idelalisib and Vi	ncristine						
Any Indicatio	n						
2014	1	1	1.01%				
2015	0	0	0.00%				
Chronic lymp	hocytic leul	kemia (CLL)					
2014	0	0	0.00%				
2015	0	0	0.00%				
B-cell follicule	ar non-Hod	gkin lymphoi	ma (FL)				
2014	0	0	0.00%				
2015	0	0	0.00%				
Small lympho	cytic lympl	homa (SLL)					
2014	1	1	1.20%				
2015	0	0	0.00%				
	-						



# Appendix A: Available Data in the Sentinel Distributed Database (SDD) as of May 19, 2016

DP ID	Start Date	End Date
DP0001	7/23/2014	9/30/2015
DP0002	7/23/2014	4/30/2015
DP0003	7/23/2014	10/31/2014
DP0004	7/23/2014	6/30/2015
DP0005	7/23/2014	2/28/2015
DP0006	7/23/2014	7/31/2014
DP0007	7/23/2014	6/30/2012
DP0008	7/23/2014	7/31/2015
DP0009	7/23/2014	10/31/2015
DP0010	7/23/2014	11/30/2015
DP0011	7/23/2014	9/30/2015
DP0012	7/23/2014	12/31/2015
DP0013	7/23/2014	11/30/2015
DP0014	7/23/2014	6/30/2015
DP0015	7/23/2014	12/31/2014



# Appendix B: Generic and Brand Drug Names used to Define Exposures in this Request

Generic Name	Brand Name
DOXORUBICIN HCL	Adriamycin
DOXORUBICIN HCL	Adriamycin PFS
OFATUMUMAB	Arzerra
BENDAMUSTINE HCL	Bendeka
CHLORAMBUCIL	chlorambucil
CYCLOPHOSPHAMIDE	cyclophosphamide
CYCLOPHOSPHAMIDE	cyclophosphamide (bulk)
PREDNISONE	Deltasone
DOXORUBICIN HCL PEGYLATED LIPOSOMAL	Doxil
DOXORUBICIN HCL	doxorubicin
DOXORUBICIN HCL PEGYLATED LIPOSOMAL	doxorubicin, peg-liposomal
OBINUTUZUMAB	Gazyva
IBRUTINIB	Imbruvica
CHLORAMBUCIL	Leukeran
DOXORUBICIN HCL PEGYLATED LIPOSOMAL	Lipodox
DOXORUBICIN HCL PEGYLATED LIPOSOMAL	Lipodox 50
VINCRISTINE SULFATE LIPOSOMAL	Marqibo
PREDNISONE	prednisone
PREDNISONE	Prednisone Intensol
PREDNISONE MICRONIZED	prednisone micronized (bulk)
PREDNISONE	Rayos
LENALIDOMIDE	Revlimid
RITUXIMAB	Rituxan
BENDAMUSTINE HCL	Treanda
BORTEZOMIB	Velcade
VINCRISTINE SULFATE	Vincasar PFS
VINCRISTINE SULFATE	vincristine
KIT FOR PREP INDIUM-111/IBRITUMOMAB TIUXETAN/ALBUMIN HUMAN	Zevalin (In-111)
KIT FOR PREP YTTRIUM-90/IBRITUMOMAB TIUXETAN/ALBUMIN HUMAN	Zevalin (Y-90)
IDELALISIB	Zydelig



# Appendix C: Healthcare Common Procedure Coding System (HCPCS) Codes Used to Define Exposures in this Request

Code	Code Type	Description
Bendan		
J9033	HCPCS	Injection, bendamustine HCl, 1 mg
Bortezo	mib	
J9041	HCPCS	Injection, bortezomib, 0.1 mg
Chloran	nbucil	
S0172	HCPCS	Chlorambucil, oral, 2 mg
Cycloph	nosphamide	
J8530	HCPCS	Cyclophosphamide, oral, 25 mg
J9070	HCPCS	Cyclophosphamide, 100 mg
Doxoru	bicin	
J9000	HCPCS	Injection, doxorubicin HCl, 10 mg
Q2049	HCPCS	Injection, doxorubicin hydrochloride, liposomal, imported Lipodox, 10 mg
Q2050	HCPCS	Injection, doxorubicin hydrochloride, liposomal, not otherwise specified, 10 mg
<b>Ibritum</b>	omab	
A9542	HCPCS	Indium In-111 ibritumomab tiuxetan, diagnostic, per study dose, up to 5 millicuries
A9543	HCPCS	Yttrium Y-90 ibritumomab tiuxetan, therapeutic, per treatment dose, up to 40 millicuries
Obinuti	uzumab	
C9021	HCPCS	Injection, obinutuzumab, 10 mg
J9301	HCPCS	Injection, obinutuzumab, 10 mg
<b>Ofatum</b>	umab	
J9302	HCPCS	Injection, ofatumumab, 10 mg
<b>Prednis</b>	one	
J7506	HCPCS	Prednisone, oral, per 5 mg
Rituxim	ıab	
J9310	HCPCS	Injection, rituximab, 100 mg
Vincrist	ine	
J9370	HCPCS	Vincristine sulfate, 1 mg
J9371	HCPCS	Injection, vincristine sulfate liposome, 1 mg



Appendix D: International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Indications in this Request

Code	Code Type	Description
Chronic lyr	nphocytic leuk	·
204.1	ICD-9-CM	Chronic Lymphoid Leukemia, any
204.10	ICD-9-CM	Chronic Lymphoid Leukemia, no prior
204.11	ICD-9-CM	Chronic Lymphoid Leukemia, remission
204.12	ICD-9-CM	Chronic Lymphoid Leukemia, relapse
C91.1	ICD-10-CM	Chronic Lymphoid Leukemia, any
C91.10	ICD-10-CM	Chronic Lymphoid Leukemia, no prior
C91.11	ICD-10-CM	Chronic Lymphoid Leukemia, remission
C91.12	ICD-10-CM	Chronic Lymphoid Leukemia, relapse
202.8	hocytic lymph ICD-9-CM	Small lymphocytic lymphoma (Other malignant lymphomas)
202.80	ICD-9-CM	Small lymphocytic lymphoma (Other malignant lymphomas, unspecified extranodal solid organ)
202.81	ICD-9-CM	Small lymphocytic lymphoma (Other malignant lymphomas, head face neck)
202.82	ICD-9-CM	Small lymphocytic lymphoma (Other malignant lymphomas, intrathoracic)
202.83	ICD-9-CM	Small lymphocytic lymphoma (Other malignant lymphomas, intra-abdominal)
202.84	ICD-9-CM	Small lymphocytic lymphoma (Other malignant lymphomas, axilla upper limb)
202.85	ICD-9-CM	Small lymphocytic lymphoma (Other malignant lymphomas, inguinal lower limb)
202.86	ICD-9-CM	Small lymphocytic lymphoma (Other malignant lymphomas, intrapelvic)
202.87	ICD-9-CM	Small lymphocytic lymphoma (Other malignant lymphomas, spleen)
202.88	ICD-9-CM	Small lymphocytic lymphoma (Other malignant lymphomas, multiple)
83.0	ICD-10-CM	Small lymphocytic lymphoma (Non-follicular lymphoma, small cell B-cell lymphoma)
83.00	ICD-10-CM	Small lymphocytic lymphoma (Non-follicular lymphoma, small cell B-cell lymphoma, unspecified)
83.01	ICD-10-CM	Small lymphocytic lymphoma (Non-follicular lymphoma, small cell B-cell lymphoma, head face neck)
83.02	ICD-10-CM	Small lymphocytic lymphoma (Non-follicular lymphoma, small cell B-cell lymphoma, intrathoracic)
83.03	ICD-10-CM	Small lymphocytic lymphoma (Non-follicular lymphoma, small cell B-cell lymphoma, intra-abdominal)
83.04	ICD-10-CM	Small lymphocytic lymphoma (Non-follicular lymphoma, small cell B-cell lymphoma, axilla upper limb) Small lymphocytic lymphoma (Non-follicular lymphoma, small cell B-cell lymphoma, inguinal lower limb)
83.04 83.06	ICD-10-CM ICD-10-CM	Small lymphocytic lymphoma (Non-follicular lymphoma, small cell B-cell lymphoma, intrapelvic)
83.07	ICD-10-CM	Small lymphocytic lymphoma (Non-follicular lymphoma, small cell B-cell lymphoma, spleen)
83.08	ICD-10-CM	Small lymphocytic lymphoma (Non-follicular lymphoma, small cell B-cell lymphoma, multiple)
83.09	ICD-10-CM	Small lymphocytic lymphoma (Non-follicular lymphoma, small cell B-cell lymphoma, extranodal solid organ)
		kin lymphoma (FL)
202.0	ICD-9-CM	Follicular lymphoma (Nodular lymphoma)
202.00	ICD-9-CM	Follicular lymphoma (Nodular lymphoma, unspecified extranodal solid organ)
202.01	ICD-9-CM	Follicular lymphoma (Nodular lymphoma, head face neck)
202.02	ICD-9-CM	Follicular lymphoma (Nodular lymphoma, intrathoracic)
202.03	ICD-9-CM	Follicular lymphoma (Nodular lymphoma, intra-abdominal)
202.04	ICD-9-CM	Follicular lymphoma (Nodular lymphoma, axilla upper limb)
202.05	ICD-9-CM	Follicular lymphoma (Nodular lymphoma, inguinal lower limb)
202.06	ICD-9-CM	Follicular lymphoma (Nodular lymphoma, intrapelvic)
202.07	ICD-9-CM	Follicular lymphoma (Nodular lymphoma, spleen)
202.08 C82	ICD-9-CM ICD-10-CM	Follicular lymphoma (Nodular lymphoma, multiple) Follicular lymphoma, any
C82.0	ICD-10-CM	Follicular lymphoma grade I,
C82.00	ICD-10-CM	Follicular lymphoma grade I, unspecified site
C82.01	ICD-10-CM	Follicular lymphoma grade I, lymph nodes of head, face, and neck
C82.02	ICD-10-CM	Follicular lymphoma grade I, intrathoracic lymph nodes
C82.03	ICD-10-CM	Follicular lymphoma grade I, intra-abdominal lymph nodes
C82.04	ICD-10-CM	Follicular lymphoma grade I, lymph nodes of axilla and upper limb
C82.05	ICD-10-CM	Follicular lymphoma grade I, lymph nodes of inguinal region and lower limb
C82.06	ICD-10-CM	Follicular lymphoma grade I, intrapelvic lymph nodes
C82.07	ICD-10-CM	Follicular lymphoma grade I, spleen
C82.08	ICD-10-CM	Follicular lymphoma grade I, lymph nodes of multiple sites
C82.09	ICD-10-CM	Follicular lymphoma grade I, extranodal and solid organ sites
C82.1	ICD-10-CM	Follicular lymphoma grade II,
C82.10	ICD-10-CM	Follicular lymphoma grade II, unspecified site
C82.11	ICD-10-CM	Follicular lymphoma grade II, lymph nodes of head, face, and neck
C82.12	ICD-10-CM	Follicular lymphoma grade II, intrathoracic lymph nodes



B-cell foll	icular non-Hods	gkin lymphoma (FL)
C82.13	ICD-10-CM	Follicular lymphoma grade II, intra-abdominal lymph nodes
C82.14	ICD-10-CM	Follicular lymphoma grade II, lymph nodes of axilla and upper limb
C82.15	ICD-10-CM	Follicular lymphoma grade II, lymph nodes of inguinal region and lower limb
C82.16	ICD-10-CM	Follicular lymphoma grade II, intrapelvic lymph nodes
C82.17	ICD-10-CM	Follicular lymphoma grade II, spleen
C82.18	ICD-10-CM	Follicular lymphoma grade II, lymph nodes of multiple sites
C82.19	ICD-10-CM	Follicular lymphoma grade II, extranodal and solid organ sites
C82.2	ICD-10-CM	Follicular lymphoma grade III,
C82.20	ICD-10-CM	Follicular lymphoma grade III, unspecified site
C82.21	ICD-10-CM	Follicular lymphoma grade III, lymph nodes of head, face, and neck
C82.22	ICD-10-CM	Follicular lymphoma grade III, intrathoracic lymph nodes
C82.23	ICD-10-CM	Follicular lymphoma grade III, intra-abdominal lymph nodes
C82.24	ICD-10-CM	Follicular lymphoma grade III, lymph nodes of axilla and upper limb
C82.25	ICD-10-CM	Follicular lymphoma grade III, lymph nodes of inguinal region and lower limb
C82.26	ICD-10-CM	Follicular lymphoma grade III, intrapelvic lymph nodes
C82.27	ICD-10-CM	Follicular lymphoma grade III, spleen
C82.28	ICD-10-CM	Follicular lymphoma grade III, lymph nodes of multiple sites
C82.29	ICD-10-CM	Follicular lymphoma grade III, extranodal and solid organ sites
C82.3	ICD-10-CM	Follicular lymphoma grade IIIa,
C82.30	ICD-10-CM	Follicular lymphoma grade IIIa, unspecified site
C82.31	ICD-10-CM	Follicular lymphoma grade IIIa, lymph nodes of head, face, and neck
C82.32	ICD-10-CM	Follicular lymphoma grade Illa, intrathoracic lymph nodes
C82.33	ICD-10-CM	Follicular lymphoma grade IIIa, intra-abdominal lymph nodes
C82.34	ICD-10-CM	Follicular lymphoma grade IIIa, lymph nodes of axilla and upper limb
C82.35	ICD-10-CM	Follicular lymphoma grade IIIa, lymph nodes of inguinal region and lower limb
C82.36	ICD-10-CM	Follicular lymphoma grade IIIa, intrapelvic lymph nodes
C82.37	ICD-10-CM	Follicular lymphoma grade IIIa, spleen
C82.38	ICD-10-CM	Follicular lymphoma grade IIIa, lymph nodes of multiple sites
C82.39	ICD-10-CM	Follicular lymphoma grade IIIa, extranodal and solid organ sites
C82.4	ICD-10-CM	Follicular lymphoma grade IIIb,
C82.40	ICD-10-CM	Follicular lymphoma grade IIIb, unspecified site
C82.41	ICD-10-CM	Follicular lymphoma grade IIIb, lymph nodes of head, face, and neck
C82.42	ICD-10-CM	Follicular lymphoma grade IIIb, intrathoracic lymph nodes
C82.43	ICD-10-CM	Follicular lymphoma grade IIIb, intra-abdominal lymph nodes
C82.44 C82.45	ICD-10-CM	Follicular lymphoma grade IIIb, lymph nodes of axilla and upper limb
C82.45	ICD-10-CM ICD-10-CM	Follicular lymphoma grade IIIb, lymph nodes of inguinal region and lower limb  Follicular lymphoma grade IIIb, intrapelvic lymph nodes
C82.40	ICD-10-CM	Follicular lymphoma grade IIIb, spleen
C82.47	ICD-10-CM	Follicular lymphoma grade IIIb, lymph nodes of multiple sites
C82.49	ICD-10-CM	Follicular lymphoma grade IIIb, extranodal and solid organ sites
C82.5	ICD-10-CM	Follicular lymphoma(Diffuse follicle center lymphoma, )
C82.50	ICD-10-CM	Follicular lymphoma(Diffuse follicle center lymphoma, unspecified site)
C82.51	ICD-10-CM	Follicular lymphoma(Diffuse follicle center lymphoma, lymph nodes of head, face, and neck)
C82.52	ICD-10-CM	Follicular lymphoma(Diffuse follicle center lymphoma, intrathoracic lymph nodes)
C82.53	ICD-10-CM	Follicular lymphoma(Diffuse follicle center lymphoma, intra-abdominal lymph nodes)
C82.54	ICD-10-CM	Follicular lymphoma(Diffuse follicle center lymphoma, lymph nodes of axilla and upper limb)
C82.55	ICD-10-CM	Follicular lymphoma(Diffuse follicle center lymphoma, lymph nodes of inguinal region and lower limb)
C82.56	ICD-10-CM	Follicular lymphoma(Diffuse follicle center lymphoma, intrapelvic lymph nodes)
C82.57	ICD-10-CM	Follicular lymphoma(Diffuse follicle center lymphoma, spleen)
C82.58	ICD-10-CM	Follicular lymphoma(Diffuse follicle center lymphoma, lymph nodes of multiple sites)
C82.59	ICD-10-CM	Follicular lymphoma(Diffuse follicle center lymphoma, extranodal and solid organ sites)
C82.6	ICD-10-CM	Follicular lymphoma(Cutaneous follicle center lymphoma, )
C82.60	ICD-10-CM	Follicular lymphoma(Cutaneous follicle center lymphoma, unspecified site)
C82.61	ICD-10-CM	Follicular lymphoma(Cutaneous follicle center lymphoma, lymph nodes of head, face, and neck)
C82.62	ICD-10-CM	Follicular lymphoma(Cutaneous follicle center lymphoma, intrathoracic lymph nodes)
C82.63	ICD-10-CM	Follicular lymphoma(Cutaneous follicle center lymphoma, intra-abdominal lymph nodes)
C82.64	ICD-10-CM	Follicular lymphoma(Cutaneous follicle center lymphoma, lymph nodes of axilla and upper limb)
C82.65	ICD-10-CM	Follicular lymphoma(Cutaneous follicle center lymphoma, lymph nodes of inguinal region and lower limb)
C82.66	ICD-10-CM	Follicular lymphoma(Cutaneous follicle center lymphoma, intrapelvic lymph nodes)
C82.67	ICD-10-CM	Follicular lymphoma(Cutaneous follicle center lymphoma, spleen)



<b>B-cell foll</b>	icular non-Hodg	gkin lymphoma (FL)
C82.68	ICD-10-CM	Follicular lymphoma(Cutaneous follicle center lymphoma, lymph nodes of multiple sites)
C82.69	ICD-10-CM	Follicular lymphoma(Cutaneous follicle center lymphoma, extranodal and solid organ sites)
C82.8	ICD-10-CM	Follicular lymphoma(Other types of follicular lymphoma, )
C82.80	ICD-10-CM	Follicular lymphoma(Other types of follicular lymphoma, unspecified site)
C82.81	ICD-10-CM	Follicular lymphoma(Other types of follicular lymphoma, lymph nodes of head, face, and neck)
C82.82	ICD-10-CM	Follicular lymphoma(Other types of follicular lymphoma, intrathoracic lymph nodes)
C82.83	ICD-10-CM	Follicular lymphoma(Other types of follicular lymphoma, intra-abdominal lymph nodes)
C82.84	ICD-10-CM	Follicular lymphoma(Other types of follicular lymphoma, lymph nodes of axilla and upper limb)
C82.85	ICD-10-CM	Follicular lymphoma(Other types of follicular lymphoma, lymph nodes of inguinal region and lower limb)
C82.86	ICD-10-CM	Follicular lymphoma(Other types of follicular lymphoma, intrapelvic lymph nodes)
C82.87	ICD-10-CM	Follicular lymphoma(Other types of follicular lymphoma, spleen)
C82.88	ICD-10-CM	Follicular lymphoma(Other types of follicular lymphoma, lymph nodes of multiple sites)
C82.89	ICD-10-CM	Follicular lymphoma(Other types of follicular lymphoma, extranodal and solid organ sites)
C82.9	ICD-10-CM	Follicular lymphoma, unspecified,
C82.90	ICD-10-CM	Follicular lymphoma, unspecified, unspecified site
C82.91	ICD-10-CM	Follicular lymphoma, unspecified, lymph nodes of head, face, and neck
C82.92	ICD-10-CM	Follicular lymphoma, unspecified, intrathoracic lymph nodes
C82.93	ICD-10-CM	Follicular lymphoma, unspecified, intra-abdominal lymph nodes
C82.94	ICD-10-CM	Follicular lymphoma, unspecified, lymph nodes of axilla and upper limb
C82.95	ICD-10-CM	Follicular lymphoma, unspecified, lymph nodes of inguinal region and lower limb
C82.96	ICD-10-CM	Follicular lymphoma, unspecified, intrapelvic lymph nodes
C82.97	ICD-10-CM	Follicular lymphoma, unspecified, spleen
C82.98	ICD-10-CM	Follicular lymphoma, unspecified, lymph nodes of multiple sites
C82.99	ICD-10-CM	Follicular lymphoma, unspecified, extranodal and solid organ sites



#### Appendix E: Specifications for Request ID CDER\_MPL1R\_WP017\_NSDP\_V01

The Center for Drug Evaluation and Research (CDER) requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool, v 2.2.0, to investigate idelalisib (Zydelig\*) use and concomitant use of idalalisib with several anti-caner agents among patients with various indications in the Sentinel Distributed Database (SDD).

Enrollment Gap: 45 days

**Age Groups:** 18-44, 45-54, 55-64, 65+ **Query Period:** July 23, 2014 - All available data

Pre-Exposure Enrollment Requirement: 0 days

Coverage Requirement: Drug and Medical

·	Drug/Exposure								Conco	e Criteria	Inclusion Criteria				
Scenario	Incident Exposure	Incident w/ respect to:	Washout (days)	Cohort Definition	Episode Gap	Exposure Extension Period	Min Days Supplied	Min Episode Duration	Concomitant Exposure	Lookback Start	 Lookback End	Inclusion Condition	Care Setting	Lookback Start	Lookbac k End
1	Idelalisib	N/A	0	Include all valid incident index dates during the query period	N/A	0	0	0	None	N/A	N/A	CLL	Any	-365	90
2	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Bendamustine	-7	30 days following end of treatment	CLL	Any	-365	90
3	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Bortezomib	-7	30 days following end of treatment	CLL	Any	-365	90
4	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Chlorambucil	-7	30 days following end of treatment	CLL	Any	-365	90
5	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Cyclophosphamide	-7	30 days following end of treatment	CLL	Any	-365	90
6	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Doxorubicin	-7	30 days following end of treatment	CLL	Any	-365	90
7	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Ibritumomab	-7	30 days following end of treatment	CLL	Any	-365	90
8	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Ibrutinib	-7	30 days following end of treatment	CLL	Any	-365	90
9	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Lenalidomide	-7	30 days following end of treatment	CLL	Any	-365	90
10	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Obinutuzumab	-7	30 days following end of treatment	CLL	Any	-365	90
11	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Ofatumumab	-7	30 days following end of treatment	CLL	Any	-365	90
12	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Prednisone	-7	30 days following end of treatment	CLL	Any	-365	90



Drug/Exposure Concominant Use Criteria Inclusion Criteria Inclusion Criteria

Scenario	Incident Exposure	Incident w/ respect to:	Washout (days)	Cohort Definition	Episode Gap	Exposure Extension Period	Min Days Supplied	Min Episode Duration	Concomitant Exposure	Lookback Start	Lookback End	Inclusion Condition	Care Setting	Lookback Start	Lookbac k End
13	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Rituximab	-7	30 days following end of treatment	CLL	Any	-365	90
14	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Vincristine	-7	30 days following end of treatment	CLL	Any	-365	90
15	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	None	N/A	N/A	FL	Any	-365	90
16	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Bendamustine	-7	30 days following end of treatment	FL	Any	-365	90
17	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Bortezomib	-7	30 days following end of treatment	FL	Any	-365	90
18	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Chlorambucil	-7	30 days following end of treatment	FL	Any	-365	90
19	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Cyclophosphamide	-7	30 days following end of treatment	FL	Any	-365	90
20	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Doxorubicin	-7	30 days following end of treatment	FL	Any	-365	90
21	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Ibritumomab	-7	30 days following end of treatment	FL	Any	-365	90
22	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Ibrutinib	-7	30 days following end of treatment	FL	Any	-365	90
23	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Lenalidomide	-7	30 days following end of treatment	FL	Any	-365	90
24	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Obinutuzumab	-7	30 days following end of treatment	FL	Any	-365	90
25	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Ofatumumab	-7	30 days following end of treatment	FL	Any	-365	90
26	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Prednisone	-7	30 days following end of treatment	FL	Any	-365	90
27	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Rituximab	-7	30 days following end of treatment	FL	Any	-365	90
28	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Vincristine	-7	30 days following end of treatment	FL	Any	-365	90



Drug/Exposure Concominant Use Criteria Inclusion Criteria Inclusion Criteria

Scenario	Incident Exposure	Incident w/ respect to:	Washout (days)	Cohort Definition	Episode Gap	Exposure Extension Period	Min Days Supplied	Min Episode Duration	Concomitant Exposure	Lookback Start	Lookback End	Inclusion Condition	Care Setting	Lookback Start	Lookbac k End
29	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	None	N/A	N/A	SLL	Any	-365	90
30	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Bendamustine	-7	30 days following end of treatment	SLL	Any	-365	90
31	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Bortezomib	-7	30 days following end of treatment	SLL	Any	-365	90
32	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Chlorambucil	-7	30 days following end of treatment	SLL	Any	-365	90
33	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Cyclophosphamide	-7	30 days following end of treatment	SLL	Any	-365	90
34	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Doxorubicin	-7	30 days following end of treatment	SLL	Any	-365	90
35	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Ibritumomab	-7	30 days following end of treatment	SLL	Any	-365	90
36	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Ibrutinib	-7	30 days following end of treatment	SLL	Any	-365	90
37	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Lenalidomide	-7	30 days following end of treatment	SLL	Any	-365	90
38	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Obinutuzumab	-7	30 days following end of treatment	SLL	Any	-365	90
39	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Ofatumumab	-7	30 days following end of treatment	SLL	Any	-365	90
40	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Prednisone	-7	30 days following end of treatment	SLL	Any	-365	90
41	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Rituximab	-7	30 days following end of treatment	SLL	Any	-365	90
42	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Vincristine	-7	30 days following end of treatment	SLL	Any	-365	90
43	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	None	N/A	N/A	None	N/A	N/A	N/A
44	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Bendamustine	-7	30 days following end of treatment	None	N/A	N/A	N/A



Drug/Exposure Concominant Use Criteria Inclusion Criteria

Scenario	Incident Exposure	Incident w/ respect to:	Washout (days)	Cohort Definition	Episode Gap	Exposure Extension Period	Min Days Supplied	Min Episode Duration	Concomitant Exposure	Lookback Start	Lookback End	Inclusion Condition	Care Setting	Lookback Start	Lookbac k End
45	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Bortezomib	-7	30 days following end of treatment	None	N/A	N/A	N/A
46	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Chlorambucil	-7	30 days following end of treatment	None	N/A	N/A	N/A
47	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Cyclophosphamide	-7	30 days following end of treatment	None	N/A	N/A	N/A
48	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Doxorubicin	-7	30 days following end of treatment	None	N/A	N/A	N/A
49	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Ibritumomab	-7	30 days following end of treatment	None	N/A	N/A	N/A
50	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Ibrutinib	-7	30 days following end of treatment	None	N/A	N/A	N/A
51	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Lenalidomide	-7	30 days following end of treatment	None	N/A	N/A	N/A
52	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Obinutuzumab	-7	30 days following end of treatment	None	N/A	N/A	N/A
53	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Ofatumumab	-7	30 days following end of treatment	None	N/A	N/A	N/A
54	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Rituximab	-7	30 days following end of treatment	None	N/A	N/A	N/A
55	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Rituximab	-7	30 days following end of treatment	None	N/A	N/A	N/A
56	Idelalisib	N/A	0	Include all valid incident index dates during the query period	30	0	0	0	Vincristine	-7	30 days following end of treatment	None	N/A	N/A	N/A



Appendix F: Count of Users, Episodes, Dispensings, Total Days Supplied, Years at risk, Eligible Members, Member-Years, Episodes with Events, and Number of Events by Scenario, Age Group, Sex, and Year

				Count
Any idelalisib use, Any Indication	TOTAL	Total	Users	219
			Episodes	781
			Dispensings	781
			Days Supplied	21,274
			Amount Supplied	42,354
			Eligible Members	45,938,002
			MemberYears	34,458,133.1
	AgeGroup	18-44 Years	Users	9
			Episodes	24
			Dispensings	24
			Days Supplied	673
			Amount Supplied	1,316
			Eligible Members	23,614,134
			MemberYears	16,258,012.1
		45-54 Years	Users	26
			Episodes	93
			Dispensings	93
			Days Supplied	2,528
			Amount Supplied	5,026
			Eligible Members	9,304,524
			MemberYears	6,575,969.8
		55-64 Years	Users	67
			Episodes	223
			Dispensings	223
			Days Supplied	5,965
			Amount Supplied	11,864
			Eligible Members	8,219,330
			MemberYears	5,975,767.6
		65+ Years	Users	119
			Episodes	441
			Dispensings	441
			Days Supplied	12,108
			Amount Supplied	24,148
			Eligible Members	6,592,965
			MemberYears	5,648,383.5
	Sex	Female	Users	96
			Episodes	336
			Dispensings	336
			Days Supplied	9,272
			Amount Supplied	18,502
			Eligible Members	23,519,031
			MemberYears	17,719,236.5
		Male	Users	123
			Episodes	445
			Dispensings	445
			Days Supplied	12,002
			Amount Supplied	23,852
			Eligible Members	22,416,713
			MemberYears	16,737,341.4
		Unknown	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	2,258
			MemberYears	1,555.1
				•



	Year	2014	Users	99
			Episodes	212
			Dispensings	212
			Days Supplied	6,064
			Amount Supplied	12,068
			Eligible Members	37,580,728
			MemberYears	14,924,033.6
		2015	Users	169
			Episodes	569
			Dispensings	569
			Days Supplied	15,210
			Amount Supplied	30,286
			Eligible Members	•
			MemberYears	38,386,167
Any idelalisib use, CLL	TOTAL	Total	Users	19,534,099.5
Any ideiansib use, CLL	IUIAL	TOLAI		105
			Episodes	405
			Dispensings	405
			Days Supplied	10,931
			Amount Supplied	21,890
			Eligible Members	37,389
			MemberYears	29,277.0
	AgeGroup	18-44 Years	Users	2
			Episodes	10
			Dispensings	10
			Days Supplied	279
			Amount Supplied	558
			Eligible Members	1,028
			MemberYears	594.0
		45-54 Years	Users	5
			Episodes	10
			Dispensings	10
			Days Supplied	282
			Amount Supplied	564
			Eligible Members	3,173
			MemberYears	2,063.2
		55-64 Years	Users	38
			Episodes	127
			Dispensings	127
			Days Supplied	3,416
			Amount Supplied	6,832
			Eligible Members	9,262
			MemberYears	6,462.2
		65+ Years	Users	62
		os: rears	Episodes	258
			Dispensings	258
			Days Supplied	6,954
			Amount Supplied	13,936
			Eligible Members	25,103
			MemberYears	20,157.5
	Sex	Female	Users	40
	Jex	remaie	Episodes	164
			Dispensings	164
			Days Supplied	4,529
			Amount Supplied	9,086
			Eligible Members	15,900
		Mala	MemberYears	12,461.7
		Male	Users	65 341
			Episodes	241
			Dispensings	241
			Days Supplied	6,402
			Amount Supplied	12,804
			Eligible Members	21,487
			MemberYears	16,814.0



				_
		Unknown	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	2
	.,	224	MemberYears	1.3
	Year	2014	Users	47
			Episodes	106
			Dispensings	106
			Days Supplied	3,061
			Amount Supplied Eligible Members	6,122 32,634
			MemberYears	12,875.6
		2015	Users	84
		2015	Episodes	04 299
			Dispensings	299
			Days Supplied	7,870
			Amount Supplied	15,768
			Eligible Members	31,284
			MemberYears	16,401.4
Idelalisib and Bendamustine, Any				10,401.4
Indication	TOTAL	Total	Users	9
			Episodes	9
			Dispensings	9
			Days Supplied	452
			Amount Supplied	8
			Eligible Members	45,938,002
			MemberYears	34,458,133.1
	AgeGroup	18-44 Years	Users	1
			Episodes	1
			Dispensings	1
			Days Supplied	30
			Amount Supplied	1
			Eligible Members	23,614,134
			MemberYears	16,258,012.1
		45-54 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	9,304,524
		55-64 Years	MemberYears Users	6,575,969.8 4
		33-04 Teals	Episodes	4
			Dispensings	4
			Days Supplied	222
			Amount Supplied	4
			Eligible Members	8,219,330
			MemberYears	5,975,767.6
		65+ Years	Users	4
			Episodes	4
			Dispensings	4
			Days Supplied	200
			Amount Supplied	3
			Eligible Members	6,592,965
			MemberYears	5,648,383.5
	Sex	Female	Users	4
			Episodes	4
			Dispensings	4
			Days Supplied	136
			Amount Supplied	3
			Eligible Members	23,519,031
			MemberYears	17,719,236.5



				-
		Male	Users	5
			Episodes	5
			Dispensings	5
			Days Supplied	316
			Amount Supplied	5
			Eligible Members	
				22,416,713
			MemberYears	16,737,341.4
		Unknown	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	2,258
			MemberYears	1,555.1
	Year	2014	Users	5
			Episodes	5
			•	5
			Dispensings	
			Days Supplied	282
			Amount Supplied	5
			Eligible Members	37,580,728
			MemberYears	14,924,033.6
		2015	Users	4
		2013		
			Episodes	4
			Dispensings	4
			Days Supplied	170
			Amount Supplied	3
			Eligible Members	38,386,167
			MemberYears	
Ideletet and Bendament of CII	TOTAL	T-4-1		19,534,099.5
Idelalisib and Bendamustine, CLL	TOTAL	Total	Users	1
			Episodes	1
			Dispensings	1
			Days Supplied	30
			Amount Supplied	1
			Eligible Members	37,389
			MemberYears	29,277.0
	AgeGroup	18-44 Years	Users	0
			Episodes	0
			Lpisoues	U
			•	0
			Dispensings	0
			Dispensings Days Supplied	0 0
			Dispensings Days Supplied Amount Supplied	0 0 0
			Dispensings Days Supplied Amount Supplied Eligible Members	0 0 0 1,028
			Dispensings Days Supplied Amount Supplied Eligible Members MemberYears	0 0 0 1,028 594.0
		45-54 Years	Dispensings Days Supplied Amount Supplied Eligible Members	0 0 0 1,028
		45-54 Years	Dispensings Days Supplied Amount Supplied Eligible Members MemberYears	0 0 0 1,028 594.0
		45-54 Years	Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes	0 0 0 1,028 594.0 0
		45-54 Years	Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings	0 0 0 1,028 594.0 0
		45-54 Years	Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied	0 0 0 1,028 594.0 0 0
		45-54 Years	Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied	0 0 0 1,028 594.0 0 0
		45-54 Years	Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members	0 0 1,028 594.0 0 0 0 0 0 0 3,173
			Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied	0 0 0 1,028 594.0 0 0
		45-54 Years 55-64 Years	Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members	0 0 1,028 594.0 0 0 0 0 0 0 3,173
			Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears	0 0 1,028 594.0 0 0 0 0 0 3,173 2,063.2
			Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes	0 0 1,028 594.0 0 0 0 0 3,173 2,063.2
			Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings	0 0 1,028 594.0 0 0 0 0 3,173 2,063.2 1
			Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied	0 0 1,028 594.0 0 0 0 0 3,173 2,063.2 1 1 1
			Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Amount Supplied	0 0 1,028 594.0 0 0 0 0 3,173 2,063.2 1 1 1 30
			Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members Episodes Dispensings Days Supplied Amount Supplied Eligible Members	0 0 1,028 594.0 0 0 0 0 3,173 2,063.2 1 1 1 30 1
			Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Amount Supplied	0 0 1,028 594.0 0 0 0 0 3,173 2,063.2 1 1 1 30
			Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members Episodes Dispensings Days Supplied Amount Supplied Eligible Members	0 0 1,028 594.0 0 0 0 0 3,173 2,063.2 1 1 1 30 1
		55-64 Years	Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users	0 0 1,028 594.0 0 0 0 0 3,173 2,063.2 1 1 1 30 1 9,262 6,462.2
		55-64 Years	Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes	0 0 1,028 594.0 0 0 0 0 3,173 2,063.2 1 1 1 30 1 9,262 6,462.2 0
		55-64 Years	Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings	0 0 1,028 594.0 0 0 0 0 3,173 2,063.2 1 1 1 30 1 9,262 6,462.2 0
		55-64 Years	Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied	0 0 1,028 594.0 0 0 0 0 3,173 2,063.2 1 1 1 30 1 9,262 6,462.2 0 0
		55-64 Years	Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members WemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Amount Supplied	0 0 1,028 594.0 0 0 0 0 3,173 2,063.2 1 1 1 30 1 9,262 6,462.2 0 0
		55-64 Years	Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied	0 0 1,028 594.0 0 0 0 0 3,173 2,063.2 1 1 1 30 1 9,262 6,462.2 0 0
		55-64 Years	Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members WemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Amount Supplied	0 0 1,028 594.0 0 0 0 0 3,173 2,063.2 1 1 1 30 1 9,262 6,462.2 0 0



	_			_
	Sex	Female	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	15,900
			MemberYears	12,461.7
		Male	Users	1
			Episodes	1
			Dispensings	1
			Days Supplied	30
			Amount Supplied	1
			• •	
			Eligible Members	21,487
			MemberYears	16,814.0
		Unknown	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	2
			MemberYears	1.3
	Year	2014	Users	1
			Episodes	1
			Dispensings	1
			Days Supplied	30
			Amount Supplied	1
			Eligible Members	32,634
			-	-
		2015	MemberYears	12,875.6
		2015	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	31,284
			Eligible Members MemberYears	31,284 16,401.4
Idelalisib and Bortezomib, Any				16,401.4
Idelalisib and Bortezomib, Any Indication	TOTAL	Total	MemberYears Users	16,401.4 2
	TOTAL	Total	MemberYears  Users  Episodes	16,401.4 2 2
	TOTAL	Total	MemberYears Users	16,401.4 2
	TOTAL	Total	MemberYears  Users  Episodes	16,401.4 2 2
	TOTAL	Total	MemberYears Users Episodes Dispensings	16,401.4 2 2 2
	TOTAL	Total	MemberYears Users Episodes Dispensings Days Supplied	16,401.4 2 2 2 2 60 2
	TOTAL	Total	MemberYears  Users Episodes Dispensings Days Supplied Amount Supplied	16,401.4 2 2 2 2 60
	TOTAL	Total	Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members	16,401.4 2 2 2 2 60 2 45,938,002
			Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users	16,401.4 2 2 2 60 2 45,938,002 34,458,133.1
			Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes	16,401.4 2 2 2 60 2 45,938,002 34,458,133.1 0 0
			Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings	16,401.4 2 2 2 60 2 45,938,002 34,458,133.1 0 0
			Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied	16,401.4 2 2 2 60 2 45,938,002 34,458,133.1 0 0 0
			Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied	16,401.4 2 2 2 60 2 45,938,002 34,458,133.1 0 0 0 0
			Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members	16,401.4 2 2 2 60 2 45,938,002 34,458,133.1 0 0 0 0 0 0 23,614,134
		18-44 Years	Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears	16,401.4  2 2 2 60 2 45,938,002 34,458,133.1 0 0 0 0 23,614,134 16,258,012.1
			Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Users Users Users Users Users	16,401.4 2 2 2 60 2 45,938,002 34,458,133.1 0 0 0 0 0 0 23,614,134 16,258,012.1 0
		18-44 Years	MemberYears  Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Ligible Members MemberYears Users Episodes	16,401.4  2 2 2 60 2 45,938,002 34,458,133.1 0 0 0 0 23,614,134 16,258,012.1 0 0
		18-44 Years	Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings	16,401.4  2 2 2 60 2 45,938,002 34,458,133.1 0 0 0 23,614,134 16,258,012.1 0 0 0
		18-44 Years	Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied	16,401.4  2 2 2 60 2 45,938,002 34,458,133.1 0 0 0 23,614,134 16,258,012.1 0 0 0 0
		18-44 Years	Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Amount Supplied	16,401.4  2 2 2 60 2 45,938,002 34,458,133.1 0 0 0 23,614,134 16,258,012.1 0 0 0 0 0
		18-44 Years	Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members	16,401.4  2 2 2 60 2 45,938,002 34,458,133.1 0 0 0 23,614,134 16,258,012.1 0 0 0 0 9,304,524
		18-44 Years 45-54 Years	Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears	16,401.4  2 2 2 60 2 45,938,002 34,458,133.1 0 0 0 23,614,134 16,258,012.1 0 0 0 9,304,524 6,575,969.8
		18-44 Years	Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Users	16,401.4  2 2 2 60 2 45,938,002 34,458,133.1 0 0 0 23,614,134 16,258,012.1 0 0 0 0 9,304,524 6,575,969.8 2
		18-44 Years 45-54 Years	Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Users Episodes	16,401.4  2 2 2 60 2 45,938,002 34,458,133.1 0 0 0 23,614,134 16,258,012.1 0 0 0 0 9,304,524 6,575,969.8 2 2
		18-44 Years 45-54 Years	Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Users Episodes Dispensings	16,401.4  2 2 2 60 2 45,938,002 34,458,133.1 0 0 0 23,614,134 16,258,012.1 0 0 0 9,304,524 6,575,969.8 2 2 2
		18-44 Years 45-54 Years	Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied	16,401.4  2 2 2 60 2 45,938,002 34,458,133.1 0 0 0 23,614,134 16,258,012.1 0 0 0 9,304,524 6,575,969.8 2 2 2 60
		18-44 Years 45-54 Years	Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Amount Supplied	16,401.4  2 2 2 60 2 45,938,002 34,458,133.1 0 0 0 23,614,134 16,258,012.1 0 0 0 9,304,524 6,575,969.8 2 2 2
		18-44 Years 45-54 Years	Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members	16,401.4  2 2 2 60 2 45,938,002 34,458,133.1 0 0 0 0 23,614,134 16,258,012.1 0 0 0 9,304,524 6,575,969.8 2 2 2 60 2 8,219,330
		18-44 Years 45-54 Years	Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Amount Supplied	16,401.4  2 2 2 60 2 45,938,002 34,458,133.1 0 0 0 0 23,614,134 16,258,012.1 0 0 0 0 9,304,524 6,575,969.8 2 2 2 60 2
		18-44 Years 45-54 Years	Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members	16,401.4  2 2 2 60 2 45,938,002 34,458,133.1 0 0 0 0 23,614,134 16,258,012.1 0 0 0 9,304,524 6,575,969.8 2 2 2 60 2 8,219,330



			Entrada.	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	6,592,965
			MemberYears	5,648,383.5
	Sex	Female	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	23,519,031
			MemberYears	17,719,236.5
		Male	Users	2
			Episodes	2
			Dispensings	2
			Days Supplied	60
			Amount Supplied	2
			Eligible Members	22,416,713
			MemberYears	16,737,341.4
		Unknown	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	2,258
			MemberYears	1,555.1
	Year	2014	Users	2
			Episodes	2
			Dispensings	2
			Days Supplied	60
			Amount Supplied	2
			Eligible Members	37,580,728
			MemberYears	14,924,033.6
		2015	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	38,386,167
			MemberYears	19,534,099.5
	TOTAL	Total	Users	0
Ildelalisin and Kortezomin (11	IOIAL	. Ottai		
Idelalisib and Bortezomib, CLL				
Ideialisib and Bortezomib, CLL			Episodes	0
Idelalisib and Bortezomib, CLL			Episodes Dispensings	0 0
Idelalisib and Bortezomib, CLL			Episodes Dispensings Days Supplied	0 0 0
Idelalisib and Bortezomib, CLL			Episodes Dispensings Days Supplied Amount Supplied	0 0 0 0
Idelalisib and Bortezomib, CLL			Episodes Dispensings Days Supplied Amount Supplied Eligible Members	0 0 0 0 37,389
Idelalisib and Bortezomib, CLL	AgoGroup	19.44 Voors	Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears	0 0 0 0 37,389 29,277.0
Idelalisib and Bortezomib, CLL	AgeGroup	18-44 Years	Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users	0 0 0 0 37,389 29,277.0
Idelalisib and Bortezomib, CLL	AgeGroup	18-44 Years	Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes	0 0 0 0 37,389 29,277.0 0
Idelalisib and Bortezomib, CLL	AgeGroup	18-44 Years	Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings	0 0 0 0 37,389 29,277.0 0
Idelalisib and Bortezomib, CLL	AgeGroup	18-44 Years	Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied	0 0 0 0 37,389 29,277.0 0 0
Idelalisib and Bortezomib, CLL	AgeGroup	18-44 Years	Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied	0 0 0 0 37,389 29,277.0 0 0
Idelalisib and Bortezomib, CLL	AgeGroup	18-44 Years	Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members	0 0 0 0 37,389 29,277.0 0 0 0
Idelalisib and Bortezomib, CLL	AgeGroup		Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears	0 0 0 0 37,389 29,277.0 0 0 0 0 1,028 594.0
Idelalisib and Bortezomib, CLL	AgeGroup	18-44 Years 45-54 Years	Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users	0 0 0 0 37,389 29,277.0 0 0 0 0 1,028 594.0
Idelalisib and Bortezomib, CLL	AgeGroup		Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Users Episodes	0 0 0 0 37,389 29,277.0 0 0 0 0 1,028 594.0 0
Idelalisib and Bortezomib, CLL	AgeGroup		Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings	0 0 0 0 37,389 29,277.0 0 0 0 0 1,028 594.0 0
Idelalisib and Bortezomib, CLL	AgeGroup		Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied	0 0 0 0 37,389 29,277.0 0 0 0 0 1,028 594.0 0
Idelalisib and Bortezomib, CLL	AgeGroup		Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied	0 0 0 0 37,389 29,277.0 0 0 0 0 1,028 594.0 0 0
Idelalisib and Bortezomib, CLL	AgeGroup		Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied	0 0 0 0 37,389 29,277.0 0 0 0 0 1,028 594.0 0



		cav		•
		55-64 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	9,262
			MemberYears	6,462.2
		65+ Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	25,103
			MemberYears	20,157.5
	Sex	Female	Users	0
	Jex	Telliale	Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	15,900
			MemberYears	12,461.7
		Male	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	21,487
			MemberYears	16,814.0
		Unknown	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	2
			MemberYears	1.3
	Year	2014	Users	0
	rear	2014	Episodes	0
			Dispensings	0
			Days Supplied	0
				0
			Amount Supplied	
			Eligible Members	32,634
		2015	MemberYears	12,875.6
		2015	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	31,284
			MemberYears	16,401.4
Idelalisib and Chlorambucil, Any				
Indication	TOTAL	Total	Users	5
			Episodes	5
			Dispensings	5
			Days Supplied	195
			Amount Supplied	4
			Eligible Members	45,938,002
			MemberYears	34,458,133.1
	AgeGroup	18-44 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	23,614,134
			MemberYears	16,258,012.1
		45-54 Years	Users	0
		.5 54 15413		-



			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	9,304,524
			MemberYears	6,575,969.8
		55-64 Years	Users	4
			Episodes	4
			Dispensings	4
			Days Supplied	165
			Amount Supplied	3
			Eligible Members	8,219,330
			MemberYears	5,975,767.6
		65+ Years	Users	1
			Episodes	1
			Dispensings	1
			Days Supplied	30
			Amount Supplied	1
			Eligible Members	6,592,965
			MemberYears	5,648,383.5
	Sex	Female	Users	2
			Episodes	2
			Dispensings	2
			Days Supplied	122
			Amount Supplied	2
			Eligible Members	23,519,031
			MemberYears	17,719,236.5
		Male	Users	3
			Episodes	3
			Dispensings	3
			Days Supplied	73
			Amount Supplied	2
			Eligible Members	22,416,713
			MemberYears	16,737,341.4
		Unknown	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	2,258
			MemberYears	1,555.1
	Year	2014	Users	3
			Episodes	3
			Dispensings	3
			Days Supplied	152
			Amount Supplied	3
			Eligible Members	37,580,728
			MemberYears	14,924,033.6
		2015	Users	2
			Episodes	2
			Dispensings	2
			Days Supplied	43
			Amount Supplied	1
			Eligible Members	38,386,167
			MemberYears	19,534,099.5
Idelalisib and Chlorambucil, CLL	TOTAL	Total	Users	5
			Episodes	5
			Dispensings	5
			Days Supplied	195
			Amount Supplied	4
			Eligible Members	37,389
			MemberYears	29,277.0



	AgeGroup	18-44 Years	Hears	0
	Agedroup	10-44 fears	Users Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	1,028
			MemberYears	594.0
		45-54 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	3,173
			MemberYears	2,063.2
		55-64 Years	Users	4
			Episodes	4
			Dispensings	4
			Days Supplied	165
			Amount Supplied	3
			Eligible Members	9,262
			MemberYears	6,462.2
		65+ Years	Users	1
			Episodes	1
			Dispensings	1
			Days Supplied	30
			Amount Supplied	1
			Eligible Members	25,103
	C	Famala	MemberYears	20,157.5
	Sex	Female	Users Episodes	2
			Dispensings	2
			Days Supplied	122
			Amount Supplied	2
			Eligible Members	15,900
			MemberYears	12,461.7
		Male	Users	3
			Episodes	3
			Dispensings	3
			Days Supplied	73
			Amount Supplied	2
			Eligible Members	21,487
			MemberYears	16,814.0
		Unknown	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	2
			MemberYears	1.3
	Year	2014	Users	3
			Episodes	3
			Dispensings	3
			Days Supplied	152
			Amount Supplied	3
			Eligible Members MemberYears	32,634 12,875,6
		2015	Users	12,875.6 2
		2013	Episodes	2
			Dispensings	2
			Days Supplied	43
			Amount Supplied	45 1
			Eligible Members	31,284
			MemberYears	16,401.4
Idelalisib and Cyclophosphamide,			]	, .0
Any Indication	TOTAL	Total	Users	2
			<b>=</b>	



			Episodes	2
			Dispensings	2
			Days Supplied	294
			Amount Supplied	2
			Eligible Members	45,938,002
	1 ~ a C * a	10 44 Voors	MemberYears	34,458,133.1
,	AgeGroup	18-44 Years	Users	0
			Episodes Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	23,614,134
			MemberYears	16,258,012.1
		45-54 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	9,304,524
			MemberYears	6,575,969.8
		55-64 Years	Users	0
			Episodes	0
			Dispensings Days Supplied	0
			Amount Supplied	0
			Eligible Members	8,219,330
			MemberYears	5,975,767.6
		65+ Years	Users	2
		00 / 100.0	Episodes	2
			Dispensings	2
			Days Supplied	294
			Amount Supplied	2
			Eligible Members	6,592,965
			Eligible Members MemberYears	6,592,965 5,648,383.5
9	Sex	Female	MemberYears Users	5,648,383.5 1
5	Sex	Female	MemberYears Users Episodes	5,648,383.5 1 1
S	Sex	Female	MemberYears Users Episodes Dispensings	5,648,383.5 1 1
S	Sex	Female	MemberYears Users Episodes Dispensings Days Supplied	5,648,383.5 1 1 1 267
S	Sex	Female	MemberYears Users Episodes Dispensings Days Supplied Amount Supplied	5,648,383.5 1 1 1 267 1
S	Sex	Female	MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members	5,648,383.5 1 1 1 267 1 23,519,031
5	Sex	Female  Male	MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears	5,648,383.5 1 1 1 267 1 23,519,031 17,719,236.5
5	Sex		MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users	5,648,383.5 1 1 1 267 1 23,519,031 17,719,236.5 1
S	Sex		MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears	5,648,383.5 1 1 1 267 1 23,519,031 17,719,236.5
S	Sex		MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes	5,648,383.5 1 1 1 267 1 23,519,031 17,719,236.5 1
S	Sex		MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied	5,648,383.5 1 1 1 267 1 23,519,031 17,719,236.5 1 1 1 27 1
S	Sex		MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members	5,648,383.5 1 1 1 267 1 23,519,031 17,719,236.5 1 1 1 27 1 22,416,713
S	Sex	Male	MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears	5,648,383.5 1 1 1 267 1 23,519,031 17,719,236.5 1 1 27 1 22,416,713 16,737,341.4
S	Sex		MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Users	5,648,383.5 1 1 1 267 1 23,519,031 17,719,236.5 1 1 27 1 22,416,713 16,737,341.4 0
S	Sex	Male	MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Users Episodes Users Episodes	5,648,383.5 1 1 1 267 1 23,519,031 17,719,236.5 1 1 27 1 22,416,713 16,737,341.4 0 0
S	Sex	Male	MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Users Episodes Dispensings	5,648,383.5 1 1 1 267 1 23,519,031 17,719,236.5 1 1 27 1 22,416,713 16,737,341.4 0 0
S	Sex	Male	MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied	5,648,383.5 1 1 1 267 1 23,519,031 17,719,236.5 1 1 27 1 22,416,713 16,737,341.4 0 0 0
	Sex	Male	MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied	5,648,383.5 1 1 1 267 1 23,519,031 17,719,236.5 1 1 27 1 22,416,713 16,737,341.4 0 0 0 0
	Sex	Male	MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied	5,648,383.5 1 1 1 267 1 23,519,031 17,719,236.5 1 1 27 1 22,416,713 16,737,341.4 0 0 0
	Sex	Male	MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members	5,648,383.5 1 1 1 267 1 23,519,031 17,719,236.5 1 1 27 1 22,416,713 16,737,341.4 0 0 0 0 0 0 0 2,258
		Male	MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears MemberYears	5,648,383.5 1 1 1 267 1 23,519,031 17,719,236.5 1 1 27 1 22,416,713 16,737,341.4 0 0 0 0 0 0 0 0 2,258 1,555.1
		Male	MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Users Episodes Dispensings	5,648,383.5 1 1 1 267 1 23,519,031 17,719,236.5 1 1 1 27 1 22,416,713 16,737,341.4 0 0 0 0 2,258 1,555.1 2 2
		Male	MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Users Episodes Dispensings Days Supplied	5,648,383.5 1 1 1 267 1 23,519,031 17,719,236.5 1 1 1 27 1 22,416,713 16,737,341.4 0 0 0 0 2,258 1,555.1 2 2 2 294
		Male	MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied	5,648,383.5 1 1 1 267 1 23,519,031 17,719,236.5 1 1 1 27 1 22,416,713 16,737,341.4 0 0 0 0 2,258 1,555.1 2 2 2 294 2
		Male	MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members WemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members	5,648,383.5 1 1 1 267 1 23,519,031 17,719,236.5 1 1 1 27 1 22,416,713 16,737,341.4 0 0 0 0 2,258 1,555.1 2 2 2 294 2 37,580,728
		Male Unknown 2014	MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears MemberYears	5,648,383.5 1 1 1 267 1 23,519,031 17,719,236.5 1 1 1 27 1 22,416,713 16,737,341.4 0 0 0 0 2,258 1,555.1 2 2 2 294 2 37,580,728 14,924,033.6
		Male	MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users	5,648,383.5 1 1 1 267 1 23,519,031 17,719,236.5 1 1 1 27 1 22,416,713 16,737,341.4 0 0 0 0 2,258 1,555.1 2 2 2 294 2 37,580,728 14,924,033.6 0
		Male Unknown 2014	MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears MemberYears	5,648,383.5 1 1 1 267 1 23,519,031 17,719,236.5 1 1 1 27 1 22,416,713 16,737,341.4 0 0 0 0 2,258 1,555.1 2 2 2 294 2 37,580,728 14,924,033.6



			Days Supplied	0
			Amount Supplied	0
			Eligible Members MemberYears	38,386,167
Idelalisib and Cyclophosphamide,			Niemberrears	19,534,099.5
CLL	TOTAL	Total	Users	0
011	101712	rotai	Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	37,389
			MemberYears	29,277.0
	AgeGroup	18-44 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	1,028
		45 54 Vaara	MemberYears	594.0
		45-54 Years	Users Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	3,173
			MemberYears	2,063.2
		55-64 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	9,262
			MemberYears	6,462.2
		65+ Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied Amount Supplied	0
			Eligible Members	25,103
			MemberYears	20,157.5
	Sex	Female	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	15,900
			MemberYears	12,461.7
		Male	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied Amount Supplied	0
			Eligible Members	21,487
			MemberYears	16,814.0
		Unknown	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	2
			MemberYears	1.3
	Year	2014	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0



			Amount Supplied	0
			Eligible Members	32,634
			MemberYears	12,875.6
		2015	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members MemberYears	31,284 16,401.4
Idelalisib and Doxorubicin, Any				10,401.4
Indication	TOTAL	Total	Users	1
	7 0 17 12	1000	Episodes	1
			Dispensings	1
			Days Supplied	30
			Amount Supplied	1
			Eligible Members	45,938,002
			MemberYears	34,458,133.1
	AgeGroup	18-44 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members MemberYears	23,614,134
		45-54 Years	Users	16,258,012.1 0
		43-34 Tears	Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	9,304,524
			MemberYears	6,575,969.8
		55-64 Years	Users	1
			Episodes	1
			Dispensings	1
			Days Supplied	30
			Amount Supplied	1
			Eligible Members MemberYears	8,219,330
		65+ Years	Users	5,975,767.6 0
		OJT TEATS	Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	6,592,965
			MemberYears	5,648,383.5
	Sex	Female	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied Eligible Members	0
			MemberYears	23,519,031 17,719,236.5
		Male	Users	17,713,230.3
			Episodes	1
			Dispensings	1
			Days Supplied	30
			Amount Supplied	1
			Eligible Members	22,416,713
			MemberYears	16,737,341.4
		Unknown	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0



			Eligible Members	2,258
			MemberYears	1,555.1
	Year	2014	Users	1
			Episodes	1
			Dispensings	1
			Days Supplied	30
			Amount Supplied	1
			Eligible Members	37,580,728
			MemberYears	14,924,033.6
		2015	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	38,386,167
Idelalisib and Deverybisin, CII	TOTAL	Total	MemberYears	19,534,099.5
Idelalisib and Doxorubicin, CLL	IUIAL	TOTAL	Users Episodes	0 0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	37,389
			MemberYears	29,277.0
	AgeGroup	18-44 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	1,028
			MemberYears	594.0
		45-54 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	3,173
			MemberYears	2,063.2
		55-64 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	9,262
		CF : Vaava	MemberYears	6,462.2
		65+ Years	Users Episodes	0 0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	25,103
			MemberYears	20,157.5
	Sex	Female	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	15,900
			MemberYears	12,461.7



		Male	Users	0
		IVIAIC	Episodes	0
			Dispensings	0
				0
			Days Supplied Amount Supplied	0
			Eligible Members	
			MemberYears	21,487
				16,814.0
		Unknown	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	2
			MemberYears	1.3
	Year	2014	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	32,634
			MemberYears	12,875.6
		2015	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	31,284
			MemberYears	16,401.4
Idelalisib and Ibritumomab, Any			1	
Indication	TOTAL	Total	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Amount Supplied Eligible Members	
			Eligible Members	45,938,002
	AgeGroup	18-44 Years	Eligible Members MemberYears	45,938,002 34,458,133.1
	AgeGroup	18-44 Years	Eligible Members MemberYears Users	45,938,002
	AgeGroup	18-44 Years	Eligible Members MemberYears Users Episodes	45,938,002 34,458,133.1 0
	AgeGroup	18-44 Years	Eligible Members MemberYears Users Episodes Dispensings	45,938,002 34,458,133.1 0 0
	AgeGroup	18-44 Years	Eligible Members MemberYears Users Episodes Dispensings Days Supplied	45,938,002 34,458,133.1 0 0 0
	AgeGroup	18-44 Years	Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied	45,938,002 34,458,133.1 0 0 0 0 0
	AgeGroup	18-44 Years	Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members	45,938,002 34,458,133.1 0 0 0 0 0 0 0 23,614,134
	AgeGroup		Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears	45,938,002 34,458,133.1 0 0 0 0 0 0 0 23,614,134 16,258,012.1
	AgeGroup	18-44 Years 45-54 Years	Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users	45,938,002 34,458,133.1 0 0 0 0 0 0 23,614,134 16,258,012.1 0
	AgeGroup		Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes	45,938,002 34,458,133.1 0 0 0 0 0 0 0 23,614,134 16,258,012.1
	AgeGroup		Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings	45,938,002 34,458,133.1 0 0 0 0 0 0 23,614,134 16,258,012.1 0
	AgeGroup		Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied	45,938,002 34,458,133.1 0 0 0 0 0 0 23,614,134 16,258,012.1 0 0
	AgeGroup		Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied	45,938,002 34,458,133.1 0 0 0 0 0 0 23,614,134 16,258,012.1 0 0 0
	AgeGroup		Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied	45,938,002 34,458,133.1 0 0 0 0 0 0 23,614,134 16,258,012.1 0 0 0 0 0 9,304,524
	AgeGroup		Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members	45,938,002 34,458,133.1 0 0 0 0 0 0 23,614,134 16,258,012.1 0 0 0
	AgeGroup	45-54 Years	Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears	45,938,002 34,458,133.1 0 0 0 0 0 0 23,614,134 16,258,012.1 0 0 0 0 0 9,304,524 6,575,969.8
	AgeGroup	45-54 Years	Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Users Episodes	45,938,002 34,458,133.1 0 0 0 0 0 0 23,614,134 16,258,012.1 0 0 0 0 9,304,524 6,575,969.8 0
	AgeGroup	45-54 Years	Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings	45,938,002 34,458,133.1 0 0 0 0 0 0 23,614,134 16,258,012.1 0 0 0 0 9,304,524 6,575,969.8 0 0
	AgeGroup	45-54 Years	Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied	45,938,002 34,458,133.1 0 0 0 0 0 0 23,614,134 16,258,012.1 0 0 0 0 9,304,524 6,575,969.8 0 0
	AgeGroup	45-54 Years	Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Users Episodes Dispensings Days Supplied Amount Supplied Amount Supplied	45,938,002 34,458,133.1 0 0 0 0 0 0 23,614,134 16,258,012.1 0 0 0 0 9,304,524 6,575,969.8 0 0
	AgeGroup	45-54 Years	Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members Dispensings Days Supplied Amount Supplied Amount Supplied Eligible Members	45,938,002 34,458,133.1 0 0 0 0 0 0 23,614,134 16,258,012.1 0 0 0 0 0 9,304,524 6,575,969.8 0 0 0 0 0 0 0 0 0 0 0 0 0
	AgeGroup	45-54 Years 55-64 Years	Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears	45,938,002 34,458,133.1 0 0 0 0 0 0 23,614,134 16,258,012.1 0 0 0 0 0 9,304,524 6,575,969.8 0 0 0 0 0 0 0 0 0 0 0 0 0
	AgeGroup	45-54 Years	Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users MemberYears Users	45,938,002 34,458,133.1 0 0 0 0 0 0 23,614,134 16,258,012.1 0 0 0 0 0 9,304,524 6,575,969.8 0 0 0 0 0 0 0 0 0 0 0 0 0
	AgeGroup	45-54 Years 55-64 Years	Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes	45,938,002 34,458,133.1 0 0 0 0 0 0 23,614,134 16,258,012.1 0 0 0 0 9,304,524 6,575,969.8 0 0 0 0 0 0 0 0 0 0 0 0 0
	AgeGroup	45-54 Years 55-64 Years	Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Users Episodes Dispensings	45,938,002 34,458,133.1 0 0 0 0 0 0 23,614,134 16,258,012.1 0 0 0 0 9,304,524 6,575,969.8 0 0 0 0 0 0 0 0 0 0 0 0 0
	AgeGroup	45-54 Years 55-64 Years	Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied	45,938,002 34,458,133.1 0 0 0 0 0 0 23,614,134 16,258,012.1 0 0 0 0 9,304,524 6,575,969.8 0 0 0 0 0 0 0 0 0 0 0 0 0
	AgeGroup	45-54 Years 55-64 Years	Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Amount Supplied Amount Supplied Amount Supplied	45,938,002 34,458,133.1 0 0 0 0 0 0 23,614,134 16,258,012.1 0 0 0 0 9,304,524 6,575,969.8 0 0 0 0 0 0 0 0 0 0 0 0 0
	AgeGroup	45-54 Years 55-64 Years	Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members Dispensings Days Supplied Amount Supplied Eligible Members	45,938,002 34,458,133.1 0 0 0 0 0 0 23,614,134 16,258,012.1 0 0 0 0 9,304,524 6,575,969.8 0 0 0 0 0 0 0 0 0 0 0 0 0
	AgeGroup	45-54 Years 55-64 Years	Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Amount Supplied Amount Supplied Amount Supplied	45,938,002 34,458,133.1 0 0 0 0 0 0 23,614,134 16,258,012.1 0 0 0 0 9,304,524 6,575,969.8 0 0 0 0 0 0 0 0 0 0 0 0 0



			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	23,519,031
			MemberYears	17,719,236.5
		Male	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	22,416,713
			MemberYears	16,737,341.4
		Unknown	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	2,258
			MemberYears	1,555.1
	Year	2014	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	37,580,728
			MemberYears	14,924,033.6
		2015	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
				0 38,386,167
			Amount Supplied	
Idelalisib and Ibritumomab, CLL	TOTAL	Total	Amount Supplied Eligible Members	38,386,167
Idelalisib and Ibritumomab, CLL	TOTAL	Total	Amount Supplied Eligible Members MemberYears	38,386,167 19,534,099.5
Idelalisib and Ibritumomab, CLL	TOTAL	Total	Amount Supplied Eligible Members MemberYears Users	38,386,167 19,534,099.5 0
Idelalisib and Ibritumomab, CLL	TOTAL	Total	Amount Supplied Eligible Members MemberYears Users Episodes	38,386,167 19,534,099.5 0
Idelalisib and Ibritumomab, CLL	TOTAL	Total	Amount Supplied Eligible Members MemberYears Users Episodes Dispensings	38,386,167 19,534,099.5 0 0
Idelalisib and Ibritumomab, CLL	TOTAL	Total	Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied	38,386,167 19,534,099.5 0 0 0
Idelalisib and Ibritumomab, CLL	TOTAL	Total	Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied	38,386,167 19,534,099.5 0 0 0 0
Idelalisib and Ibritumomab, CLL	TOTAL	Total  18-44 Years	Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members	38,386,167 19,534,099.5 0 0 0 0 0 0 37,389
Idelalisib and Ibritumomab, CLL			Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears	38,386,167 19,534,099.5 0 0 0 0 0 0 37,389 29,277.0
Idelalisib and Ibritumomab, CLL			Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users	38,386,167 19,534,099.5 0 0 0 0 0 37,389 29,277.0
Idelalisib and Ibritumomab, CLL			Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes	38,386,167 19,534,099.5 0 0 0 0 0 37,389 29,277.0 0
Idelalisib and Ibritumomab, CLL			Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied	38,386,167 19,534,099.5 0 0 0 0 0 37,389 29,277.0 0 0
Idelalisib and Ibritumomab, CLL			Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible MemberS	38,386,167 19,534,099.5 0 0 0 0 0 37,389 29,277.0 0 0 0
Idelalisib and Ibritumomab, CLL		18-44 Years	Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears	38,386,167 19,534,099.5 0 0 0 0 0 37,389 29,277.0 0 0 0 0 1,028 594.0
Idelalisib and Ibritumomab, CLL			Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users	38,386,167 19,534,099.5 0 0 0 0 0 37,389 29,277.0 0 0 0 0 1,028 594.0
Idelalisib and Ibritumomab, CLL		18-44 Years	Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members Users Episodes Users Users Users Users Episodes	38,386,167 19,534,099.5 0 0 0 0 0 37,389 29,277.0 0 0 0 1,028 594.0 0
Idelalisib and Ibritumomab, CLL		18-44 Years	Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members Users Episodes Dispensings Users Users Users Episodes Users Users	38,386,167 19,534,099.5 0 0 0 0 0 37,389 29,277.0 0 0 0 0 1,028 594.0 0
Idelalisib and Ibritumomab, CLL		18-44 Years	Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied	38,386,167 19,534,099.5 0 0 0 0 0 0 37,389 29,277.0 0 0 0 0 1,028 594.0 0 0
Idelalisib and Ibritumomab, CLL		18-44 Years	Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members WemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Amount Supplied	38,386,167 19,534,099.5 0 0 0 0 0 37,389 29,277.0 0 0 1,028 594.0 0 0 0 0
Idelalisib and Ibritumomab, CLL		18-44 Years	Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members	38,386,167 19,534,099.5 0 0 0 0 0 37,389 29,277.0 0 0 1,028 594.0 0 0 0 0 3,173
Idelalisib and Ibritumomab, CLL		18-44 Years 45-54 Years	Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears	38,386,167 19,534,099.5 0 0 0 0 0 37,389 29,277.0 0 0 1,028 594.0 0 0 0 0 3,173 2,063.2
Idelalisib and Ibritumomab, CLL		18-44 Years	Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Users Users	38,386,167 19,534,099.5 0 0 0 0 0 37,389 29,277.0 0 0 1,028 594.0 0 0 0 3,173 2,063.2 0
Idelalisib and Ibritumomab, CLL		18-44 Years 45-54 Years	Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Users Episodes	38,386,167 19,534,099.5 0 0 0 0 0 37,389 29,277.0 0 0 1,028 594.0 0 0 0 3,173 2,063.2 0 0
Idelalisib and Ibritumomab, CLL		18-44 Years 45-54 Years	Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Users Episodes Dispensings	38,386,167 19,534,099.5 0 0 0 0 0 37,389 29,277.0 0 0 1,028 594.0 0 0 0 3,173 2,063.2 0 0
Idelalisib and Ibritumomab, CLL		18-44 Years 45-54 Years	Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied	38,386,167 19,534,099.5 0 0 0 0 0 37,389 29,277.0 0 0 1,028 594.0 0 0 0 3,173 2,063.2 0 0 0 0
Idelalisib and Ibritumomab, CLL		18-44 Years 45-54 Years	Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Amount Supplied	38,386,167 19,534,099.5 0 0 0 0 0 37,389 29,277.0 0 0 1,028 594.0 0 0 0 3,173 2,063.2 0 0 0 0
Idelalisib and Ibritumomab, CLL		18-44 Years 45-54 Years	Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied	38,386,167 19,534,099.5 0 0 0 0 0 37,389 29,277.0 0 0 1,028 594.0 0 0 0 3,173 2,063.2 0 0 0 0



				_
		65+ Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	25,103
			MemberYears	20,157.5
	Sex	Female	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			• •	
			Eligible Members	15,900
			MemberYears	12,461.7
		Male	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	21,487
			MemberYears	16,814.0
		Unknown	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	2
			MemberYears	1.3
	Year	2014	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	32,634
			MemberYears	12,875.6
		2015	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	31,284
			MemberYears	16,401.4
Idelalisib and Ibrutinib, Any				
Indication	TOTAL	Total	Users	21
			Episodes	21
			Dispensings	21
			Days Supplied	1,662
			Amount Supplied	18
			Eligible Members	45,938,002
			MemberYears	34,458,133.1
	AgeGroup	18-44 Years	Users	2
			Episodes	2
			Dispensings	2
			Days Supplied	182
			Amount Supplied	2
			Eligible Members	23,614,134
			MemberYears	
		45-54 Years		16,258,012.1
		45-54 Years	Users	2
			Episodes	2
			Dispensings	2
			Days Supplied	60
			Amount Supplied	2
			Eligible Members	9,304,524
			MemberYears	6,575,969.8
		55-64 Years	Users	8
			_	



			e · · ·	0
			Episodes	8
			Dispensings	8
			Days Supplied	350
			Amount Supplied	7
			Eligible Members	8,219,330
			MemberYears	5,975,767.6
		65+ Years	Users	9
			Episodes	9
			Dispensings	9
			Days Supplied	1,070
			Amount Supplied	8
			Eligible Members	6,592,965
			MemberYears	5,648,383.5
	Sex	Female	Users	7
			Episodes	7
			Dispensings	7
			Days Supplied	975
			Amount Supplied	6
			Eligible Members	23,519,031
			MemberYears	17,719,236.5
		Male	Users	14
			Episodes	14
			Dispensings	14
			Days Supplied	687
			Amount Supplied	12
			Eligible Members	22,416,713
			MemberYears	16,737,341.4
		Unknown	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	2,258
			MemberYears	1,555.1
	Year	2014	Users	15
			Episodes	15
			Dispensings	15
			Days Supplied	1,370
			Amount Supplied	14
			Eligible Members	37,580,728
		2015	MemberYears	14,924,033.6
		2015	Users	6
			Episodes	6
			Dispensings	6
			Days Supplied	292
			Amount Supplied	4
			Eligible Members MemberYears	38,386,167
Idelalisib and Ibrutinib, CLL	TOTAL	Total	-	19,534,099.5
ideialisis and isrudilis, CLL	TOTAL	TOTAL	Users Episodes	15 15
			Dispensings	15
			Dispensings  Days Supplied	983
			Amount Supplied	13
			Eligible Members	37,389
			MemberYears	29,277.0
		18-44 Years	Users	0
	AgeGroup			•
	AgeGroup	10-44 (6413		
	AgeGroup	10-44 Teals	Episodes	0
	AgeGroup	10-44 Teals	Episodes Dispensings	0 0
	AgeGroup	10-44 Teal3	Episodes Dispensings Days Supplied	0 0 0
	AgeGroup	10-44 Teals	Episodes Dispensings Days Supplied Amount Supplied	0 0 0
	AgeGroup	10-44 reals	Episodes Dispensings Days Supplied	0 0 0



		45.54.		2
		45-54 Years	Users	2
			Episodes	2
			Dispensings	2 60
			Days Supplied Amount Supplied	2
			Eligible Members	3,173
			MemberYears	2,063.2
		55-64 Years	Users	6
		33-04 Tears	Episodes	6
			Dispensings	6
			Days Supplied	260
			Amount Supplied	5
			Eligible Members	9,262
			MemberYears	6,462.2
		65+ Years	Users	7
			Episodes	7
			Dispensings	7
			Days Supplied	663
			Amount Supplied	6
			Eligible Members	25,103
			MemberYears	20,157.5
	Sex	Female	Users	4
			Episodes	4
			Dispensings	4
			Days Supplied	416
			Amount Supplied	4
			Eligible Members	15,900
			MemberYears	12,461.7
		Male	Users	11
			Episodes Dispensings	11 11
			Dispensings  Days Supplied	567
			Amount Supplied	9
			Eligible Members	21,487
			MemberYears	16,814.0
		Unknown	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	2
			MemberYears	1.3
	Year	2014	Users	9
			Episodes	9
			Dispensings	9
			Days Supplied	691
			Amount Supplied	9
			Eligible Members MemberYears	32,634 12,875,6
		2015	Users	12,875.6 6
		2013	Episodes	6
			Dispensings	6
			Days Supplied	292
			Amount Supplied	4
			Eligible Members	31,284
			MemberYears	16,401.4
Idelalisib and Lenalidomide, Any				
Indication	TOTAL	Total	Users	5
			Episodes	5
			Dispensings	5
			Days Supplied	311
			Amount Supplied	5
			Eligible Members	45,938,002
	A 00 C 11 0 11 11	10 // Vaan	MemberYears	34,458,133.1
	AgeGroup	18-44 Years	Users	1



		F : 1	
		Episodes	1
		Dispensings	1
		Days Supplied	30
		Amount Supplied	1
		Eligible Members	23,614,134
	45 54 Veers	MemberYears	16,258,012.1
	45-54 Years	Users	0
		Episodes	0
		Dispensings	0
		Days Supplied	0
		Amount Supplied	0
		Eligible Members	9,304,524
	EE CAV	MemberYears	6,575,969.8
	55-64 Years	Users	1
		Episodes	1
		Dispensings	1 30
		Days Supplied Amount Supplied	1
		Eligible Members	8,219,330
	65+ Years	MemberYears	5,975,767.6
	os+ rears	Users Episodes	3
		Dispensings	3
		Days Supplied	251
		Amount Supplied	3
		Eligible Members	6,592,965
		MemberYears	5,648,383.5
Sex	Female	Users	3
Jex	remaie	Episodes	3
		Dispensings	3
		Days Supplied	251
		Amount Supplied	3
		Eligible Members	23,519,031
		MemberYears	17,719,236.5
	Male	Users	2
		Episodes	2
		Dispensings	2
		Days Supplied	60
		Amount Supplied	2
		Eligible Members	22,416,713
		MemberYears	16,737,341.4
	Unknown	Users	0
		Episodes	0
		Dispensings	0
		Days Supplied	0
		Amount Supplied	0
		Eligible Members	2,258
		MemberYears	1,555.1
Year	2014	Users	4
		Episodes	4
		Dispensings	4
		Days Supplied	212
		Amount Supplied	4
		Eligible Members	37,580,728
		MemberYears	14,924,033.6
	2015	Users	1
		Episodes	1
		Dispensings	1
		Days Supplied	99
		Amount Supplied	1
		Eligible Members	38,386,167
		MemberYears	19,534,099.5



Idelalisib and Lenalidomide, CLL	TOTAL	Total	Users	0
,			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	37,389
			MemberYears	29,277.0
	AgeGroup	18-44 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	1,028
		45-54 Years	MemberYears Users	594.0 0
		45-54 fears	Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	3,173
			MemberYears	2,063.2
		55-64 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	9,262
			MemberYears	6,462.2
		65+ Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied Eligible Members	0 25,103
			MemberYears	20,157.5
	Sex	Female	Users	0
	Jex	remaie	Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	15,900
			MemberYears	12,461.7
		Male	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members MemberYears	21,487 16,814.0
		Unknown	Users	0
		Olikilowii	Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	2
			MemberYears	1.3
	Year	2014	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	32,634
			MemberYears	12,875.6



		2015	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members MemberYears	31,284 16,401.4
Idelalisib and Obinutuzumab, Any			Iviember rears	10,401.4
Indication	TOTAL	Total	Users	4
			Episodes	4
			Dispensings	4
			Days Supplied	908
			Amount Supplied Eligible Members	4 45,938,002
			MemberYears	34,458,133.1
	AgeGroup	18-44 Years	Users	1
			Episodes	1
			Dispensings	1
			Days Supplied	152
			Amount Supplied	1
			Eligible Members	23,614,134
		45-54 Years	MemberYears Users	16,258,012.1 0
		43-34 Teals	Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	9,304,524
			MemberYears	6,575,969.8
		55-64 Years	Users	1
			Episodes Dispensings	1
			Days Supplied	133
			Amount Supplied	1
			Eligible Members	8,219,330
			MemberYears	5,975,767.6
		65+ Years	Users	2
			Episodes	2
			Dispensings Days Supplied	623
			Amount Supplied	2
			Eligible Members	6,592,965
			MemberYears	5,648,383.5
	Sex	Female	Users	2
			Episodes	2
			Dispensings Days Supplied	2 362
			Amount Supplied	2
			Eligible Members	23,519,031
			MemberYears	17,719,236.5
		Male	Users	2
			Episodes	2
			Dispensings	2
			Days Supplied Amount Supplied	546 2
			Eligible Members	22,416,713
			MemberYears	16,737,341.4
		Unknown	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied Eligible Members	0 2,258
			MemberYears	1,555.1
	Year	2014	Users	3



			Episodes	3
			Dispensings	3
			Days Supplied	775
			Amount Supplied	3
			Eligible Members	37,580,728
			MemberYears	14,924,033.6
		2015	Users	1
		2013	Episodes	1
			Dispensings	1
			Days Supplied	133
				1
			Amount Supplied	
			Eligible Members	38,386,167
			MemberYears	19,534,099.5
Idelalisib and Obinutuzumab, CLL	TOTAL	Total	Users	3
			Episodes	3
			Dispensings	3
			Days Supplied	756
			Amount Supplied	3
			Eligible Members	37,389
			MemberYears	29,277.0
	AgeGroup	18-44 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	1,028
			MemberYears	594.0
		45-54 Years	Users	0
		45 54 10015	Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			• •	
			Eligible Members	3,173
		FF CA V	MemberYears	2,063.2
		55-64 Years	Users	1
			Episodes	1
			Dispensings	1
			Days Supplied	133
			Amount Supplied	1
			Eligible Members	9,262
			MemberYears	6,462.2
		65+ Years	Users	2
			Episodes	2
			Dispensings	2
			Days Supplied	623
			Amount Supplied	2
			Eligible Members	25,103
			MemberYears	20,157.5
	Sex	Female	Users	1
			Episodes	1
			Dispensings	1
			Days Supplied	210
			Amount Supplied	1
			Eligible Members	15,900
			MemberYears	12,461.7
		Male	Users	2
			Episodes	2
			Dispensings	2
			Days Supplied	546
			Amount Supplied	2
			Eligible Members	21,487
			MemberYears	16,814.0
			ivicinisci rears	10,017.0



				•
		Unknown	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	2
			MemberYears	1.3
	Year	2014	Users	2
			Episodes	2
			Dispensings	2
			Days Supplied	623
			Amount Supplied	2
			• •	
			Eligible Members	32,634
			MemberYears	12,875.6
		2015	Users	1
			Episodes	1
			Dispensings	1
			Days Supplied	133
			Amount Supplied	1
			Eligible Members	31,284
			MemberYears	16,401.4
Idelalisib and Ofatumumab, Any			1	-, -
Indication	TOTAL	Total	Users	2
marcation	TOTAL	Total	Episodes	2
			Dispensings	2
			Days Supplied	379
			Amount Supplied	2
			Eligible Members	45,938,002
			MemberYears	34,458,133.1
	AgeGroup	18-44 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	23,614,134
			MemberYears	16,258,012.1
		45-54 Years	Users	0
		45 54 Tears	Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	9,304,524
			MemberYears	6,575,969.8
		55-64 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	8,219,330
			MemberYears	5,975,767.6
		65+ Years	Users	2
			Episodes	2
			Dispensings	2
			Days Supplied	379
			Amount Supplied	2
			Eligible Members	6,592,965
			MemberYears	5,648,383.5
	Sex	Female	Users	1
	JCA	· Ciliare		1
			Episodes	
			Dispensings	1
			Days Supplied	142
			Amount Supplied	1
			Eligible Members	23,519,031
			MemberYears	17,719,236.5
		Male	Users	1



			Episodes	1
			Dispensings	1
			Days Supplied	237
			Amount Supplied	1
			Eligible Members	22,416,713
			MemberYears	16,737,341.4
		Unknown	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	2,258
			MemberYears	1,555.1
	Year	2014	Users	2
			Episodes	2
			Dispensings	2
			Days Supplied	379
			Amount Supplied	2
			Eligible Members	37,580,728
			MemberYears	14,924,033.6
		2015	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	38,386,167
			MemberYears	19,534,099.5
Idelalisib and Ofatumumab, CLL	TOTAL	Total	Users	2
			Episodes	2
			Dispensings	2
			Days Supplied	379
			A	1
			Amount Supplied	2
			Eligible Members	37,389
	AcaCraus	19 44 Voors	Eligible Members MemberYears	37,389 29,277.0
	AgeGroup	18-44 Years	Eligible Members MemberYears Users	37,389 29,277.0 0
	AgeGroup	18-44 Years	Eligible Members MemberYears Users Episodes	37,389 29,277.0 0 0
	AgeGroup	18-44 Years	Eligible Members MemberYears Users Episodes Dispensings	37,389 29,277.0 0 0
	AgeGroup	18-44 Years	Eligible Members MemberYears Users Episodes Dispensings Days Supplied	37,389 29,277.0 0 0 0
	AgeGroup	18-44 Years	Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied	37,389 29,277.0 0 0 0 0
	AgeGroup	18-44 Years	Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members	37,389 29,277.0 0 0 0 0 0 0 1,028
	AgeGroup	18-44 Years	Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears	37,389 29,277.0 0 0 0 0 0 0 1,028 594.0
	AgeGroup		Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users	37,389 29,277.0 0 0 0 0 0 0 1,028 594.0
	AgeGroup		Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes	37,389 29,277.0 0 0 0 0 0 0 1,028 594.0
	AgeGroup		Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings	37,389 29,277.0 0 0 0 0 0 1,028 594.0 0
	AgeGroup		Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes	37,389 29,277.0 0 0 0 0 0 1,028 594.0 0
	AgeGroup		Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied	37,389 29,277.0 0 0 0 0 0 1,028 594.0 0
	AgeGroup		Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied	37,389 29,277.0 0 0 0 0 1,028 594.0 0 0 0
	AgeGroup		Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members	37,389 29,277.0 0 0 0 0 1,028 594.0 0 0 0 3,173
	AgeGroup	45-54 Years	Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears	37,389 29,277.0 0 0 0 1,028 594.0 0 0 0 3,173 2,063.2
	AgeGroup	45-54 Years	Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Users Users Users Users	37,389 29,277.0 0 0 0 1,028 594.0 0 0 0 3,173 2,063.2
	AgeGroup	45-54 Years	Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied	37,389 29,277.0 0 0 0 1,028 594.0 0 0 3,173 2,063.2 0 0 0
	AgeGroup	45-54 Years	Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Amount Supplied	37,389 29,277.0 0 0 0 1,028 594.0 0 0 3,173 2,063.2 0 0 0
	AgeGroup	45-54 Years	Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members	37,389 29,277.0 0 0 0 1,028 594.0 0 0 0 3,173 2,063.2 0 0 0 9,262
	AgeGroup	45-54 Years 55-64 Years	Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears MemberYears	37,389 29,277.0 0 0 0 1,028 594.0 0 0 3,173 2,063.2 0 0 0 9,262 6,462.2
	AgeGroup	45-54 Years	Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users	37,389 29,277.0 0 0 0 1,028 594.0 0 0 0 3,173 2,063.2 0 0 0 9,262 6,462.2 2
	AgeGroup	45-54 Years 55-64 Years	Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes	37,389 29,277.0 0 0 0 1,028 594.0 0 0 3,173 2,063.2 0 0 0 9,262 6,462.2 2
	AgeGroup	45-54 Years 55-64 Years	Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Users Episodes Dispensings	37,389 29,277.0 0 0 0 1,028 594.0 0 0 3,173 2,063.2 0 0 0 9,262 6,462.2 2 2
	AgeGroup	45-54 Years 55-64 Years	Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied	37,389 29,277.0 0 0 0 1,028 594.0 0 0 0 3,173 2,063.2 0 0 0 9,262 6,462.2 2 2 2 379
	AgeGroup	45-54 Years 55-64 Years	Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Amount Supplied	37,389 29,277.0 0 0 0 1,028 594.0 0 0 3,173 2,063.2 0 0 0 9,262 6,462.2 2 2 379 2
	AgeGroup	45-54 Years 55-64 Years	Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied	37,389 29,277.0 0 0 0 1,028 594.0 0 0 0 3,173 2,063.2 0 0 0 9,262 6,462.2 2 2 2 379



		_		
	Sex	Female	Users	1
			Episodes	1
			Dispensings	1
			Days Supplied	142
			Amount Supplied	1
			Eligible Members	15,900
			-	•
			MemberYears	12,461.7
		Male	Users	1
			Episodes	1
			Dispensings	1
			Days Supplied	237
			Amount Supplied	1
			Eligible Members	21,487
			-	
			MemberYears	16,814.0
		Unknown	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	2
			MemberYears	
	V	204.5		1.3
	Year	2014	Users	2
			Episodes	2
			Dispensings	2
			Days Supplied	379
			Amount Supplied	2
			Eligible Members	32,634
			MemberYears	
		2045		12,875.6
		2015	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
				31.284
			Eligible Members	31,284 16.401.4
Idelalisib and Prednisone Any				31,284 16,401.4
Idelalisib and Prednisone, Any	TOTAL	Total	Eligible Members MemberYears	16,401.4
Idelalisib and Prednisone, Any Indication	TOTAL	Total	Eligible Members MemberYears Users	16,401.4 46
	TOTAL	Total	Eligible Members MemberYears Users Episodes	16,401.4 46 47
	TOTAL	Total	Eligible Members MemberYears  Users Episodes Dispensings	16,401.4 46 47 47
	TOTAL	Total	Eligible Members MemberYears  Users Episodes Dispensings Days Supplied	16,401.4 46 47
	TOTAL	Total	Eligible Members MemberYears  Users Episodes Dispensings	16,401.4 46 47 47
	TOTAL	Total	Eligible Members MemberYears  Users Episodes Dispensings Days Supplied	16,401.4 46 47 47 5,698 42
	TOTAL	Total	Eligible Members MemberYears  Users Episodes Dispensings Days Supplied Amount Supplied	16,401.4 46 47 47 5,698
		Total	Eligible Members MemberYears  Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears	16,401.4 46 47 47 5,698 42 45,938,002 34,458,133.1
	TOTAL AgeGroup		Eligible Members MemberYears  Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users	16,401.4 46 47 47 5,698 42 45,938,002 34,458,133.1 2
			Eligible Members MemberYears  Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes	16,401.4 46 47 47 5,698 42 45,938,002 34,458,133.1 2 2
			Eligible Members MemberYears  Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings	16,401.4 46 47 47 5,698 42 45,938,002 34,458,133.1 2 2 2
			Eligible Members MemberYears  Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied	16,401.4 46 47 47 5,698 42 45,938,002 34,458,133.1 2 2 2 327
			Eligible Members MemberYears  Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Amount Supplied	16,401.4 46 47 47 5,698 42 45,938,002 34,458,133.1 2 2 2 327 2
			Eligible Members MemberYears  Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members	16,401.4 46 47 47 5,698 42 45,938,002 34,458,133.1 2 2 2 327 2 23,614,134
			Eligible Members MemberYears  Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Amount Supplied	16,401.4 46 47 47 5,698 42 45,938,002 34,458,133.1 2 2 2 327 2
			Eligible Members MemberYears  Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members	16,401.4 46 47 47 5,698 42 45,938,002 34,458,133.1 2 2 2 327 2 23,614,134
		18-44 Years	Eligible Members MemberYears  Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears  MemberYears	16,401.4 46 47 47 5,698 42 45,938,002 34,458,133.1 2 2 2 327 2 23,614,134 16,258,012.1
		18-44 Years	Eligible Members MemberYears  Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Users Episodes	16,401.4 46 47 47 5,698 42 45,938,002 34,458,133.1 2 2 327 2 23,614,134 16,258,012.1 3
		18-44 Years	Eligible Members MemberYears  Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Users Episodes Dispensings	16,401.4  46 47 47 5,698 42 45,938,002 34,458,133.1 2 2 327 2 23,614,134 16,258,012.1 3 3 3
		18-44 Years	Eligible Members MemberYears  Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied	16,401.4  46 47 47 5,698 42 45,938,002 34,458,133.1 2 2 327 2 23,614,134 16,258,012.1 3 3 3 462
		18-44 Years	Eligible Members MemberYears  Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Amount Supplied	16,401.4  46 47 47 5,698 42 45,938,002 34,458,133.1 2 2 327 2 23,614,134 16,258,012.1 3 3 3 462 3
		18-44 Years	Eligible Members MemberYears  Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members	16,401.4  46 47 47 5,698 42 45,938,002 34,458,133.1 2 2 327 2 23,614,134 16,258,012.1 3 3 3 462 3 9,304,524
		18-44 Years 45-54 Years	Eligible Members MemberYears  Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears	16,401.4  46 47 47 5,698 42 45,938,002 34,458,133.1 2 2 2 327 2 23,614,134 16,258,012.1 3 3 462 3 9,304,524 6,575,969.8
		18-44 Years	Eligible Members MemberYears  Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users	16,401.4  46 47 47 5,698 42 45,938,002 34,458,133.1 2 2 2 327 2 23,614,134 16,258,012.1 3 3 462 3 9,304,524 6,575,969.8 17
		18-44 Years 45-54 Years	Eligible Members MemberYears  Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears	16,401.4  46 47 47 5,698 42 45,938,002 34,458,133.1 2 2 2 327 2 23,614,134 16,258,012.1 3 3 462 3 9,304,524 6,575,969.8
		18-44 Years 45-54 Years	Eligible Members MemberYears  Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users	16,401.4  46 47 47 5,698 42 45,938,002 34,458,133.1 2 2 2 327 2 23,614,134 16,258,012.1 3 3 462 3 9,304,524 6,575,969.8 17
		18-44 Years 45-54 Years	Eligible Members MemberYears  Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes	16,401.4  46 47 47 5,698 42 45,938,002 34,458,133.1 2 2 2 327 2 23,614,134 16,258,012.1 3 3 462 3 9,304,524 6,575,969.8 17 17
		18-44 Years 45-54 Years	Eligible Members MemberYears  Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied	16,401.4  46 47 47 5,698 42 45,938,002 34,458,133.1 2 2 2 327 2 23,614,134 16,258,012.1 3 3 462 3 9,304,524 6,575,969.8 17 17
		18-44 Years 45-54 Years	Eligible Members MemberYears  Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Amount Supplied	16,401.4  46 47 47 5,698 42 45,938,002 34,458,133.1 2 2 2 327 2 23,614,134 16,258,012.1 3 3 462 3 9,304,524 6,575,969.8 17 17 17 1,719 15
		18-44 Years 45-54 Years	Eligible Members MemberYears  Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members Dispensings Days Supplied Amount Supplied Eligible Members	16,401.4  46 47 47 5,698 42 45,938,002 34,458,133.1 2 2 2 327 2 23,614,134 16,258,012.1 3 3 462 3 9,304,524 6,575,969.8 17 17 1,719 15 8,219,330
		18-44 Years 45-54 Years 55-64 Years	Eligible Members MemberYears  Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears	16,401.4  46 47 47 5,698 42 45,938,002 34,458,133.1 2 2 2 327 2 23,614,134 16,258,012.1 3 3 462 3 9,304,524 6,575,969.8 17 17 1,719 15 8,219,330 5,975,767.6
		18-44 Years 45-54 Years	Eligible Members MemberYears  Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members Dispensings Days Supplied Amount Supplied Eligible Members	16,401.4  46 47 47 5,698 42 45,938,002 34,458,133.1 2 2 2 327 2 23,614,134 16,258,012.1 3 3 462 3 9,304,524 6,575,969.8 17 17 1,719 15 8,219,330



			Fatandan	25
			Episodes	25
			Dispensings	25
			Days Supplied	3,190
			Amount Supplied	23
			Eligible Members	6,592,965
	C	F	MemberYears	5,648,383.5
	Sex	Female	Users	17
			Episodes	18
			Dispensings	18
			Days Supplied	2,320
			Amount Supplied	16
			Eligible Members	23,519,031
		0.0-1-	MemberYears	17,719,236.5
		Male	Users	29
			Episodes	29
			Dispensings	29
			Days Supplied	3,378
			Amount Supplied	26
			Eligible Members	22,416,713
			MemberYears	16,737,341.4
		Unknown	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	2,258
			MemberYears	1,555.1
	Year	2014	Users	20
			Episodes	20
			Dispensings	20
			Days Supplied	3,089
			Amount Supplied	19
			Eligible Members	37,580,728
			MemberYears	14,924,033.6
		2015	Users	26
			Episodes	27
			Dispensings	27
			Days Supplied	2,609
			Amount Supplied	22
			Eligible Members	38,386,167
Idelalisib and Prednisone, CLL	TOTAL	Total	MemberYears	19,534,099.5 29
ideialisib and Prednisone, CLL	TOTAL	Total	Users Episodes	
			Dispensings	29 29
			Dispensings  Days Supplied	
			Amount Supplied	3,622 26
			Eligible Members	37,389
			MemberYears	29,277.0
	AgeGroup	18-44 Years	Users	1
	Agedioup	10-44 (Cais	Episodes	1
			Dispensings	1
			Days Supplied	175
			Amount Supplied	1
			Eligible Members	1,028
			MemberYears	594.0
		45-54 Years	Users	1
		25 5 1 TC015	Episodes	1
			Dispensings	1
			Days Supplied	218
			Amount Supplied	1
			Eligible Members	3,173
			MemberYears	2,063.2
			ciiibci i cui s	_,003.2



		== cav	l	4.2
		55-64 Years	Users	12
			Episodes	12
			Dispensings	12
			Days Supplied	1,036
			Amount Supplied	10
			Eligible Members	9,262
			MemberYears	6,462.2
		65+ Years	Users	15
			Episodes	15
			Dispensings	15
			Days Supplied	2,193
			Amount Supplied	14
			Eligible Members	25,103
			MemberYears	20,157.5
	Sex	Female	Users	8
			Episodes	8
			Dispensings	8
			Days Supplied	1,267
			Amount Supplied	8
			Eligible Members	15,900
			MemberYears	12,461.7
		Male	Users	21
			Episodes	21
			Dispensings	21
			Days Supplied	2,355
			Amount Supplied	18
			Eligible Members	21,487
			MemberYears	16,814.0
		Unknown	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	2
			MemberYears	1.3
	Year	2014	Users	11
			Episodes	11
			Dispensings	11
			Days Supplied	1,665
			Amount Supplied	11
			Eligible Members	32,634
			MemberYears	12,875.6
		2015	Users	18
			Episodes	18
			Dispensings	18
			Days Supplied	1,957
			Amount Supplied	15
			Eligible Members	31,284
			MemberYears	16,401.4
Idelalisib and Rituximab, Any			1	
Indication	TOTAL	Total	Users	81
			Episodes	85
			Dispensings	85
			Days Supplied	9,625
			Amount Supplied	79
			Eligible Members	45,938,002
			MemberYears	34,458,133.1
	AgeGroup	18-44 Years	Users	2
			Episodes	2
			Dispensings	2
			Days Supplied	129
			Amount Supplied	2
			Eligible Members	23,614,134
			MemberYears	16,258,012.1
		45-54 Years	Users	8
			_	



		55-64 Years	Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears	8 8 940 8 9,304,524 6,575,969.8 24 25 25 2,889 23 8,219,330
		65+ Years	Users	5,975,767.6 47
			Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears	50 50 5,667 46 6,592,965 5,648,383.5
	Sex	Female	Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears	29 29 3,678 28 23,519,031 17,719,236.5
		Male	Users	52
			Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears	56 56 5,947 51 22,416,713 16,737,341.4
		Unknown	Users	0
			Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears	0 0 0 0 2,258 1,555.1
	Year	2014	Users	42
			Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears	42 42 5,629 41 37,580,728 14,924,033.6
		2015	Users	41
			Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears	43 43 3,996 38 38,386,167 19,534,099.5
Idelalisib and Rituximab, CLL	TOTAL	Total	Users	51
			Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears	55 55 6,623 50 37,389 29,277.0



	2015	Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears	25 25 3,668 24 32,634 12,875.6 28 30 30 2,955 26 31,284 16,401.4
	2015	Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied	25 3,668 24 32,634 12,875.6 28 30 30 2,955 26
	2015	Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings	25 3,668 24 32,634 12,875.6 28 30
	2015	Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes	25 3,668 24 32,634 12,875.6 28 30
	2015	Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users	25 3,668 24 32,634 12,875.6 28
		Dispensings Days Supplied Amount Supplied Eligible Members MemberYears	25 3,668 24 32,634 12,875.6
		Dispensings Days Supplied Amount Supplied Eligible Members	25 3,668 24 32,634
		Dispensings Days Supplied	25 3,668
		Dispensings	25
		•	
			25
Year	2014	Users	25
	201	MemberYears	1.3
		Eligible Members	2
		Amount Supplied	0
		Dispensings Days Supplied	0
		Episodes Dispensings	0 0
	Unknown	Users Episodes	0
		MemberYears	16,814.0
		Eligible Members	21,487
		Amount Supplied	32
		Dispensings  Days Supplied	4,105
		Episodes Dispensings	36 36
	Male	Users	32 36
	Mala	MemberYears	12,461.7
		Eligible Members	15,900
		Amount Supplied	18
		Days Supplied	2,518
		Dispensings	19
ЭЕХ	remaie	Episodes	19
Sex	Female	MemberYears Users	20,157.5 19
		Eligible Members	25,103
		Amount Supplied	31
		Days Supplied	4,108
		Dispensings	34
	OST TEATS	Episodes	34
	65+ Years	MemberYears Users	6,462.2 31
		Eligible Members	9,262
		Amount Supplied	17
		Days Supplied	2,267
		Dispensings	19
	55-64 Years	Users Episodes	18 19
	EE 64 Vaara	MemberYears	2,063.2
		Eligible Members	3,173
		Amount Supplied	2
		Days Supplied	248
		Dispensings	2
	43-34 Tears	Episodes	2
	45-54 Years	Users	594.0 2
		Eligible Members MemberYears	1,028
		Amount Supplied	0
		Days Supplied	0
		Dispensings	0
-7Pc-Gloub	10 77 1Ca13	Episodes	0
AgeGroup	18-44 Years	Users	0



		Episodes	1
		Dispensings	1
		Days Supplied	267
		Amount Supplied	1
		Eligible Members	45,938,002
AgoCo	10 44 Voors	MemberYears	34,458,133.1
AgeGr	oup 18-44 Years	Users	0
		Episodes Dispensings	0 0
		Days Supplied	0
		Amount Supplied	0
		Eligible Members	23,614,134
		MemberYears	16,258,012.1
	45-54 Years	Users	0
		Episodes	0
		Dispensings	0
		Days Supplied	0
		Amount Supplied	0
		Eligible Members	9,304,524
		MemberYears	6,575,969.8
	55-64 Years	Users	0
		Episodes	0
		Dispensings	0
		Days Supplied	0
		Amount Supplied	0
		Eligible Members MemberYears	8,219,330
	65+ Years	Users	5,975,767.6 1
	UST Teats	Episodes	1
		Dispensings	1
		Days Supplied	267
		Amount Supplied	1
			6 502 065
		Eligible Members	6,592,965
		Eligible Members MemberYears	6,592,965 5,648,383.5
Sex	Female	J	
Sex	Female	MemberYears	5,648,383.5
Sex	Female	MemberYears Users Episodes Dispensings	5,648,383.5 1 1 1
Sex	Female	MemberYears Users Episodes Dispensings Days Supplied	5,648,383.5 1 1 1 267
Sex	Female	MemberYears Users Episodes Dispensings Days Supplied Amount Supplied	5,648,383.5 1 1 1 267 1
Sex	Female	MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members	5,648,383.5 1 1 1 267 1 23,519,031
Sex		MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears	5,648,383.5 1 1 1 267 1 23,519,031 17,719,236.5
Sex	Female Male	MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users	5,648,383.5 1 1 1 267 1 23,519,031 17,719,236.5 0
Sex		MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes	5,648,383.5 1 1 1 267 1 23,519,031 17,719,236.5 0
Sex		MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings	5,648,383.5 1 1 1 267 1 23,519,031 17,719,236.5 0 0
Sex		MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied	5,648,383.5 1 1 1 267 1 23,519,031 17,719,236.5 0
Sex		MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings	5,648,383.5 1 1 1 267 1 23,519,031 17,719,236.5 0 0
Sex		MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied	5,648,383.5 1 1 1 267 1 23,519,031 17,719,236.5 0 0 0
Sex		MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members	5,648,383.5 1 1 1 267 1 23,519,031 17,719,236.5 0 0 0 22,416,713
Sex	Male	MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Ligible Members MemberYears Users Episodes	5,648,383.5 1 1 1 267 1 23,519,031 17,719,236.5 0 0 0 22,416,713 16,737,341.4 0 0
Sex	Male	MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Dispensings Days Supplied Eligible Members MemberYears Users Episodes Dispensings	5,648,383.5 1 1 1 267 1 23,519,031 17,719,236.5 0 0 0 22,416,713 16,737,341.4 0 0 0
Sex	Male	MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied	5,648,383.5 1 1 1 267 1 23,519,031 17,719,236.5 0 0 0 0 22,416,713 16,737,341.4 0 0 0 0
Sex	Male	MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Amount Supplied	5,648,383.5 1 1 1 267 1 23,519,031 17,719,236.5 0 0 0 0 22,416,713 16,737,341.4 0 0 0 0 0
Sex	Male	MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members	5,648,383.5 1 1 1 267 1 23,519,031 17,719,236.5 0 0 0 0 22,416,713 16,737,341.4 0 0 0 0 2,258
	Male Unknown	MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears	5,648,383.5 1 1 1 267 1 23,519,031 17,719,236.5 0 0 0 0 22,416,713 16,737,341.4 0 0 0 0 2,258 1,555.1
Year	Male	MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users	5,648,383.5 1 1 1 267 1 23,519,031 17,719,236.5 0 0 0 22,416,713 16,737,341.4 0 0 0 2,258 1,555.1 1
	Male Unknown	MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes	5,648,383.5 1 1 1 267 1 23,519,031 17,719,236.5 0 0 0 0 22,416,713 16,737,341.4 0 0 0 2,258 1,555.1 1
	Male Unknown	MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings	5,648,383.5 1 1 1 267 1 23,519,031 17,719,236.5 0 0 0 0 22,416,713 16,737,341.4 0 0 0 2,258 1,555.1 1 1
	Male Unknown	MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied	5,648,383.5 1 1 1 267 1 23,519,031 17,719,236.5 0 0 0 0 22,416,713 16,737,341.4 0 0 0 2,258 1,555.1 1
	Male Unknown	MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings	5,648,383.5 1 1 1 267 1 23,519,031 17,719,236.5 0 0 0 22,416,713 16,737,341.4 0 0 0 2,258 1,555.1 1 1 1 267
	Male Unknown	MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied	5,648,383.5 1 1 1 267 1 23,519,031 17,719,236.5 0 0 0 22,416,713 16,737,341.4 0 0 0 2,258 1,555.1 1 1 1 267 1
	Male Unknown	MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users	5,648,383.5 1 1 1 267 1 23,519,031 17,719,236.5 0 0 0 0 22,416,713 16,737,341.4 0 0 0 2,258 1,555.1 1 1 1 267 1 37,580,728 14,924,033.6 0
	Male Unknown	MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears	5,648,383.5 1 1 1 267 1 23,519,031 17,719,236.5 0 0 0 0 22,416,713 16,737,341.4 0 0 0 2,258 1,555.1 1 1 267 1 37,580,728 14,924,033.6



Idelalisib and Vincristine, CLL	TOTAL	Total	Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears	0 0 38,386,167 19,534,099.5 0 0 0 0 0 37,389 29,277.0
	AgeGroup	18-44 Years	Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears	0 0 0 0 0 0 1,028 594.0
		45-54 Years	Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears	0 0 0 0 0 3,173 2,063.2
		55-64 Years	Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears	0 0 0 0 0 9,262 6,462.2
		65+ Years	Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears	0 0 0 0 0 0 25,103 20,157.5
	Sex	Female	Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears	0 0 0 0 0 15,900 12,461.7
		Male	Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears	0 0 0 0 0 21,487 16,814.0
		Unknown	Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears	0 0 0 0 0 0 2 1.3



Voor	2014	Hears	0
Year	2014	Users	0 0
		Episodes Dispensings	0
		Days Supplied	0
		Amount Supplied	0
		Eligible Members	32,634
		MemberYears	12,875.6
	2015	Users	0
	2013	Episodes	0
		Dispensings	0
		Days Supplied	0
		Amount Supplied	0
		Eligible Members	31,284
		MemberYears	16,401.4
Any idelalisib use, FL TOTAL	Total	Users	82
		Episodes	278
		Dispensings	278
		Days Supplied	7,757
		Amount Supplied	15,332
		Eligible Members	22,182
		MemberYears	15,238.4
AgeGrou	ip 18-44 Years	Users	5
		Episodes	9
		Dispensings	9
		Days Supplied	244
		Amount Supplied	488
		Eligible Members	2,015
		MemberYears	1,195.7
	45-54 Years	Users	15
		Episodes	59
		Dispensings	59
		Days Supplied	1,615
		Amount Supplied	3,200
		Eligible Members	3,545
		MemberYears	2,217.5
	55-64 Years	Users	18
		Episodes	74
		Dispensings	74
		Days Supplied	1,944
		Amount Supplied Eligible Members	3,832
		MemberYears	6,511 4,249.9
	65+ Years	Users	4,249.9 44
	UJ+ Teals	Episodes	136
		Dispensings	136
		Days Supplied	3,954
		Amount Supplied	7,812
		Eligible Members	10,917
		MemberYears	7,575.3
Sex	Female	Users	38
		Episodes	121
		Dispensings	121
		Days Supplied	3,380
		Amount Supplied	6,730
		Eligible Members	11,031
		MemberYears	7,610.8
	Male	Users	44
		Episodes	157
		Dispensings	157
		Days Supplied	4,377
		Days Supplied Amount Supplied	4,377 8,602
		Days Supplied	4,377



		Unknown	Users	0
		Olikilowii	Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	0
	.,		MemberYears	0.0
	Year	2014	Users	43
			Episodes	91
			Dispensings	91
			Days Supplied	2,614
			Amount Supplied	5,198
			Eligible Members	19,019
			MemberYears	7,024.3
		2015	Users	58
			Episodes	187
			Dispensings	187
			Days Supplied	5,143
			Amount Supplied	10,134
			Eligible Members	17,326
			MemberYears	8,214.2
Any idelalisib, SLL	TOTAL	Total	Users	171
•			 Episodes	575
			Dispensings	575
			Days Supplied	15,782
			Amount Supplied	31,342
			Eligible Members	86,698
			MemberYears	60,976.1
	AgeGroup	18-44 Years	Users	7
	Agedioup	10-44 (Cais	Episodes	13
			Dispensings	13
			Days Supplied	364
			Amount Supplied	698
			Eligible Members	11,206
		45 54 V	MemberYears	6,918.1
		45-54 Years	Users	25
			Episodes	90
			Dispensings	90
			Days Supplied	2,452
			Amount Supplied	4,874
			Eligible Members	12,933
			MemberYears	8,140.3
		55-64 Years	Users	48
			Episodes	165
			Dispensings	165
			Days Supplied	4,515
			Amount Supplied	8,964
			Eligible Members	22,742
			MemberYears	14,936.2
		65+ Years	Users	92
			Episodes	307
			Dispensings	307
			Days Supplied	8,451
			Amount Supplied	16,806
			Eligible Members	42,871
			MemberYears	30,981.4
	Sex	Female	Users	74
			Episodes	235
			Dispensings	235
			Days Supplied	6,502
			Amount Supplied	12,934
			Eligible Members	41,121
			MemberYears	29,089.2



			_	
		Male	Users	97
			Episodes	340
			Dispensings	340
			Days Supplied	9,280
			Amount Supplied	18,408
			Eligible Members	45,573
			MemberYears	31,884.3
		Unknown	Users	0
		Onknown	Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			• •	
			Eligible Members	4
			MemberYears	2.6
	Year	2014	Users	83
			Episodes	172
			Dispensings	172
			Days Supplied	4,940
			Amount Supplied	9,820
			Eligible Members	74,416
			MemberYears	27,766.1
		2015	Users	126
			Episodes	403
			Dispensings	403
			Days Supplied	10,842
			Amount Supplied	21,522
			Eligible Members	68,805
			MemberYears	33,210.0
Idelalisib and Bendamustine, FL	TOTAL	Total	Users	3
			Episodes	3
			Dispensings	3
			Days Supplied	286
			Amount Supplied	3
			Eligible Members	22,182
			MemberYears	15,238.4
	AgeGroup	18-44 Years	Users	0
	Agedioup	10-44 (Cal3	Episodes	0
			•	
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	2,015
			MemberYears	1,195.7
		45-54 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	3,545
			MemberYears	2,217.5
		55-64 Years	Users	1
			Episodes	1
			Dispensings	1
			Days Supplied	132
			Days Supplied Amount Supplied	132 1
			Days Supplied	132
			Days Supplied Amount Supplied	132 1
		65+ Years	Days Supplied Amount Supplied Eligible Members	132 1 6,511
		65+ Years	Days Supplied Amount Supplied Eligible Members MemberYears	132 1 6,511 4,249.9
		65+ Years	Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes	132 1 6,511 4,249.9 2
		65+ Years	Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings	132 1 6,511 4,249.9 2 2 2
		65+ Years	Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied	132 1 6,511 4,249.9 2 2 2 2
		65+ Years	Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied	132 1 6,511 4,249.9 2 2 2 2 154
		65+ Years	Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied	132 1 6,511 4,249.9 2 2 2 2



	C	Famala	Llaava	1
	Sex	Female	Users	1
			Episodes	1
			Dispensings	1
			Days Supplied	60
			Amount Supplied	1
			Eligible Members	11,031
			MemberYears	7,610.8
		Male	Users	2
			Episodes	2
			Dispensings	2
			Days Supplied	226
			Amount Supplied	2
			Eligible Members	11,151
			MemberYears	7,627.6
		Unknown	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	0
			MemberYears	0.0
	Year	2014	Users	2
	i cai	2014	Episodes	2
			•	2
			Dispensings	
			Days Supplied	192
			Amount Supplied	2
			Eligible Members	19,019
			MemberYears	7,024.3
		2015	Users	1
			Episodes	1
			Dispensings	1
			Days Supplied	94
			Days Supplied Amount Supplied	94 1
			Days Supplied	
			Days Supplied Amount Supplied Eligible Members MemberYears	1
Idelalisib and Bendamustine, SLL	TOTAL	Total	Days Supplied Amount Supplied Eligible Members	1 17,326 8,214.2 7
Idelalisib and Bendamustine, SLL	TOTAL	Total	Days Supplied Amount Supplied Eligible Members MemberYears	1 17,326 8,214.2
Idelalisib and Bendamustine, SLL	TOTAL	Total	Days Supplied Amount Supplied Eligible Members MemberYears Users	1 17,326 8,214.2 7
Idelalisib and Bendamustine, SLL	TOTAL	Total	Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes	1 17,326 8,214.2 7 7
Idelalisib and Bendamustine, SLL	TOTAL	Total	Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings	1 17,326 8,214.2 7 7
Idelalisib and Bendamustine, SLL	TOTAL	Total	Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied	1 17,326 8,214.2 7 7 7 392
Idelalisib and Bendamustine, SLL	TOTAL	Total	Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied	1 17,326 8,214.2 7 7 7 7 392 6
Idelalisib and Bendamustine, SLL	TOTAL	Total  18-44 Years	Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members	1 17,326 8,214.2 7 7 7 392 6 86,698
Idelalisib and Bendamustine, SLL			Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears	1 17,326 8,214.2 7 7 7 392 6 86,698 60,976.1
Idelalisib and Bendamustine, SLL			Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes	1 17,326 8,214.2 7 7 7 392 6 86,698 60,976.1 1
Idelalisib and Bendamustine, SLL			Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings	1 17,326 8,214.2 7 7 7 392 6 86,698 60,976.1 1
Idelalisib and Bendamustine, SLL			Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied	1 17,326 8,214.2 7 7 7 392 6 86,698 60,976.1 1 1
Idelalisib and Bendamustine, SLL			Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Amount Supplied Amount Supplied Amount Supplied	1 17,326 8,214.2 7 7 7 392 6 86,698 60,976.1 1 1 1 30
Idelalisib and Bendamustine, SLL			Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied	1 17,326 8,214.2 7 7 7 7 392 6 86,698 60,976.1 1 1 30 1 11,206
Idelalisib and Bendamustine, SLL			Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members Episodes Dispensings Days Supplied Amount Supplied Eligible Members	1 17,326 8,214.2 7 7 7 392 6 86,698 60,976.1 1 1 1 30
Idelalisib and Bendamustine, SLL		18-44 Years	Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Users Users Users Users	1 17,326 8,214.2 7 7 7 7 392 6 86,698 60,976.1 1 1 30 1 11,206 6,918.1 0
Idelalisib and Bendamustine, SLL		18-44 Years	Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Users Episodes Users Episodes	1 17,326 8,214.2 7 7 7 7 392 6 86,698 60,976.1 1 1 30 1 11,206 6,918.1 0
Idelalisib and Bendamustine, SLL		18-44 Years	Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings	1 17,326 8,214.2 7 7 7 7 392 6 86,698 60,976.1 1 1 30 1 11,206 6,918.1 0
Idelalisib and Bendamustine, SLL		18-44 Years	Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied	1 17,326 8,214.2 7 7 7 7 392 6 86,698 60,976.1 1 1 30 1 11,206 6,918.1 0 0
Idelalisib and Bendamustine, SLL		18-44 Years	Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Amount Supplied	1 17,326 8,214.2 7 7 7 7 392 6 86,698 60,976.1 1 1 30 1 11,206 6,918.1 0 0
Idelalisib and Bendamustine, SLL		18-44 Years	Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members	1 17,326 8,214.2 7 7 7 7 392 6 86,698 60,976.1 1 1 30 1 11,206 6,918.1 0 0 0 0
Idelalisib and Bendamustine, SLL		18-44 Years 45-54 Years	Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears MemberYears	1 17,326 8,214.2 7 7 7 7 392 6 86,698 60,976.1 1 1 1,206 6,918.1 0 0 0 0 12,933 8,140.3
Idelalisib and Bendamustine, SLL		18-44 Years	Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Users	1 17,326 8,214.2 7 7 7 7 392 6 86,698 60,976.1 1 1 1,206 6,918.1 0 0 0 0 12,933 8,140.3 2
Idelalisib and Bendamustine, SLL		18-44 Years 45-54 Years	Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Users Episodes	1 17,326 8,214.2 7 7 7 7 392 6 86,698 60,976.1 1 1 30 1 11,206 6,918.1 0 0 0 0 0 12,933 8,140.3 2 2
Idelalisib and Bendamustine, SLL		18-44 Years 45-54 Years	Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Users Episodes Dispensings	1 17,326 8,214.2 7 7 7 7 392 6 86,698 60,976.1 1 1 11,206 6,918.1 0 0 0 0 12,933 8,140.3 2 2
Idelalisib and Bendamustine, SLL		18-44 Years 45-54 Years	Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied	1 17,326 8,214.2 7 7 7 7 392 6 86,698 60,976.1 1 1 11,206 6,918.1 0 0 0 0 12,933 8,140.3 2 2 2 162
Idelalisib and Bendamustine, SLL		18-44 Years 45-54 Years	Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Amount Supplied	1 17,326 8,214.2 7 7 7 392 6 86,698 60,976.1 1 1 11,206 6,918.1 0 0 0 12,933 8,140.3 2 2 2 162 2
Idelalisib and Bendamustine, SLL		18-44 Years 45-54 Years	Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied	1 17,326 8,214.2 7 7 7 7 392 6 86,698 60,976.1 1 1 11,206 6,918.1 0 0 0 0 12,933 8,140.3 2 2 2 162



		65+ Years	Users	4
		05. 100.5	Episodes	4
			Dispensings	4
			Days Supplied	200
			Amount Supplied	3
			Eligible Members	42,871
			MemberYears	30,981.4
	Sex	Female	Users	3
	JCA	remare	Episodes	3
			Dispensings	3
			Days Supplied	106
			Amount Supplied	2
			Eligible Members	41,121
			MemberYears	29,089.2
		Male	Users	4
			Episodes	4
			Dispensings	4
			Days Supplied	286
			Amount Supplied	4
			Eligible Members	45,573
			MemberYears	31,884.3
		Unknown	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	4
			MemberYears	2.6
	Year	2014	Users	4
			Episodes	4
			Dispensings	4
			Days Supplied	252
			Amount Supplied	4
			Eligible Members	74,416
			MemberYears	27,766.1
		2015	Users	3
			Episodes	3
			Dispensings	3
			Days Supplied	140
			Amount Supplied	2
			Eligible Members	68,805
			MemberYears	33,210.0
Idelalisib and Bortezomib, FL	TOTAL	Total	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	22,182
			MemberYears	15,238.4
	AgeGroup	18-44 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	2,015
			MemberYears	1,195.7
		45-54 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	3,545
			MemberYears	2,217.5



		55-64 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	6,511
			MemberYears	4,249.9
		65+ Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	10,917
			MemberYears	7,575.3
	Sex	Female	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	11,031
		_	MemberYears	7,610.8
		Male	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	11,151
			MemberYears	7,627.6
		Unknown	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	0
	W	2014	MemberYears	0.0
	Year	2014	Users	0
			Episodes	0
			Dispensings	0 0
			Days Supplied Amount Supplied	0
			Eligible Members	19,019
			MemberYears	7,024.3
		2015		_
		2015	Users Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	17,326
			MemberYears	8,214.2
Idelalisib and Bortezomib, SLL	TOTAL	Total	Users	0
raciansis and Bortezonnis, 522	101712	10101	Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	86,698
			MemberYears	60,976.1
	AgeGroup	18-44 Years	Users	0
	UP		Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
				-
			Eligible Members	11,206



		45 54 V	Harris	0
		45-54 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	12,933
			MemberYears	8,140.3
		55-64 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	22,742
			MemberYears	
		CE . V		14,936.2
		65+ Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	42,871
			MemberYears	30,981.4
	Sex	Female	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	41,121
			MemberYears	29,089.2
		Male	Users	0
		Willie	Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	45,573
			MemberYears	31,884.3
		Unknown	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	4
			MemberYears	2.6
	Year	2014	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	74,416
			MemberYears	27,766.1
		2015	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			• •	
			Eligible Members MemberYears	68,805
Idololisib and Chlarambusil Fi	TOTAL	Total		33,210.0
Idelalisib and Chlorambucil, FL	TOTAL	Total	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	22,182
			MemberYears	15,238.4



AgeGroup	18-44 Years	Users	0
0		Episodes	0
		Dispensings	0
		Days Supplied	0
		Amount Supplied	0
		Eligible Members	2,015
		MemberYears	1,195.7
	45-54 Years	Users	0
		Episodes	0
		Dispensings	0
		Days Supplied	0
		Amount Supplied	0
		Eligible Members	3,545
	cav	MemberYears	2,217.5
	55-64 Years	Users	0
		Episodes	0
		Dispensings Days Supplied	0 0
		Amount Supplied	0
		Eligible Members	6,511
		MemberYears	4,249.9
	65+ Years	Users	0
		Episodes	0
		Dispensings	0
		Days Supplied	0
		Amount Supplied	0
		Eligible Members	10,917
		MemberYears	7,575.3
Sex	Female	Users	0
		Episodes	0
		Dispensings	0
		Days Supplied	0
		Amount Supplied	0
		Eligible Members MemberYears	11,031 7,610.8
	Male	Users	0
	IVICIC	Episodes	0
		Dispensings	0
		Days Supplied	0
		Amount Supplied	0
		Eligible Members	11,151
		MemberYears	7,627.6
	Unknown	Users	0
		Episodes	0
		Dispensings	0
		Days Supplied	0
		Amount Supplied	0
		Eligible Members	0
Year	2014	MemberYears Users	0.0
Tear	2014	Episodes	0 0
		Dispensings	0
		Days Supplied	0
		Amount Supplied	0
		Eligible Members	19,019
		MemberYears	7,024.3
	2015	Users	0
		Episodes	0
		Dispensings	0
		Days Supplied	0
		Amount Supplied	0
		Eligible Members	17,326
		MemberYears	8,214.2



Idelalisib and Chlorambucil, SLL	TOTAL	Total	Users	3
			Episodes	3
			Dispensings	3
			Days Supplied	126
			Amount Supplied	2
			Eligible Members	86,698
			MemberYears	60,976.1
	AgeGroup	18-44 Years	Users	0
			Episodes	0
			Dispensings Days Supplied	0 0
			Amount Supplied	0
			Eligible Members	11,206
			MemberYears	6,918.1
		45-54 Years	Users	0,510.1
		10 0 1 100.10	Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	12,933
			MemberYears	8,140.3
		55-64 Years	Users	3
			Episodes	3
			Dispensings	3
			Days Supplied	126
			Amount Supplied	2
			Eligible Members	22,742
		65 · V	MemberYears	14,936.2
		65+ Years	Users	0
			Episodes Dispensings	0 0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	42,871
			MemberYears	30,981.4
	Sex	Female	Users	2
			Episodes	2
			Dispensings	2
			Days Supplied	122
			Amount Supplied	2
			Eligible Members	41,121
			MemberYears	29,089.2
		Male	Users	1
			Episodes Dispensings	1 1
			Days Supplied	4
			Amount Supplied	0
			Eligible Members	45,573
			MemberYears	31,884.3
		Unknown	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	4
			MemberYears	2.6
	Year	2014	Users	2
			Episodes	2
			Dispensings	2 122
			Days Supplied Amount Supplied	2
			Eligible Members	74,416
			MemberYears	27,766.1
			ciiibci i cui s	27,700.1



		2015	Haara	1
		2015	Users Episodes	1 1
			Dispensings	1
			Days Supplied	4
			Amount Supplied	0
			Eligible Members	68,805
			MemberYears	33,210.0
Idelalisib and Cyclophosphamide, FL	TOTAL	Total	Users Episodes	1 1
			Dispensings	1
			Days Supplied	27
			Amount Supplied	1
			Eligible Members	22,182
			MemberYears	15,238.4
	AgeGroup	18-44 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	2,015
			MemberYears	1,195.7
		45-54 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	3,545
		55-64 Years	MemberYears Users	2,217.5 0
		55-64 fears	Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	6,511
			MemberYears	4,249.9
		65+ Years	Users	1
			Episodes	1
			Dispensings	1
			Days Supplied	27
			Amount Supplied	1
			Eligible Members	10,917
	Sex	Female	MemberYears Users	7,575.3 0
	JEX	remaie	Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	11,031
			MemberYears	7,610.8
		Male	Users	1
			Episodes	1
			Dispensings	1
			Days Supplied	27
			Amount Supplied	1
			Eligible Members MemberYears	11,151 7,627.6
		Unknown	Users	7,627.6 0
		JIMIOWII	Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	0
			MemberYears	0.0
	Year	2014	Users	1



			Episodes	1
			Dispensings	1
			Days Supplied	27
			Amount Supplied	1
			Eligible Members	19,019
			MemberYears	7,024.3
		2015	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	17,326
			MemberYears	8,214.2
Idelalisib and Cyclophosphamide,			l	2
SLL	TOTAL	Total	Users	2
			Episodes	2
			Dispensings	2
			Days Supplied	294
			Amount Supplied	2
			Eligible Members MemberYears	86,698
	A == C ==	10 44 Veens		60,976.1
	AgeGroup	18-44 Years	Users	0
			Episodes Dispensings	0
				0 0
			Days Supplied Amount Supplied	0
			Eligible Members	11,206
			MemberYears	6,918.1
		45-54 Years	Users	0,918.1
		43-34 Teals	Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	12,933
			MemberYears	8,140.3
		55-64 Years	Users	0
		00 01 100.0	Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	22,742
			MemberYears	14,936.2
		65+ Years	Users	2
			Episodes	2
			Dispensings	2
			Days Supplied	294
			Amount Supplied	2
			Eligible Members	42,871
			MemberYears	30,981.4
	Sex	Female	Users	1
			Episodes	1
			Dispensings	1
			Days Supplied	267
			Amount Supplied	1
			Eligible Members	41,121
			MemberYears	29,089.2
		Male	Users	1
			Episodes	1
			Dispensings	1
			Days Supplied	27
			Amount Supplied	1
			Eligible Members	45,573
			MemberYears	31,884.3
		Unknown	Users	0
			Episodes	0



			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	4
			MemberYears	2.6
	Year	2014	Users	2
			Episodes	2
			Dispensings	2
			Days Supplied	294
			Amount Supplied	2
			Eligible Members	74,416
			MemberYears	27,766.1
		2015	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	68,805
			MemberYears	33,210.0
Idelalisib and Doxorubicin, FL	TOTAL	Total	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	22,182
			MemberYears	15,238.4
	AgeGroup	18-44 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	2,015
			MemberYears	1,195.7
		45-54 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	3,545
		== 64.4	MemberYears	2,217.5
		55-64 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0 6 F11
			Eligible Members MemberYears	6,511
		65+ Years	Users	4,249.9
		05+ feats	Episodes	0 0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	10,917
			MemberYears	7,575.3
	Sex	Female	Users	0
	JUA	· cmaic	Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	11,031
			MemberYears	7,610.8
				.,510.0



		-		
		Male	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	11,151
			MemberYears	7,627.6
		Unknown	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
				0
			Amount Supplied	
			Eligible Members	0
			MemberYears	0.0
	Year	2014	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	19,019
			MemberYears	7,024.3
		2015	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	17,326
			MemberYears	8,214.2
Idelalisib and Doxorubicin, SLL	TOTAL	Total	Users	0,214.2
idelalisib and boxorubicin, see	IOIAL	Total	Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	86,698
		40.44	MemberYears	60,976.1
	AgeGroup	18-44 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	11,206
			MemberYears	6,918.1
		45-54 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	12,933
				,
			MemberYears	8 140 3
		55-64 Vears	MemberYears	8,140.3 0
		55-64 Years	Users	0
		55-64 Years	Users Episodes	0 0
		55-64 Years	Users Episodes Dispensings	0 0 0
		55-64 Years	Users Episodes Dispensings Days Supplied	0 0 0 0
		55-64 Years	Users Episodes Dispensings Days Supplied Amount Supplied	0 0 0 0
		55-64 Years	Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members	0 0 0 0 0 22,742
			Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears	0 0 0 0 0 22,742 14,936.2
		55-64 Years 65+ Years	Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users	0 0 0 0 0 22,742 14,936.2
			Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes	0 0 0 0 0 22,742 14,936.2 0
			Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings	0 0 0 0 0 22,742 14,936.2 0
			Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied	0 0 0 0 0 22,742 14,936.2 0 0
			Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied	0 0 0 0 0 22,742 14,936.2 0 0 0
			Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members	0 0 0 0 0 22,742 14,936.2 0 0 0 0
			Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied	0 0 0 0 0 22,742 14,936.2 0 0 0



	C	F I -	Harris	^
	Sex	Female	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	41,121
			MemberYears	29,089.2
		Male	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	45,573
			MemberYears	31,884.3
		Unknown	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	4
			MemberYears	2.6
	Year	2014	Users	0
	icai	2014	Episodes	0
			Dispensings	0
				0
			Days Supplied	
			Amount Supplied	0
			Eligible Members	74,416
			MemberYears	27,766.1
		2015	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Amount Supplied Eligible Members	68,805
			Eligible Members MemberYears	
Idelalisib and Ibritumomab, FL	TOTAL	Total	Eligible Members MemberYears Users	68,805 33,210.0 0
Idelalisib and Ibritumomab, FL	TOTAL	Total	Eligible Members MemberYears Users Episodes	68,805 33,210.0 0 0
Idelalisib and Ibritumomab, FL	TOTAL	Total	Eligible Members MemberYears Users Episodes Dispensings	68,805 33,210.0 0
Idelalisib and Ibritumomab, FL	TOTAL	Total	Eligible Members MemberYears Users Episodes Dispensings Days Supplied	68,805 33,210.0 0 0
Idelalisib and Ibritumomab, FL	TOTAL	Total	Eligible Members MemberYears Users Episodes Dispensings	68,805 33,210.0 0 0
Idelalisib and Ibritumomab, FL	TOTAL	Total	Eligible Members MemberYears Users Episodes Dispensings Days Supplied	68,805 33,210.0 0 0 0
Idelalisib and Ibritumomab, FL	TOTAL	Total	Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied	68,805 33,210.0 0 0 0 0
Idelalisib and Ibritumomab, FL	TOTAL	Total  18-44 Years	Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members	68,805 33,210.0 0 0 0 0 0 0 22,182
Idelalisib and Ibritumomab, FL			Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears	68,805 33,210.0 0 0 0 0 0 0 22,182 15,238.4
Idelalisib and Ibritumomab, FL			Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users	68,805 33,210.0 0 0 0 0 0 22,182 15,238.4 0
Idelalisib and Ibritumomab, FL			Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes	68,805 33,210.0 0 0 0 0 0 22,182 15,238.4 0
Idelalisib and Ibritumomab, FL			Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings	68,805 33,210.0 0 0 0 0 0 22,182 15,238.4 0 0
Idelalisib and Ibritumomab, FL			Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied	68,805 33,210.0 0 0 0 0 0 22,182 15,238.4 0 0
Idelalisib and Ibritumomab, FL			Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied	68,805 33,210.0 0 0 0 0 0 22,182 15,238.4 0 0 0
Idelalisib and Ibritumomab, FL			Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members	68,805 33,210.0 0 0 0 0 0 22,182 15,238.4 0 0 0 0
Idelalisib and Ibritumomab, FL		18-44 Years	Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears	68,805 33,210.0 0 0 0 0 0 22,182 15,238.4 0 0 0 0 2,015 1,195.7
Idelalisib and Ibritumomab, FL		18-44 Years	Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Users	68,805 33,210.0 0 0 0 0 0 22,182 15,238.4 0 0 0 0 2,015 1,195.7 0
Idelalisib and Ibritumomab, FL		18-44 Years	Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings	68,805 33,210.0 0 0 0 0 0 22,182 15,238.4 0 0 0 0 2,015 1,195.7 0
Idelalisib and Ibritumomab, FL		18-44 Years	Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied	68,805 33,210.0 0 0 0 0 0 22,182 15,238.4 0 0 0 0 2,015 1,195.7 0 0
Idelalisib and Ibritumomab, FL		18-44 Years	Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Amount Supplied	68,805 33,210.0 0 0 0 0 22,182 15,238.4 0 0 2,015 1,195.7 0 0 0 0 0
Idelalisib and Ibritumomab, FL		18-44 Years	Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members	68,805 33,210.0 0 0 0 0 0 22,182 15,238.4 0 0 0 2,015 1,195.7 0 0 0 0 3,545
Idelalisib and Ibritumomab, FL		18-44 Years 45-54 Years	Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears	68,805 33,210.0 0 0 0 0 0 22,182 15,238.4 0 0 0 2,015 1,195.7 0 0 0 0 3,545 2,217.5
Idelalisib and Ibritumomab, FL		18-44 Years	Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users	68,805 33,210.0 0 0 0 0 0 22,182 15,238.4 0 0 2,015 1,195.7 0 0 0 3,545 2,217.5 0
Idelalisib and Ibritumomab, FL		18-44 Years 45-54 Years	Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes	68,805 33,210.0 0 0 0 0 0 22,182 15,238.4 0 0 2,015 1,195.7 0 0 0 3,545 2,217.5 0 0
Idelalisib and Ibritumomab, FL		18-44 Years 45-54 Years	Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings	68,805 33,210.0 0 0 0 0 0 22,182 15,238.4 0 0 2,015 1,195.7 0 0 0 3,545 2,217.5 0 0 0
Idelalisib and Ibritumomab, FL		18-44 Years 45-54 Years	Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied	68,805 33,210.0 0 0 0 0 0 22,182 15,238.4 0 0 2,015 1,195.7 0 0 0 3,545 2,217.5 0 0 0 0
Idelalisib and Ibritumomab, FL		18-44 Years 45-54 Years	Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Amount Supplied	68,805 33,210.0 0 0 0 0 0 22,182 15,238.4 0 0 2,015 1,195.7 0 0 0 3,545 2,217.5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Idelalisib and Ibritumomab, FL		18-44 Years 45-54 Years	Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied	68,805 33,210.0 0 0 0 0 0 22,182 15,238.4 0 0 2,015 1,195.7 0 0 0 3,545 2,217.5 0 0 0 0



		65+ Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	10,917
			MemberYears	7,575.3
	Sex	Female	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	11,031
			MemberYears	7,610.8
		Male	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	11,151
			MemberYears	7,627.6
		Unknown		-
		Unknown	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	0
			MemberYears	0.0
	Year	2014	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	19,019
			MemberYears	7,024.3
		2015	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	17,326
			MemberYears	8,214.2
Idelalisib and Ibritumomab, SLL	TOTAL	Total	Users	0
,		10101	Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	85,326
			MemberYears	60,194.2
	AgeGroup	18-44 Years	Users	00,134.2
	Ageoroup	10 44 ICUIS	Episodes	0
			Dispensings	0
			Days Supplied	0
				0
			Amount Supplied Eligible Members	11,024
			MemberYears	
		AF FA Veers		6,821.4
		45-54 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	12,693
			MemberYears	8,015.4



		55-64 Years	Licore	0
		55-04 fears	Users	
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	22,307
			MemberYears	14,698.5
		65+ Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	42,310
			MemberYears	30,658.9
	Sex	Female	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	40,483
			MemberYears	28,725.3
		Male	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	44,839
			MemberYears	31,466.4
		Unknown	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	4
			MemberYears	2.6
	Year	2014	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	73,071
			MemberYears	27,252.3
		2015	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	67,683
			MemberYears	32,941.9
Idelalisib and Ibrutinib, FL	TOTAL	Total	Users	2
			Episodes	2
			Dispensings	2
			Days Supplied	325
			Amount Supplied	2
			Eligible Members	22,182
			MemberYears	15,238.4
	AgeGroup	18-44 Years	Users	1
			Episodes	1
			Dispensings	1
			Days Supplied	30
			Amount Supplied	1
			Eligible Members	2,015



		45-54 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	3,545
			MemberYears	2,217.5
		55-64 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	6,511
			MemberYears	4,249.9
		65+ Years	Users	1
			Episodes	1
			Dispensings	1
			Days Supplied	295
			Amount Supplied	1
			Eligible Members	10,917
			MemberYears	7,575.3
	Sex	Female	Users	1
			Episodes	1
			Dispensings	1
			Days Supplied	295
			Amount Supplied	1
			Eligible Members	11,031
			MemberYears	7,610.8
		Male	Users	1
			Episodes	1
			Dispensings	1
			Days Supplied	30
			Amount Supplied	1
			Eligible Members	11,151
			MemberYears	7,627.6
		Unknown	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	0
			MemberYears	0.0
	Year	2014	Users	2
			Episodes	2
			Dispensings	2
			Days Supplied	325
			Amount Supplied	2
			Eligible Members	19,019
			MemberYears	7,024.3
		2015	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	17,326
			MemberYears	8,214.2
Idelalisib and Ibrutinib, SLL	TOTAL	Total	Users	15
			 Episodes	15
			Dispensings	15
			Days Supplied	1,220
			Amount Supplied	13
			Eligible Members	85,326
			MemberYears	60,194.2



AgeGroup	18-44 Years	Users	2
		Episodes	2
		Dispensings	2
		Days Supplied	182
		Amount Supplied	2
		Eligible Members	11,024
		MemberYears	6,821.4
	45-54 Years	Users	2
		Episodes	2
		Dispensings	2
		Days Supplied	60
		Amount Supplied	2
		Eligible Members	12,693
		MemberYears	8,015.4
	55-64 Years	Users	5
		Episodes	5
		Dispensings	5
		Days Supplied	203
		Amount Supplied	4
		Eligible Members	22,307
		MemberYears	14,698.5
	65+ Years	Users	6
		Episodes	6
		Dispensings	6
		Days Supplied	775
		Amount Supplied	5
		Eligible Members	42,310
		MemberYears	30,658.9
Sex	Female	Users	6
		Episodes	6
		Dispensings	6
		Days Supplied	792
		Amount Supplied	5
		Eligible Members	40,483
		MemberYears	28,725.3
	Male	Users	9
		Episodes	9
		Dispensings	9
		Days Supplied	428
		Amount Supplied	8
		Eligible Members	44,839
		MemberYears	31,466.4
	Unknown	Users	0
		Episodes	0
		Dispensings	0
		Days Supplied	0
		Amount Supplied	0
		Eligible Members	4
		MemberYears	2.6
Year	2014	Users	12
		Episodes	12
		Dispensings	12
		Days Supplied	1,097
		Amount Supplied	11
		Eligible Members	73,071
		MemberYears	27,252.3
	2015	Users	3
		Episodes	3
		Dispensings	3
		Days Supplied	123
		Amount Supplied	2
		Eligible Members	67,683
		MemberYears	32,941.9



Idelalisib and Lenalidomide, FL	TOTAL	Total	Users	2
·			Episodes	2
			Dispensings	2
			Days Supplied	122
			Amount Supplied	2
			Eligible Members	22,182
			MemberYears	15,238.4
	AgeGroup	18-44 Years	Users	1
			Episodes	1
			Dispensings	1
			Days Supplied	30
			Amount Supplied	1
			Eligible Members	2,015
			MemberYears	1,195.7
		45-54 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	3,545
		55-64 Years	MemberYears Users	2,217.5
		55-64 fears	Episodes	0 0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	6,511
			MemberYears	4,249.9
		65+ Years	Users	1,2 13.3
			Episodes	1
			Dispensings	1
			Days Supplied	92
			Amount Supplied	1
			Eligible Members	10,917
			MemberYears	7,575.3
	Sex	Female	Users	1
			Episodes	1
			Dispensings	1
			Days Supplied	92
			Amount Supplied	1
			Eligible Members	11,031
			MemberYears	7,610.8
		Male	Users	1
			Episodes	1
			Dispensings	1
			Days Supplied Amount Supplied	30 1
			Eligible Members	11,151
			MemberYears	7,627.6
		Unknown	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	0
			MemberYears	0.0
	Year	2014	Users	2
			Episodes	2
			Dispensings	2
			Days Supplied	122
			Amount Supplied	2
			Eligible Members	19,019
			MemberYears	7,024.3



		2015	Users	0
		2013	Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	17,326
			MemberYears	8,214.2
Idelalisib and Lenalidomide, SLL	TOTAL	Total	Users	5
			Episodes	5
			Dispensings	5
			Days Supplied	311
			Amount Supplied	5
			Eligible Members	85,326
			MemberYears	60,194.2
	AgeGroup	18-44 Years	Users	1
			Episodes	1
			Dispensings	1
			Days Supplied	30
			Amount Supplied	1
			Eligible Members MemberYears	11,024
		45-54 Years	Users	6,821.4 0
		45-54 fedis	Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	12,693
			MemberYears	8,015.4
		55-64 Years	Users	1
			Episodes	1
			Dispensings	1
			Days Supplied	30
			Amount Supplied	1
			Eligible Members	22,307
			MemberYears	14,698.5
		65+ Years	Users	3
			Episodes	3
			Dispensings	3
			Days Supplied	251
			Amount Supplied Eligible Members	3 42,310
			MemberYears	30,658.9
	Sex	Female	Users	30,038.3
	JCA	Temale	Episodes	3
			Dispensings	3
			Days Supplied	251
			Amount Supplied	3
			Eligible Members	40,483
			MemberYears	28,725.3
		Male	Users	2
			Episodes	2
			Dispensings	2
			Days Supplied	60
			Amount Supplied	2
			Eligible Members	44,839
		I Inka av	MemberYears	31,466.4
		Unknown	Users	0 0
			Episodes Dispensings	0
			Dispensings  Days Supplied	0
			Amount Supplied	0
			Eligible Members	4
			MemberYears	2.6



	Year	2014	Users	4
			Episodes	4
			Dispensings	4
			Days Supplied	212
			Amount Supplied	4
			Eligible Members MemberYears	73,071
		2045		27,252.3
		2015	Users	1
			Episodes Dispensings	1
			Days Supplied	1 99
			Amount Supplied	1
			Eligible Members	67,683
			MemberYears	32,941.9
Idelalisib and Obinutuzumab, FL	TOTAL	Total	Users	1
idelalisib alid Oblitutuzulliab, FL	IOIAL	TOtal	Episodes	1
			Dispensings	1
			Days Supplied	210
			Amount Supplied	1
			Eligible Members	22,182
			MemberYears	15,238.4
	AgeGroup	18-44 Years	Users	0
	Agedioup	10-44 (6413	Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	2,015
			MemberYears	1,195.7
		45-54 Years	Users	0
		-15 5-1 Teal5	Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	3,545
			MemberYears	2,217.5
		55-64 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	6,511
			MemberYears	4,249.9
		65+ Years	Users	1
			Episodes	1
			Dispensings	1
			Days Supplied	210
			Amount Supplied	1
			Eligible Members	10,917
			MemberYears	7,575.3
	Sex	Female	Users	1
			Episodes	1
			Dispensings	1
			Days Supplied	210
			Amount Supplied	1
			Eligible Members	11,031
			MemberYears	7,610.8
		Male	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	11,151
			MemberYears	7,627.6



		Unknown	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	0
			MemberYears	0.0
	Year	2014	Users	1
			Episodes	1
			Dispensings	1
			Days Supplied	210
			Amount Supplied	1
			Eligible Members	19,019
			MemberYears	7,024.3
		2015	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	17,326
			MemberYears	8,214.2
Idelalisib and Obinutuzumab, SLL	TOTAL	Total	Users	3
idelalisis and Osmatazamas, SEE	TOTAL	Total	Episodes	3
			Dispensings	3
			Days Supplied	775
			Amount Supplied	3
			Eligible Members	85,326
	AC	10 44 Vaara	MemberYears	60,194.2
	AgeGroup	18-44 Years	Users	1
			Episodes	1
			Dispensings	1
			Days Supplied	152
			Amount Supplied	1
			Eligible Members	11,024
			MemberYears	6,821.4
		45-54 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	12,693
			MemberYears	8,015.4
		55-64 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	22,307
			MemberYears	14,698.5
		65+ Years	Users	2
			Episodes	2
			Dispensings	2
			Days Supplied	623
			Amount Supplied	2
			Eligible Members	42,310
			MemberYears	30,658.9
	Sex	Female	Users	2
			Episodes	2
			Dispensings	2
			Days Supplied	362
			Amount Supplied	2
			Eligible Members	40,483
			MemberYears	28,725.3



		•		
		Male	Users	1
			Episodes	1
			Dispensings	1
			Days Supplied	413
			Amount Supplied	1
			Eligible Members	44,839
			MemberYears	31,466.4
		Unknown	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	4
			MemberYears	2.6
	Year	2014	Users	3
			Episodes	3
			Dispensings	3
			Days Supplied	775
			Amount Supplied	3
			Eligible Members	73,071
			MemberYears	
		2015		27,252.3
		2015	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	67,683
_			MemberYears	32,941.9
Idelalisib and Ofatumumab, FL	TOTAL	Total	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	22,182
			MemberYears	15,238.4
	AgeGroup	18-44 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	2,015
			MemberYears	1,195.7
		45-54 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	
				()
				0
			Amount Supplied	0
			Amount Supplied Eligible Members	0 3,545
		55-64 Years	Amount Supplied Eligible Members MemberYears	0 3,545 2,217.5
		55-64 Years	Amount Supplied Eligible Members MemberYears Users	0 3,545 2,217.5 0
		55-64 Years	Amount Supplied Eligible Members MemberYears Users Episodes	0 3,545 2,217.5 0 0
		55-64 Years	Amount Supplied Eligible Members MemberYears Users Episodes Dispensings	0 3,545 2,217.5 0 0
		55-64 Years	Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied	0 3,545 2,217.5 0 0 0
		55-64 Years	Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied	0 3,545 2,217.5 0 0 0 0
		55-64 Years	Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members	0 3,545 2,217.5 0 0 0 0 0 0
			Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears	0 3,545 2,217.5 0 0 0 0 0 6,511 4,249.9
		55-64 Years 65+ Years	Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users	0 3,545 2,217.5 0 0 0 0 0 6,511 4,249.9
			Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes	0 3,545 2,217.5 0 0 0 0 0 6,511 4,249.9 0
			Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings	0 3,545 2,217.5 0 0 0 0 0 6,511 4,249.9 0
			Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied	0 3,545 2,217.5 0 0 0 0 6,511 4,249.9 0 0
			Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied	0 3,545 2,217.5 0 0 0 0 0 6,511 4,249.9 0 0 0
			Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members	0 3,545 2,217.5 0 0 0 0 0 6,511 4,249.9 0 0 0
			Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied	0 3,545 2,217.5 0 0 0 0 0 6,511 4,249.9 0 0 0



		- 1	1.1	^
	Sex	Female	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	11,031
			MemberYears	7,610.8
		Male	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	11,151
			MemberYears	7,627.6
		Unknown	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	0
			0	
		2014	MemberYears	0.0
	Year	2014	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	19,019
			MemberYears	7,024.3
		2015	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
				•
			Eligible Members	17,326
Idelalisib and Ofatumumab, SLL	TOTAL	Total	Eligible Members	17,326
Idelalisib and Ofatumumab, SLL	TOTAL	Total	Eligible Members MemberYears	17,326 8,214.2
Idelalisib and Ofatumumab, SLL	TOTAL	Total	Eligible Members MemberYears Users Episodes	17,326 8,214.2 0
Idelalisib and Ofatumumab, SLL	TOTAL	Total	Eligible Members MemberYears Users Episodes Dispensings	17,326 8,214.2 0 0
Idelalisib and Ofatumumab, SLL	TOTAL	Total	Eligible Members MemberYears Users Episodes Dispensings Days Supplied	17,326 8,214.2 0 0 0
Idelalisib and Ofatumumab, SLL	TOTAL	Total	Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied	17,326 8,214.2 0 0 0 0 0
Idelalisib and Ofatumumab, SLL	TOTAL	Total	Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members	17,326 8,214.2 0 0 0 0 0 0 0 85,326
Idelalisib and Ofatumumab, SLL			Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears	17,326 8,214.2 0 0 0 0 0 0 85,326 60,194.2
Idelalisib and Ofatumumab, SLL	TOTAL AgeGroup	Total  18-44 Years	Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users	17,326 8,214.2 0 0 0 0 0 85,326 60,194.2
Idelalisib and Ofatumumab, SLL			Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes	17,326 8,214.2 0 0 0 0 0 85,326 60,194.2 0
Idelalisib and Ofatumumab, SLL			Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings	17,326 8,214.2 0 0 0 0 0 85,326 60,194.2 0
Idelalisib and Ofatumumab, SLL			Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied	17,326 8,214.2 0 0 0 0 0 85,326 60,194.2 0 0
Idelalisib and Ofatumumab, SLL			Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied	17,326 8,214.2 0 0 0 0 0 85,326 60,194.2 0 0 0
Idelalisib and Ofatumumab, SLL			Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members	17,326 8,214.2 0 0 0 0 0 85,326 60,194.2 0 0 0 0
Idelalisib and Ofatumumab, SLL		18-44 Years	Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears	17,326 8,214.2 0 0 0 0 0 0 85,326 60,194.2 0 0 0 0 11,024 6,821.4
Idelalisib and Ofatumumab, SLL			Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Users Users Users Users	17,326 8,214.2 0 0 0 0 0 0 85,326 60,194.2 0 0 0 0 11,024 6,821.4 0
Idelalisib and Ofatumumab, SLL		18-44 Years	Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Ligible Members MemberYears Users Episodes	17,326 8,214.2 0 0 0 0 0 0 85,326 60,194.2 0 0 0 11,024 6,821.4 0
Idelalisib and Ofatumumab, SLL		18-44 Years	Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings	17,326 8,214.2 0 0 0 0 0 0 85,326 60,194.2 0 0 0 11,024 6,821.4 0
Idelalisib and Ofatumumab, SLL		18-44 Years	Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members WemberYears Users Episodes Dispensings Days Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied	17,326 8,214.2 0 0 0 0 0 85,326 60,194.2 0 0 0 11,024 6,821.4 0 0
Idelalisib and Ofatumumab, SLL		18-44 Years	Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied	17,326 8,214.2 0 0 0 0 0 85,326 60,194.2 0 0 0 11,024 6,821.4 0 0 0
Idelalisib and Ofatumumab, SLL		18-44 Years	Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members	17,326 8,214.2 0 0 0 0 0 0 85,326 60,194.2 0 0 0 11,024 6,821.4 0 0 0
Idelalisib and Ofatumumab, SLL		18-44 Years 45-54 Years	Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears	17,326 8,214.2 0 0 0 0 0 85,326 60,194.2 0 0 0 11,024 6,821.4 0 0 0 0
Idelalisib and Ofatumumab, SLL		18-44 Years	Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Users	17,326 8,214.2 0 0 0 0 0 85,326 60,194.2 0 0 0 11,024 6,821.4 0 0 0 0 12,693 8,015.4
Idelalisib and Ofatumumab, SLL		18-44 Years 45-54 Years	Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Users Episodes	17,326 8,214.2 0 0 0 0 0 85,326 60,194.2 0 0 0 11,024 6,821.4 0 0 0 0 12,693 8,015.4 0
Idelalisib and Ofatumumab, SLL		18-44 Years 45-54 Years	Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members WemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Users Episodes Dispensings	17,326 8,214.2 0 0 0 0 0 85,326 60,194.2 0 0 11,024 6,821.4 0 0 12,693 8,015.4 0 0
Idelalisib and Ofatumumab, SLL		18-44 Years 45-54 Years	Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members WemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied	17,326 8,214.2 0 0 0 0 0 85,326 60,194.2 0 0 11,024 6,821.4 0 0 12,693 8,015.4 0 0 0
Idelalisib and Ofatumumab, SLL		18-44 Years 45-54 Years	Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members WemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Amount Supplied	17,326 8,214.2 0 0 0 0 0 85,326 60,194.2 0 0 11,024 6,821.4 0 0 12,693 8,015.4 0 0 0 0
Idelalisib and Ofatumumab, SLL		18-44 Years 45-54 Years	Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members WemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied	17,326 8,214.2 0 0 0 0 0 85,326 60,194.2 0 0 11,024 6,821.4 0 0 12,693 8,015.4 0 0 0 22,307
Idelalisib and Ofatumumab, SLL		18-44 Years 45-54 Years	Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members WemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Eligible Members MemberYears Users Episodes Dispensings Days Supplied Amount Supplied Amount Supplied	17,326 8,214.2 0 0 0 0 0 85,326 60,194.2 0 0 11,024 6,821.4 0 0 12,693 8,015.4 0 0 0 0



				_
		65+ Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	42,310
			MemberYears	30,658.9
	Sex	Female	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	40,483
			MemberYears	28,725.3
		Male	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	44,839
			MemberYears	31,466.4
		Unknown	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	4
			MemberYears	2.6
	Year	2014	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	73,071
			MemberYears	27,252.3
		2015	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	67,683
			MemberYears	32,941.9
Idelalisib and Prednisone, FL	TOTAL	Total	Users	13
raciansia and reamsone, re	101712	Total	Episodes	13
			Dispensings	13
			Days Supplied	1,595
			Amount Supplied	12
			Eligible Members	22,182
			MemberYears	15,238.4
	AgeGroup	18-44 Years	Users	0
	Agedroup	10-44 16415	Episodes	0
			•	
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	2,015
		40.041	MemberYears	1,195.7
		45-54 Years	Users	2
			Episodes	2
			Dispensings	2
			Days Supplied	244
			Amount Supplied	2
			Eligible Members	3,545
			MemberYears	2,217.5



		55-64 Years	Harris	4
		55-64 Years	Users	4
			Episodes	4
			Dispensings	4
			Days Supplied	557
			Amount Supplied	3
			Eligible Members	6,511
			MemberYears	4,249.9
		65+ Years	Users	7
			Episodes	7
			Dispensings	7
			Days Supplied	794 -
			Amount Supplied	7
			Eligible Members	10,917
	-		MemberYears	7,575.3
	Sex	Female	Users	6
			Episodes	6
			Dispensings	6
			Days Supplied	698
			Amount Supplied	5
			Eligible Members	11,031
			MemberYears	7,610.8
		Male	Users	7
			Episodes	7
			Dispensings	7
			Days Supplied	897
			Amount Supplied	7
			Eligible Members	11,151
			MemberYears	7,627.6
		Unknown	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	0
			MemberYears	0.0
	Year	2014	Users	8
			Episodes	8
			Dispensings	8
			Days Supplied	1,215
			Amount Supplied	8
			Eligible Members	19,019
			MemberYears	7,024.3
		2015	Users	5
			Episodes	5
			Dispensings	5
			Days Supplied	380
			Amount Supplied	4
			Eligible Members	17,326
			MemberYears	8,214.2
Idelalisib and Prednisone, SLL	TOTAL	Total	Users	34
			Episodes	35
			Dispensings	35
			Days Supplied	4,042
			Amount Supplied	32
			Eligible Members	85,326
			MemberYears	60,194.2
	AgeGroup	18-44 Years	Users	1
			Episodes	1
			Dispensings	1
			Days Supplied	152
			Amount Supplied	1
			Eligible Members	11,024
			MemberYears	6,821.4



		45-54 Years	Users	3
		43 34 Tears	Episodes	3
			Dispensings	3
			Days Supplied	462
			Amount Supplied	3
			Eligible Members	12,693
			MemberYears	8,015.4
		55-64 Years	Users	14
		33-04 Tears	Episodes	14
			Dispensings	14
			Days Supplied	1,453
			Amount Supplied	1,433
			Eligible Members	22,307
			MemberYears	14,698.5
		65+ Years	Users	14,030.3
		os. icuis	Episodes	17
			Dispensings	17
			Days Supplied	1,975
			Amount Supplied	16
			Eligible Members	42,310
			MemberYears	30,658.9
	Sex	Female	Users	14
	JCX	remaie	Episodes	15
			Dispensings	15
			Days Supplied	1,725
			Amount Supplied	13
			Eligible Members	40,483
			MemberYears	28,725.3
		Male	Users	20
			Episodes	20
			Dispensings	20
			Days Supplied	2,317
			Amount Supplied	19
			Eligible Members	44,839
			MemberYears	31,466.4
		Unknown	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	4
			MemberYears	2.6
	Year	2014	Users	17
			Episodes	17
			Dispensings	17
			Days Supplied	2,445
			Amount Supplied	16
			Eligible Members	73,071
			MemberYears	27,252.3
		2015	Users	17
			Episodes	18
			Dispensings	18
			Days Supplied	1,597
			Amount Supplied	15
			Eligible Members	67,683
			MemberYears	32,941.9
Idelalisib and Rituximab, FL	TOTAL	Total	Users	24
			Episodes	24
			Dispensings	24
			Days Supplied	2,544
			Amount Supplied	23
			Eligible Members	22,182
			MemberYears	15,238.4



AgeGroup	18-44 Years	Users	1
0		Episodes	1
		Dispensings	1
		Days Supplied	99
		Amount Supplied	1
		Eligible Members	2,015
		MemberYears	1,195.7
	45-54 Years	Users	5
		Episodes	5
		Dispensings	5
		Days Supplied	600
		Amount Supplied	5
		Eligible Members	3,545
		MemberYears	2,217.5
	55-64 Years	Users	3
		Episodes	3
		Dispensings	3 436
		Days Supplied Amount Supplied	3
		Eligible Members	6,511
		MemberYears	4,249.9
	65+ Years	Users	15
	30 . 10013	Episodes	15
		Dispensings	15
		Days Supplied	1,409
		Amount Supplied	14
		Eligible Members	10,917
		MemberYears	7,575.3
Sex	Female	Users	9
		Episodes	9
		Dispensings	9
		Days Supplied	933
		Amount Supplied	9
		Eligible Members	11,031
	Male	MemberYears Users	7,610.8 15
	IVIAIC	Episodes	15
		Dispensings	15
		Days Supplied	1,611
		Amount Supplied	14
		Eligible Members	11,151
		MemberYears	7,627.6
	Unknown	Users	0
		Episodes	0
		Dispensings	0
		Days Supplied	0
		Amount Supplied	0
		Eligible Members	0
Voor	2014	MemberYears	0.0
Year	2014	Users Episodes	15 15
		Dispensings	15 15
		Days Supplied	1,825
		Amount Supplied	1,823
		Eligible Members	19,019
		MemberYears	7,024.3
	2015	Users	9
		Episodes	9
		Dispensings	9
		Days Supplied	719
		Amount Supplied	8
		Eligible Members	17,326
		MemberYears	8,214.2



Idelalisib and Rituximab, SLL	TOTAL	Total	Users	60
·			Episodes	62
			Dispensings	62
			Days Supplied	6,755
			Amount Supplied	57
			Eligible Members	86,698
			MemberYears	60,976.1
	AgeGroup	18-44 Years	Users	2
			Episodes	2
			Dispensings	2
			Days Supplied	129
			Amount Supplied	2
			Eligible Members MemberYears	11,206
		45-54 Years	Users	6,918.1 8
		43-34 Tears	Episodes	8
			Dispensings	8
			Days Supplied	940
			Amount Supplied	8
			Eligible Members	12,933
			MemberYears	8,140.3
		55-64 Years	Users	16
			Episodes	16
			Dispensings	16
			Days Supplied	2,221
			Amount Supplied	15
			Eligible Members	22,742
			MemberYears	14,936.2
		65+ Years	Users	34
			Episodes	36
			Dispensings	36
			Days Supplied	3,465
			Amount Supplied	32 42.971
			Eligible Members MemberYears	42,871 30,981.4
	Sex	Female	Users	17
	JCA	remaie	Episodes	17
			Dispensings	17
			Days Supplied	1,987
			Amount Supplied	16
			Eligible Members	41,121
			MemberYears	29,089.2
		Male	Users	43
			Episodes	45
			Dispensings	45
			Days Supplied	4,768
			Amount Supplied Eligible Members	41 45,573
			MemberYears	45,575 31,884.3
		Unknown	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	4
			MemberYears	2.6
	Year	2014	Users	32
			Episodes	32
			Dispensings	32
			Days Supplied	4,117
			Amount Supplied	31
			Eligible Members	74,416
			MemberYears	27,766.1



		2015	Users	29
		2015	Episodes	30
			Dispensings	30
			Days Supplied	2,638
			Amount Supplied	26
			Eligible Members	68,805
			MemberYears	33,210.0
Idelalisib and Vincristine, FL	TOTAL	Total	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied Amount Supplied	0 0
			Eligible Members	22,182
			MemberYears	15,238.4
	AgeGroup	18-44 Years	Users	0
	7.gcc.cap	20 11 100.0	Episodes	0
			Dispensings	0
			Days Supplied	0
			<b>Amount Supplied</b>	0
			Eligible Members	2,015
			MemberYears	1,195.7
		45-54 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	3,545
		55-64 Years	MemberYears Users	2,217.5 0
		55-04 feats	Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	6,511
			MemberYears	4,249.9
		65+ Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	10,917
	Sex	Female	MemberYears	7,575.3
	Sex	remale	Users Episodes	0 0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	11,031
			MemberYears	7,610.8
		Male	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	11,151
		I Imlemation	MemberYears	7,627.6
		Unknown	Users Episodes	0 0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	0
			MemberYears	0.0



	Year	2014	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	19,019
			MemberYears	7,024.3
		2015	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	17,326
			MemberYears	8,214.2
Idelalisib and Vincristine, SLL	TOTAL	Total	Users	1
idelalisib and vincristine, SEE	IOIAL	iotai	Episodes	1
			Dispensings	1
			Days Supplied	267
			Amount Supplied	1
			Eligible Members	86,698
			MemberYears	60,976.1
	AgeGroup	18-44 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	11,206
			MemberYears	6,918.1
		45-54 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	12,933
			MemberYears	8,140.3
		55-64 Years	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	22,742
			MemberYears	14,936.2
		CE L Voors		
		65+ Years	Users	1
			Episodes	1
			Dispensings	1
			Days Supplied	267
			Amount Supplied	1
			Eligible Members	42,871
		_	MemberYears	30,981.4
	Sex	Female	Users	1
			Episodes	1
			Dispensings	1
			Days Supplied	267
			Amount Supplied	1
			Eligible Members	41,121
			MemberYears	29,089.2
		Male	Users	0
			Episodes	0
			Dispensings	0
			Days Supplied	0
			Amount Supplied	0
			Eligible Members	45,573
			MemberYears	31,884.3
			MICHIDEL LCG13	31,004.3



	Unknown	Users	0
		Episodes	0
		Dispensings	0
		Days Supplied	0
		Amount Supplied	0
		Eligible Members	4
		MemberYears	2.6
Year	2014	Users	1
		Episodes	1
		Dispensings	1
		Days Supplied	267
		Amount Supplied	1
		Eligible Members	74,416
		MemberYears	27,766.1
	2015	Users	0
		Episodes	0
		Dispensings	0
		Days Supplied	0
		Amount Supplied	0
		Eligible Members	68,805
		MemberYears	33,210.0